Jazz Pharmaceuticals public limited company

Directors’ report and financial statements

Year ended 31 December 2020

Registered number: 399192 [THIS PAGE INTENTIONALLY LEFT BLANK] IndextoConsolidatedFinancial Statements

Page

Directors andOtherInformation 1 Directors’ Report 2 Statement of Directors’ Responsibilities in respect of the Directors’ Report and FinancialStatements 19 Independent Auditor’s Report 20 Consolidated Income Statement for theyearended 31 December2020 25 Consolidated Statement of Comprehensive Incomefor theyearended 31 December2020 26 Consolidated BalanceSheet as at 31 December2020 27 Consolidated Statement of Changes in Shareholders’Equity for theyearended 31 December2020 28 Consolidated Statement of Cash Flowsfor the year ended 31 December2020 29 Parent Company BalanceSheet as at 31 December2020 30 Parent Company Statement of Changes in Shareholders’Equity for theyearended 31 December2020 31 Parent Company Statement of Cash Flowsfor the year ended 31 December2020 32 Notes to theConsolidated Financial Statements 33 Appendix A-IFRStoU.S. GAAP Reconciliation 92 Appendix B-Risk Factors 98 [THIS PAGE INTENTIONALLY LEFT BLANK] Jazz Pharmaceuticals plc

Directors and Other Information

Directors Bruce C. Cozadd Paul L. Berns Jennifer Cook (Appointed 1 December 2020) Patrick G. Enright Peter Gray Heather Ann McSharry Seamus Mulligan Kenneth W. O'Keefe Anne O'Riordan Norbert G. Riedel, Ph.D. Elmar Schnee Mark D. Smith, M.D. (Appointed 1 December 2020) Catherine A. Sohn, Pharm.D. Rick E Winningham

Secretary Aislinn Doody

Registered office 5th Floor, Waterloo Exchange Waterloo Road Dublin 4 D04 E5W7 Ireland

Independent Auditor KPMG 1 Stokes Place St. Stephen’s Green Dublin 2 D02 DE03 Ireland

Banker J.P. Morgan Bank Luxembourg S.A., Dublin Branch, 200 Capital Dock, 79 Sir John Rogersons Quay, Dublin 2 D02 RK57 Ireland

Solicitors Arthur Cox Earlsfort Centre Earlsfort Terrace Dublin 2 D02 CK83 Ireland

Cooley LLP 3175 Hanover Street Palo Alto, CA 94304 - 1130 U.S.A.

Registered number 399192

1 Jazz Pharmaceuticals plc Directors’ Report The directors present their annual report and consolidated and parent company financial statements for the year ended 31 December 2020. Jazz Pharmaceuticals plc was formed under the laws of Ireland (registered number 399192) as a private limited liability company in March 2005 under the name Azur Pharma Limited and was subsequently re-registered as a public limited company under the name Azur Pharma Public Limited Company, or Azur Pharma, in October 2011. On 18 January 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction, in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc and we became the parent company of and successor to Jazz Pharmaceuticals, Inc. In June 2012, we acquired EUSA Pharma, Inc., in January 2014, we acquired Gentium S.r.l, in July 2016, we acquired Celator Pharmaceuticals, Inc. and in August 2019, we acquired Cavion, Inc., or Cavion.

Principal activities, business review and future developments Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercialising life- changing medicines that transform the lives of patients with serious diseases – often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, across key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumours. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Our lead marketed products are: • Xyrem® (sodium oxybate) oral solution, a product approved by the U.S. Food and Drug Administration, or FDA, and marketed in the U.S. for the treatment of both cataplexy and excessive daytime sleepiness, or EDS, in narcolepsy patients seven years of age and older; • Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product that contains 92% less sodium than Xyrem, approved by FDA and launched in the U.S. in November 2020 for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; • Sunosi® (solriamfetol), a product approved by FDA and the European Commission, or the EC, after evaluation by the European Medicines Agency and marketed in the U.S. and in Europe to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea, or OSA; • Zepzelca™ (lurbinectedin), a product approved by FDA in June 2020 and launched in July 2020 in the U.S. for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy; • Vyxeos® (daunorubicin and cytarabine) liposome for injection, a product approved in the U.S. and in Europe (where it is marketed as Vyxeos® liposomal 44 mg/100 mg powder for concentrate for solution for infusion) for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia, or AML, or AML with myelodysplasia-related changes; or AML-MRC; • Defitelio® (defibrotide sodium), a product approved in the U.S. for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, or VOD, also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Europe (where it is marketed as Defitelio® (defibrotide)) for the treatment of severe VOD in adults and children undergoing HSCT therapy; and • Erwinaze® (asparaginase Erwinia chrysanthemi), a treatment approved in the U.S. and in certain markets in Europe (where it is marketed as Erwinase®) for patients with acute lymphoblastic leukemia, or ALL, who have developed hypersensitivity to E. coli-derived asparaginase. Our strategy to create shareholder value is focused on: •Strong commercial execution to drive diversified revenue growth and address unmet medical needs of our patients across our product portfolio including with rapid adoption of Xywav in the U.S., Sunosi growth globally and establishing Zepzelca as a treatment of choice for second line SCLC patients;

2 •Expanding and advancing our pipeline with internal and external patient-centric innovation to achieve a valuable product portfolio of durable, highly differentiated programmes; •Continuing to build a flexible, efficient, and productive development engine for targeted therapeutic conditions to identify and progress early- and mid-stage assets; and •Investing in an efficient, scalable operating model and differentiated capabilities to enable growth and unlock further value through indication expansion and global markets. In 2020, consistent with our strategy, we continued to focus on research and development activities within our neuroscience and oncology therapeutic areas, such as our expansion into movement disorders and solid tumours, and exploring and investing in adjacent therapeutic areas that could further diversify our portfolio, such as post-traumatic stress disorders through our acquisition of SpringWorks Therapeutics, Inc.’s, or SpringWorks’, fatty acid amide hydrolase, or FAAH, inhibitor programme. Our total net product sales increased by 10% in 2020 compared to 2019, primarily due to an increase in oxybate net product sales and the launch of Zepzelca in the U.S. in July 2020. 2020 Highlights and Recent Developments Regulatory Approvals and Launches •In January 2020, the EC approved Sunosi to improve wakefulness in adult patients with EDS associated with narcolepsy or OSA. In May and October 2020, we launched Sunosi in Germany and Denmark, respectively. •In February 2020, FDA accepted for filing with priority review the new drug application, or NDA, for Zepzelca for the treatment of relapsed SCLC, a product candidate for which we acquired exclusive U.S. development and commercialisation rights. In June 2020, FDA granted Zepzelca accelerated approval for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy, a product for which we have exclusive U.S. commercialisation rights. In July 2020, we launched Zepzelca in the U.S. and the National Comprehensive Cancer Network added Zepzelca to the clinical practice guidelines in oncology for SCLC as a preferred treatment in patients who relapse in six months or less after prior systemic therapy and as a recommended regimen in patients who relapse more than six months after prior systemic therapy. At launch, all planned contracts with distributors and group purchasing organisations were in place for Zepzelca. •In January 2020, we submitted an NDA to FDA seeking marketing approval for Xywav (formerly JZP258), an oxybate product candidate that contains 92% less sodium than Xyrem, for the treatment of cataplexy and EDS in narcolepsy patients seven years of age and older. In March 2020, FDA accepted our NDA for filing with priority review with a Prescription Drug User Fee Act, or PDUFA. action date of 21 July 2020. In July 2020, FDA approved our NDA for Xywav. In November 2020, we commenced the U.S. launch of Xywav. The 92% reduction of sodium translates into a reduction of approximately 1,000 to 1,500 milligrams per day for a patient prescribed an oxybate product, depending on the dose. When patients start Xywav after sodium oxybate, Xywav treatment is initiated at the same dose and regimen as sodium oxybate (gram for gram) and titrated as needed based on efficacy and tolerability. The label for Xywav, unlike Xyrem, does not include a warning to prescribers to monitor patients sensitive to sodium intake, including patients with heart failure, hypertension or renal impairment. There is a well-accepted relationship between dietary sodium and blood pressure as well as published hypertension guidelines underscoring that excessive consumption of sodium is independently associated with an increased risk of stroke, cardiovascular disease and other adverse outcomes. In approving Xywav, FDA approved a risk evaluation and mitigation strategy for Xywav and Xyrem. In an effort to support strong adoption of Xywav, we are focused on providing robust patient access programmes and facilitating payor coverage for Xywav. •In July 2020, Defitelio was approved by the Australian Therapeutic Goods Administration for the treatment of VOD. Regulatory Submissions •In October 2020, we announced positive top-line results from a Phase 3 clinical trial evaluating JZP258 in adult patients with idiopathic hypersomnia, a chronic, neurological disorder that is primarily characterised by EDS and that currently has no approved therapies in the U.S. We completed the rolling submission of a supplemental new drug application, or sNDA, in February 2021 and if approved by FDA in a timely manner, we expect a potential launch of JZP258 in the fourth quarter of 2021. FDA granted Fast Track designation for JZP258 for the treatment of idiopathic hypersomnia in September 2020.

3 Research & Development •In April 2020, we announced our decision to stop enrollment in our Phase 3 clinical study of defibrotide for the prevention of VOD due to a determination that the study is highly unlikely to reach one of its primary endpoints. This does not impact the approved indication or other ongoing defibrotide studies. •In September 2020, FDA granted Rare Pediatric Disease designation for JZP458 for the treatment of pediatric ALL, and prior to that, in October 2019, FDA granted Fast Track designation for JZP458, a recombinant Erwinia asparaginase product candidate, for the treatment of pediatric and adult patients with ALL or lymphoblastic lymphoma who are hypersensitive to E. coli-derived asparaginase products. Our pivotal Phase 2/3 clinical study (conducted in collaboration with the Children’s Oncology Group) for JZP458 continues to enrol, and we initiated the submission of our biologics license application, to FDA for JZP458 in December 2020, with an objective of launching in the U.S. in mid-2021 to ensure that ALL patients have access to a reliable, high-quality recombinant product given the ongoing supply issues with Erwinaze. •In September 2020, we completed our healthy volunteer study in JZP385 for the potential treatment of essential tremor Other Significant Developments •During 2020, we repurchased an aggregate of $146.5 million of our ordinary shares under our share repurchase programme at an average price of $121.98 per share. •In June 2020, Jazz Investments I Limited, our wholly owned subsidiary, completed a private offering of an aggregate $1.0 billion principal amount of 2.00% exchangeable senior notes due 2026, or the 2026 Notes. We used a portion of the net proceeds from the issuance of the 2026 Notes to repurchase for cash $356.2 million aggregate principal amount of existing 1.875% exchangeable senior notes due 2021, or the 2021 Notes. The remaining net proceeds were used for general corporate purposes. •In September 2020, we entered into a new research collaboration agreement with Redx Pharma plc, or Redx, to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. This research collaboration follows our previously announced purchase of Redx's preclinical pan-Raf inhibitor programme for the potential treatment of Raf and Ras mutant tumours in July 2019. Under the terms of the 2020 research collaboration agreement, we made an upfront payment to Redx of $10.0 million, which will be followed by another $10.0 million in 2021, provided research work is continuing. Following delivery of an investigational new drug, or IND,-ready molecule, Redx will be eligible to receive up to a further $200.0 million from us in development, regulatory and commercial milestone payments for each programme. The first milestone is payable upon successful IND submission. In addition, Redx is eligible to receive tiered royalties in mid-single digit percentages of any future net sales. Following a successful submission of an IND application, we will be responsible for further development, manufacturing, regulatory activities and commercialisation. •In October 2020, we entered into an asset purchase and exclusive license agreement with SpringWorks under which we acquired SpringWorks’ FAAH inhibitor programme. Under the terms of the agreement, SpringWorks has assigned or exclusively licensed all assets relating to its FAAH inhibitor programme to us, including assignment of SpringWorks’ proprietary FAAH inhibitor PF-04457845, or PF-’845, now named JZP150, and its license agreement with Pfizer, Inc., or Pfizer, under which Pfizer exclusively licensed PF-’845 to SpringWorks in 2017. We will initially focus on developing JZP150 for the potential treatment of post-traumatic stress disorder and associated symptoms. In addition to assuming all milestone and royalty obligations owed by SpringWorks to Pfizer, we made an upfront payment of $35.0 million to SpringWorks, and may make potential milestone payments to SpringWorks of up to $375.0 million upon the achievement of certain clinical, regulatory and commercial milestones, and pay incremental tiered royalties to SpringWorks on future net sales of JZP150 in the mid- to high-single digit percentages. •In October 2020, we entered into an amendment and restatement of our license agreement, or the amended license agreement, with PharmaMar, S.A., which expanded our exclusive license to include rights to develop and commercialise Zepzelca in Canada. •In February 2021, we entered into a definitive transaction agreement, or the Transaction Agreement, with GW Pharmaceuticals plc, or GW. The GW Transaction Agreement provides, among other things, that, subject to the satisfaction or waiver of the conditions set forth in the GW Transaction Agreement, we will acquire the entire issued share capital of GW, which we refer to in this report as the GW Acquisition. Under the GW Transaction Agreement, the consideration to be paid by us in the GW Acquisition consists of $220.00 per American Depositary Share in GW, to be paid in the form of $200 in cash and $20 in our ordinary shares, for total consideration of approximately $7,200.0 million. The GW Acquisition is expected to close in the first half of

4 May 2021, subject to the satisfaction or waiver of the conditions set forth in the GW Transaction Agreement. In connection with the execution of the GW Transaction Agreement, we entered into a commitment letter with BofA Securities, Inc., Bank of America, N.A. and JPMorgan Chase Bank, N.A. pursuant to which these commitment parties have committed to provide us with a senior secured revolving credit facility in an aggregate principal amount of up to $500.0 million, a senior secured term loan B facility in an aggregate principal amount of up to $3,150.0 million and a senior secured bridge loan facility in an aggregate principal amount of up to $2,200.0 million to, among other things, finance our obligations in respect of the GW Acquisition. The effectiveness of such credit facilities is subject to the occurrence of customary closing conditions, including the consummation of the GW Acquisition. •In April 2021, we and certain of our wholly-owned subsidiaries, entered into Amendment No. 3 to our Credit Agreement, dated as of 18 June 2015, or the Existing Credit Agreement, with the lenders party thereto and Bank of America, N.A., as administrative agent, collateral agent, letter of credit issuer and swing line lender. The Amendment No. 3 amended the Existing Credit Agreement to permit the issuance of senior secured notes and made certain related changes as set forth therein. •In April 2021, our wholly-owned subsidiary, Jazz Securities Designated Activity Company, issued $1.5 billion in aggregate principal amount of 4.375% senior secured notes due 2029. • Concurrently with the closing of the GW Acquisition, we expect to enter into new senior secured credit facilities, which is expected to consist of a $500.0 million revolving credit facility and a term loan B facility in an aggregate amount that is expected to equal approximately $3.85 billion. We expect to use term loan B borrowings under new senior secured credit facilities and the net proceeds from the senior secured notes, together with cash on hand to fund the cash consideration payable in connection with the GW Acquisition. The senior secured notes have a mandatory redemption clause that will be triggered under certain circumstances, including failure to complete the GW Acquisition within the time period outlined in the GW Transaction Agreement or the termination of the GW Acquisition. Continued Emphasis on Research and Development A key aspect of our growth strategy is our continued investment in our evolving and expanding research and development activities. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. We are focused on research and development activities within our neuroscience and oncology therapeutic areas, such as our expansion into movement disorders and solid tumours, and exploring and investing in adjacent therapeutic areas that could further diversify our portfolio. Our development activities encompass all stages of development and currently include clinical testing of new product candidates and activities related to clinical improvements of, or additional indications or new clinical data for, our existing marketed products. We have also expanded into preclinical exploration of novel therapies primarily through external research collaborations, including precision medicines in haematology and oncology. We are increasingly leveraging our growing research and development function, and have supported additional investigator-sponsored trials, or ISTs, that will generate additional data related to our products. We have a number of licensing and collaboration agreements with third parties, including biotechnology companies, academic institutions and research-based companies and institutions, related to preclinical and clinical research and development activities in haematology and in precision oncology, as well as in neuroscience. Our current and planned development activities in our neuroscience therapeutic area are focused on Xywav for the treatment of idiopathic hypersomnia, JZP385, JZP150 and JZP324, as well as exploring additional indications for Sunosi. Xywav for the treatment of idiopathic hypersomnia. In October 2020, we announced positive top-line results from a Phase 3 clinical trial evaluating Xywav in adult patients with idiopathic hypersomnia, a chronic, neurological disorder that is primarily characterised by EDS and that currently has no approved therapies in the U.S. We completed the rolling submission of an sNDA, in February 2021. In April 2021, FDA accepted the sNDA for filing with priority review with a PDUFA action date of 12 August 2021. We expect a potential launch in the fourth quarter of 2021. JZP385. JZP385 is a T-type calcium channel modulator that is a small molecule currently in development for the treatment of essential tremor. We acquired JZP385 in our acquisition of Cavion, Inc., a clinical-stage biotechnology company, in August 2019. We expect to initiate a Phase 2b study of JZP385 in mid-year 2021. JZP150. JZP150 is a FAAH inhibitor programme for the potential treatment of post-traumatic stress disorder and associated symptoms.

5 JZP324. We are also pursuing early-stage activities related to the development of JZP324, an extended-release low sodium, oxybate formulation that we believe could provide a clinically meaningful option for narcolepsy patients Our current and planned research and development activities in our oncology therapeutic area are focused on JZP458, exploring additional indications for Defitelio and Vyxeos, generating additional clinical data for Zepzelca and Vyxeos, including in combination with other therapeutic agents, and the research and development of new product candidates through our external collaborations. JZP458. JZP458 is a recombinant Erwinia asparaginase that uses a novel Pseudomonas fluorescens expression platform, which is being developed for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients with ALL or lymphoblastic lymphoma, or LBL, who are hypersensitive to E. coli-derived asparaginase products. JZP458 was granted Fast Track designation by FDA in October 2019 for the treatment of this patient population, and in December 2019, the first patient was enrolled in the pivotal Phase 2/3 clinical study for JZP458 conducted in collaboration with the Children’s Oncology Group. In December 2020, we initiated the submission of a BLA to FDA for JZP458 under Real-Time Oncology Review, pilot programme, with the potential approval and launch in the U.S. in mid-year of 2021. Zepzelca. We anticipate the initiation in 2021 of a Phase 3 study evaluating Zepzelca in combination with immunotherapy versus immunotherapy alone in patients with extensive-stage SCLC after induction chemotherapy. Vyxeos. Our Vyxeos clinical development strategy is designed to target potential new patient segments across the AML landscape and to generate clinical data on Vyxeos when used in combination with other therapeutic agents. As reflected in the table below, we are pursuing this strategy by sponsoring clinical trials, working with cooperative groups who are conducting clinical trials, and partnering with The University of Texas MD Anderson Cancer Center, or MD Anderson. In August 2018, we announced a five-year collaboration with MD Anderson to evaluate potential treatment options for hematologic malignancies, with a near-term focus on Vyxeos, and shortly thereafter, commenced development activities under this collaboration. In addition, there are multiple ongoing ISTs studying Vyxeos. Defitelio. Our Defitelio clinical development strategy generally focuses on the prevention and treatment of serious diseases associated with stem cell transplantation and endothelial cell damage. CombiPlex Platform. We are also evaluating the use of our CombiPlex delivery technology platform in a number of therapeutic combinations in oncology as part of our internal oncology research and development activities. CombiPlex enables the design and rapid evaluation of various combinations of therapies to deliver enhanced anti-cancer activity by identifying an optimal synergistic ratio of drugs in vitro and fixing this ratio in a nanoscale delivery complex that maintains and then coordinates the release of the synergistic combination after administration. CombiPlex utilises two proprietary nanoscale delivery platforms: liposomes to control the release and distribution of water-soluble drugs and drugs that are both water- and fat-soluble (amphipathic), and nanoparticles to control the release and distribution of non-water-soluble (hydrophobic) drugs. Through third parties, we are also pursuing preclinical and clinical research and development activities in haematology and in precision oncology under a number of licensing and collaboration agreements, including with: •Codiak BioSciences, Inc., or Codiak, for an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialise potential therapeutic candidates directed at five targets to be developed using Codiak's engEx™ precision engineering platform for exosome therapeutics; •Pfenex, Inc., which was acquired by Ligand Pharmaceuticals Incorporated, or Ligand, for rights to an early-stage long-acting Erwinia asparaginase and an option to negotiate a license for a recombinant pegaspargase product candidate; •XL-protein GmbH, or XLp, for rights to use XLp’s PASylation® technology to extend the plasma half-life of selected asparaginase product candidates; and •Redx, for preclinical collaboration activities related to the pan-Raf inhibitor programme that we purchased from Redx for the potential treatment of Raf and Ras mutant tumours and to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway.

6 Below is a summary of our key ongoing and planned development projects related to our products and pipeline and their corresponding current stages of development: Neuroscience

Product Candidates Description Regulatory Xywav (oxybate; 92% sodium reduction) Idiopathic hypersomnia Phase 2b JZP385 Essential tremor (planned study) Phase 2 JZP150 Post-traumatic stress disorder (planned study) Phase 1 JZP324 Oxybate extended-release formulation Preclinical Undisclosed targets Neuroscience

Oncology

Product Candidates Description Regulatory JZP458 (recombinant Erwinia asparaginase) ALL/LBL (pivotal Phase 2/3) Phase 3 Vyxeos AML or high-risk Myelodysplastic Syndrome, or MDS (AML18 and AML 19) (cooperative group studies) Newly diagnosed adults with standard- and high-risk AML (AML Study Group cooperative group study) Newly diagnosed pediatric patients with AML (planned Children’s Oncology Group cooperative group study) Phase 2 Vyxeos High-risk MDS (European Myelodysplastic Syndromes Cooperative Group cooperative group study) Newly diagnosed older adults with high-risk AML (planned cooperative group study) Vyxeos + venetoclaxDe novo or relapsed/refractory, or R/R, AML (MD Anderson collaboration study) Phase 1 Vyxeos Low intensity dosing for higher risk MDS (MD Anderson collaboration study) Vyxeos + other approved therapies R/R AML or hypomethylating agent failure MDS (MD Anderson collaboration study) First-line, fit AML (Phase 1b study) Low intensity Vyxeos for first-line, unfit AML (Phase 1b study) Preclinical CombiPlex Haematology/oncology exploratory activities JZP341 (long-acting Erwinia asparaginase) ALL and other haematological malignancies (collaboration with Ligand Pharmaceuticals Incorporated, or Ligand) Recombinant pegaspargaseHaematological malignancies (Jazz opt-in opportunity with Ligand) Pan-Raf inhibitor programmeRaf and Ras mutant tumours (acquired from Redx, which is continuing development) Undisclosed targets Ras/Raf/MAP kinase pathway (collaboration with Redx)

7 Product Candidates Description Exosome targets (NRAS, STAT3 and 3 others)Haematological malignancies/solid tumours (collaboration with Codiak) Defitelio Exploratory activities

In 2021 and beyond, we expect that our research and development expenses will continue to increase from previous levels, particularly as we prepare for anticipated regulatory submissions and data read-outs from clinical trials, initiate and undertake additional clinical trials and related development work and potentially acquire rights to additional product candidates.

Acquisition of GW Pharmaceuticals Plc Creates Innovative High-Growth, Global Biopharma Leader In February 2021, we entered into an agreement to acquire GW with the objectives of broadening our neuroscience portfolio, further diversifying our revenue and driving sustainable, long-term value creation opportunities. Under the agreement, the total consideration to be paid by us for the entire issued share capital of GW is approximately $7,200.0 million. The GW Acquisition is expected to close in the first half of May 2021. GW specialises in discovering, developing, manufacturing and commercialising therapeutics from its proprietary cannabinoid product platform to address a broad range of diseases. GW's lead product, Epidiolex® (cannabidiol) oral solution, is approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex, all of which are rare diseases characterised by severe early- onset epilepsy. Epidiolex was the first plant-derived cannabinoid medicine ever approved by the FDA, and has also been approved in Europe under the trade name Epidyolex. In addition to the approved indications for Epidiolex, we believe there are considerable opportunities to pursue other indications within the epilepsy field, including other treatment-resistant epilepsies where significant unmet needs of patients exist. GW is leveraging its scientific platform and specialised manufacturing expertise to develop additional cannabinoid- based therapies. This pipeline includes nabiximols, for which GW is in Phase 3 clinical trials for the treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as earlier-stage cannabinoid product candidates. We view the transaction as consistent with our overall business and capital allocation strategy to expand our neuroscience portfolio and drive substantial value for our shareholders. We expect that product sales, operating expenses and interest expense, will be higher in 2021 than in 2020 due to, the impact of the inclusion of the results of operations from GW commencing on closing the GW Acquisition, the higher debt balance in connection with the GW Acquisition and the continued growth of the organisation.

Operational Excellence We remain focused on continuing to build excellence in areas that we believe will give us a competitive advantage, including building an increasingly agile and adaptable commercialisation engine and strengthening our customer-focused market expertise across patients, providers and payors. We are refining our approach to engaging our customers by strengthening alignment and integration across functions and across regions. This includes a more integrated approach to brand planning, a heightened focus on launch and operational excellence and multichannel customer engagement. We have fully adapted to virtual scientific congresses designed to ensure we can continue to provide promotional and non- promotional interactions and have supported our field-based teams with virtual customer interaction tools, training and content. These initiatives mark a significant operational evolution that is directly linked to our corporate strategy and are designed to better enable our teams to work collaboratively on an aligned and shared agenda through both virtual and in- person interactions.

COVID-19 Business Update We have implemented a comprehensive response strategy to effectively manage the impact of the COVID-19 pandemic on our employees, patients and our business. We have experienced limited financial and other impacts due to the pandemic. We expect that our business, financial condition, results of operations, and growth prospects may continue to be impacted on a limited basis by the pandemic, albeit to a lesser extent as vaccines and treatments reduce the global impact of COVID-19 and enable a resumption to more normal business practices and initiatives. We support broad public health strategies designed to prevent the spread of COVID-19 and are focused on the health and welfare of our employees. Our global organisation has mobilised to enable our employees to accomplish our most critical goals through a combination of remote work and in-person initiatives. In addition to rolling out new technologies

8 and collaboration tools, we have implemented processes and resources to support our employees in the event an employee receives a positive COVID-19 diagnosis. We have developed plans regarding the opening of our sites to enable our employees to return to work in our global offices, the field and our manufacturing facilities, which take into account applicable public health authority and local government guidelines and which are designed to ensure community and employee safety. We plan to permanently move to a more flexible mix of virtual and in-person working to advance our culture, drive innovation and agility and enable greater balance and well-being for our workforce. This will also enable us to reconfigure our physical workspaces to optimise the footprint of our company-owned or leased office spaces. Commercialisation While there continues to be some impact on demand arising from the pandemic, we have seen improvements as healthcare systems have adapted to cope with the ongoing situation. We are utilising technology to continue to engage healthcare professionals and other customers virtually to support patient care. As more clinics and institutions begin to allow in-person interactions pursuant to local health authority and government guidelines, our field teams continue to resume inperson interactions with healthcare professionals and clinics combined with virtual engagement. The level of renewed inperson engagement varies by account, region and country. The lack of access to healthcare providers has caused, and may continue to cause, delays in appropriate diagnosis, treatment and ongoing care for some patients, which could subsequently impact prescribing and use of our products. Supply Chain Our manufacturing facilities in Athlone, Ireland, which produces Xyrem and Xywav, and Villa Guardia, Italy, which produces defibrotide, are operational with essential staff onsite and office-based staff working remotely. We currently expect to have adequate global supply of Xyrem, Xywav, Sunosi, Zepzelca, Vyxeos, and Defitelio in 2021. Research and Development With respect to our clinical trial activities, we have taken measures to implement remote and virtual approaches, including remote data monitoring where possible, to maintain patient safety and trial continuity and to preserve study integrity. We have seen limited COVID-19-related impact to our mid- and late-stage clinical trial activity, despite delays in initiating trial sites. We rely on contract research organisations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the evolving effects of the COVID-19 pandemic. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact our clinical trial operations. Corporate Development and Other Financial Impacts With our strong cash balance and positive cash flow, we anticipate having sufficient liquidity to continue to make planned investments in our business in support of our long-term growth strategy. However, the COVID-19 pandemic continues to rapidly evolve and has resulted in significant volatility in the global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. The effects of the pandemic could also impact our ability to do in-person due diligence, negotiations, and other interactions to identify new opportunities. Corporate Response The COVID-19 pandemic has caused a significant burden on health systems globally and has highlighted the need for companies to evaluate existing therapies to assess if they can be utilised beyond their current indications to treat COVID-19 as well as consider developing new therapies. To this end, we have granted requests for several ISTs to evaluate the use of defibrotide in COVID-19 patients experiencing respiratory distress. In addition, we are supporting our local communities and patient-focused organisations in COVID-19 relief efforts including through corporate donations to charitable organisations providing food and medical relief to our communities in which we operate in Italy, Philadelphia and the San Francisco Bay Area, and other localities where the needs related to the impact of COVID-19 are greatest. We are engaging with patient advocacy organisations to better understand the impact of COVID-19 and working to ensure that patients living with sleep disorders and hematology and oncology conditions continue to have access to treatments and that their other needs are addressed given the impact of COVID-19 on the healthcare system. We are committed to enabling our employees to give back, including allowing licensed healthcare practitioners employed by us to support local response efforts.

9 Principal risks and uncertainties Detailsofthe principalrisks and uncertaintiesfacing the Group are set out in Appendix Btothis annual report. Results of operations and key performance indicators The following table sets forth for theyears indicatedcertain financialdataand thepercentage change in these items comparedtothe prior year, being the key performance indicators used by management (amounts in thousands):

2020 Change 2019 Productsales,net $2,346,660 10 %$2,135,601 Royaltiesand contractrevenues16,907 (35)% 26,160 Costofproductsales 575,473 (24)% 753,371 Selling, general and administrative expenses 852,394 16 %733,944 Research anddevelopment expenses 522,386 27 %410,871 Finance income 28,818 19 %24,177 Finance expense 353,914 173 %129,578 Incometax benefit$28,769 N/A (1) $156,947

(1) Comparison to prior period is not meaningful.

Total Revenues The following tablepresents productsales,royaltiesand contractrevenuesand total revenues for 2020 and 2019 (amounts in thousands):

2020 Change 2019 Xyrem$1,741,758 6% $1,642,525 Xywav 15,264 NA (1) — Total Oxybate 1,757,022 7% 1,642,525 Sunosi 28,333 663 %3,714 Total Neuroscience 1,785,355 8% 1,646,239 Zepzelca 90,380 NA (1) — Vyxeos 121,106 —% 121,407 Defitelio/defibrotide 195,842 13 %172,938 Erwinaze/Erwinase147,136 (17)% 177,465 Total Oncology 554,464 18 %471,810 Other 6,841 (61)% 17,552 Productsales,net 2,346,660 10 %2,135,601 Royaltiesand contractrevenues16,907 (35)% 26,160 Total revenues $2,363,567 9% $2,161,761

(1) Comparison to prior period is not meaningful.

ProductSales,Net Xyremproductsales increasedby6%in2020 compared to 2019, primarily due to ahigheraverage net selling price and, to alesserextent,anincreaseinsales volume, partially offsetbyhigher grosstonet deductions driven by managed care plans and commercialpayor contracts. Price increases wereinstituted in January 2020, January and July2019. Xyrem productsales volumeincreased by 3% in 2020 comparedto2019 primarilydrivenbypersistenceand compliance among existing patients. In 2020 newpatientdiagnoses and enrollments werenegativelyimpactedbyCOVID-19. Xywavproduct sales were$15.3 million in 2020 following itslaunchinNovember2020. Sunosi product sales were$28.3 million in 2020 comparedto$3.7 millionin2019. Sunosilaunched in the U.S. in July 2019 andthe European rolling launch commenced in May 2020.

10 Zepzelca product saleswere$90.4 millionin2020 following itslaunch in July 2020. Vyxeos product salesof$121.1 million in 2020 were in line with 2019. Defitelio/defibrotide productsales increasedby13% in 2020 compared to 2019, primarily due to higher sales volumes,partiallyoffsetbyloweraverage net selling price due to regional mix. Erwinaze/Erwinaseproductsales decreasedby17% in 2020 compared to 2019 primarily due to limitedavailability of supply of inventory from the manufacturer. Royaltiesand Contract Revenues Royalties and contract revenues decreased in 2020 compared to 2019, primarily due to lower milestone revenues from out-licensing agreements CostofProduct Sales Costofproductsales decreased in 2020 comparedto2019, primarilydue to adecrease in impairment charges recognised relatedtoacquired developed technologies, partiallyoffsetbyincreased intangibleassetamortisation, changes in productmix andincreases in net product sales. Impairment chargesof$163.1 million and $367.3 millionwere recognised in 2020 and 2019, respectively, relatedtoVyxeos reflecting areassessment of the estimatedfuture cash flows associatedwith this product in each period. Intangibleassetamortisation increased in 2020 comparedto2019 primarily due to the commencement of amortisation of theZepzelca intangible assetupon FDA approval in June 2020 and commencement of amortisation of theSunosi intangible assetupon U.S. Drug Enforcement Administration scheduling in June 2019, partiallyoffset by areduction in amortisation of theVyxeos intangible assetfollowing therecognition of the impairment charge in 2019. Selling, General and Administrative Expenses Selling, generaland administrative expenses increased in 2020 comparedto2019 primarilydue to increased investment in sales, marketing and launchactivitiesrelatedtothe launches of Zepzelcaand Xywavinthe U.S., andthe continuation of the launch of Sunosi in theU.S., as well as an increase in otherexpenses relatedtothe expansion of our business. Researchand Development Expenses Research anddevelopment expenses consist of costs related to clinicalstudies and outside services, personnel expenses, amortisation andimpairment of assets usedinresearchand development andotherresearch anddevelopment costs.Clinical study and outside servicescostsrelate primarily to services performed by clinical research organisations, materials and supplies, and other third party fees. Personnel expenses relateprimarilytosalaries, benefitsand share-based compensation. Otherresearch anddevelopment expenses primarilyinclude overhead allocations consisting of various support and facilities-related costs. We do not track fully-burdened researchand development expenses on aproject-by- project basis.Wemanage our research anddevelopment expenses by identifying the research anddevelopment activities thatweanticipatewillbeperformed during agiven period andthenprioritising effortsbasedonour assessment of which development activitiesare important to our business and have areasonableprobabilityofsuccess, and by dynamically allocating resources accordingly. We also continuallyreview our development pipeline projects and thestatus of their development and, as necessary, reallocate resourcesamong our development pipeline projectsthat we believe willbest support the future growth of our business. The following table providesabreakout of our researchand development expenses by major categories of expense (in thousands):

Year Ended 31 December 2020 2019 Clinicalstudiesand outside services$170,646 $133,042 Personnelexpenses 128,962 101,034 Intangibleassetamortisation 111,101 — Impairment charge 75,000 136,201 Other36,677 40,594 Total $522,386 $410,871

Researchand development expenses increasedby$111.5 million in 2020 comparedto2019. Clinical studies and outside services costs increased by $37.6 million in 2020 comparedto2019 primarilydue to the progressmade on our

11 clinical programmes, including JZP458 and JZP385. Personnel expenses increased by $27.9 million in 2020 compared to 2019, primarily due to increased headcount in support of our development programmes. Intangible asset amortisation of $111.1 million in 2020 related to the amortisation of the cost of the priority review voucher, or PRV, in full following redemption of the PRV in the submission of the NDA for Xywav in January 2020. We recorded an other non-current asset impairment charge of $75.0 million in 2020 following the decision to exercise our opt-out rights with respect to IMGN632 under the collaboration and option agreement with ImmunoGen, Inc , thereby relinquishing our development and commercialisation option. We recorded an IPR&D asset impairment charge of $136.2 million in 2019 following the decision to stop enrollment in our Phase 3 clinical study of defibrotide due to a determination that the study is highly unlikely to reach one of its primary endpoints, the prevention of VOD. Finance Income Finance income comprises interest income, gains on cash flow hedges, net gains on foreign currency forward contracts and fair value gains on embedded derivatives. Interest income decreased in 2020 compared to 2019 primarily due to lower interest rates earned on investment balances during 2020. We recognised a net gain on foreign currency forward contracts of $8.8 million in 2020. Our 1.875% exchangeable senior notes due 2021, or the 2021 Notes, our 1.50% exchangeable senior notes due 2024, or the 2024 Notes, and our 1.50% exchangeable senior notes due 2026, or the 2026 Notes, collectively referred to as the Exchangeable Senior Notes, contain embedded derivatives with economic characteristics and risks that are not closely related to the debt host contracts. The fair value of the related embedded derivative liabilities is remeasured at each reporting period, with changes in fair value recognised in the consolidated income statement. We recognised a fair value gain on embedded derivative liabilities of $8.9 million in 2020. We recognised a net gain on foreign currency forward contracts of $2.6 million in 2019. Reclassification adjustments on cash flow hedges from other comprehensive income were $1.1 million in 2019. Finance Expense Finance expense comprises interest expense, net losses on foreign currency forward contracts, loss on extinguishment of debt, foreign currency exchange loss, net, fair value losses on embedded derivatives and losses on cash flow hedges. Interest expense on borrowings increased by $3.3 million in 2020 compared to 2019, primarily due to the non-cash interest expense on the Exchangeable Senior Notes. We recorded a loss on extinguishment of debt of $17.7 million, in 2020, in connection with the partial repurchase of the 2021 Notes. Reclassification adjustments on cash flow hedges from other comprehensive income were $3.9 million in 2020. We recognised fair value losses on embedded derivative liabilities of $209.1 million in 2020 and $13.0 million in 2019. The interest expense on lease liabilities decreased by $0.3 million in 2020 compared to 2019. Foreign currency exchange loss, net increased by $3.7 million in 2020 compared to 2019 and primarily related to the translation of euro-denominated net monetary liabilities, primarily intercompany balances, held by subsidiaries with a U.S. dollar functional currency. Income Tax Benefit In 2020, we recognised an income tax benefit of $28.8 million. Our 2020 effective tax rate was (33.7)%. The effective tax rate for 2020 was lower than the Irish statutory rate of 12.5% primarily due to the impact of originating tax credits and deductions on subsidiary equity, partially offset by disallowance of certain interest deductions and provision for the settlement reached with the French tax authorities. In 2019, we recognised an income tax benefit of $156.9 million. Our 2019 effective tax rate was (101.9)%. The effective tax rate for 2019 was lower than the Irish statutory rate of 12.5% primarily due to the impact of the intra entity intellectual property asset transfer, the impairments of Vyxeos and Acquired IPR&D intangible assets and a benefit from the application of the Italian patent box incentive regime. The increase in the effective tax rate in 2020 compared to 2019 was primarily due to the impact of the intra-entity intellectual property asset transfer. Excluding this effect, the increase in the effective tax rate for 2020 compared to 2019 was primarily due to the benefit recognised in 2019 from the application of the Italian patent box incentive regime 2015 through 2019 and the impact of the disallowance of certain interest deductions and a provision for a proposed settlement reached with the French tax authorities.

Financial results and dividends The results for the year ended 31 December 2020 are set out in the consolidated income statement on page 25. The parent company did not propose or pay a dividend to the ordinary shareholders for the years ended 31 December 2020 or 2019. Financial risk management Our financial risk management objectives and policies to manage risk are set out in Note 26 to the consolidated financial statements. In 2020 and 2019, we entered into foreign exchange forward contracts to manage currency risk

12 primarily related to certain intercompany loans denominated in non-functional currencies, and interest rate swaps to hedge the interest rate exposure on a portion of our term loan borrowings. Share repurchase programme In November 2016, our board of directors authorised a share repurchase programme and as of 31 December 2020 had authorised the repurchase of up to $1.5 billion, exclusive of any brokerage commissions. Under this programme, which has no expiration date, we may repurchase ordinary shares from time to time on the open market. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the amended credit agreement, corporate and regulatory requirements and market conditions. The share repurchase programme may be modified, suspended or discontinued at any time without prior notice. In 2020, we spent a total of $146.5 million to repurchase 1.2 million of our ordinary shares at an average total purchase price, including brokerage commissions, of $121.98 per share. In 2019, we spent a total of $301.5 million to repurchase 2.3 million of our ordinary shares at an average total purchase price, including brokerage commissions, of $133.97 per share. All ordinary shares repurchased were cancelled. As of 31 December 2020, the remaining amount authorised under the share repurchase programme was $431.2 million. Non-financial reporting The EU (Disclosure of Non-Financial and Diversity Information by certain large undertakings and groups) Regulations 2017 (the “Non-Financial Information Regulations”) require us to disclose certain non-financial information in our directors’ report. The table below provides more details on where the information required to be provided by the Non- Financial Regulations has been included in our Annual Report for the financial year ended 31 December 2020. The sections referenced in the right-hand column of the table below are deemed to be incorporated within this directors’ report.

Risk Management and Additional Reporting Requirement Our Policies Information Environmental mattersEnvironmental Policy1 Environment, health and safety (page 16) Social and employee Code of Conduct2 Social and Employee matters (pages matters Employee Handbook1 13-15) Global Personal Data Privacy Policy1 Human rights Global personal data privacy policy1 Anti-corruption, Anti-bribery and Slavery and Human Trafficking Statement - 20202 Human Rights (pages 15-16) Standards of Conduct for Supply Chain1 Anti-corruption and anti- Anti-corruption policy2 Anti-corruption, Anti-bribery and bribery Human Rights (page 16) Description of the business model Principal activities, business review and future developments (pages 2-13) Description of principal risks Principal risks and uncertainties (pages 98-131)

______1. Certain Group policies and guidelines are not published externally. 2. Available on the Group website at https://www.jazzpharma.com/about/corporate-ethics/. Social and Employee matters Jazz is committed to creating a company where the culture embodies our corporate purpose to innovate to transform the lives of patients and reflects our key goals: (1) live our core values of Integrity, Collaboration, Passion, Innovation, and Pursuit of Excellence; and (2) be a great place to work. Employee Demographics As of 27 April 2021, Jazz employed 1,993 people worldwide, of which 1,289 were employed in the U.S. and 704 were outside the U.S. As an innovative biopharmaceutical company, we have over 400 full-time employees — greater than 20% of our global workforce — supporting our research and development activities. We consider our employee relations to be very good. Employee inclusion and diversity We make diversity, equity and inclusion, or DEI, a priority because it is a key to unlocking the potential of our people and living our core values.

13 We strive to create a workplace culture that fosters the ability to be your authentic self and contribute boldly. We aspire to have multi-dimensional diversity through our entire Jazz workforce. We seek to surround underrepresented groups with allies and our people practices to enable all employees to thrive equitably. Our Board and management team are committed to fostering DEI in all parts of our business. Our DEI strategy includes: (1) building a more diverse workforce in terms of gender identity, race, ethnicity and sexual orientation and that represent unique backgrounds, experiences, thoughts and talents; (2) investing in developing our diverse talent and driving equity; and (3) and creating a culture of inclusion and belonging. We designed our Employee DEI programme to empower employees to guide and support our strategy and programmes related to hiring diverse talent and using education and communication to continue fostering an inclusive environment. We also have a DEI Delegation, a committee of employees focused on helping to embed DEI into all we do. Jazz ConcERTos, our employee resource teams, are self-led teams of employee volunteers with diverse backgrounds who come together to promote innovation through inclusion and to increase awareness of all dimensions of diversity. We believe that these groups will contribute positively to Jazz’s culture and business success by working cross-functionally to drive innovation, helping to decrease unconscious bias, and encouraging employees to be their whole selves so they can perform at their best. We have established goals related to increasing all dimensions of diversity, including representation of females and people of colour, particularly at the leadership level (i.e., employees at executive director and above). In this regard, we have made some meaningful progress, as demonstrated by the following, as of 27 April 2021: •Approximately 40% of our board of directors is diverse in terms of gender and ethnicity. •45% of our Executive Committee are women. •Females represent 56% of our global workforce and 44% at the leadership level (employees at executive director and above). •In the U.S., people of colour represent 33% of our U.S. workforce and 19% at the leadership level. While we are proud of what we have accomplished to date, we recognise there is still much to do. We remain committed to furthering our goals of providing a diverse and inclusive culture that is supportive of all backgrounds, including among our broader leadership. For more information on our approach to inclusion and diversity, please see https://careers.jazzpharma.com/global/ en/diversity. Employee engagement Jazz has a strong employee value proposition anchored in our shared commitment to our purpose to innovate to transform the lives of patients. We are committed to ensuring that we create a rich culture that provides a great place to work for our employees through company-wide efforts to connect employees to our shared purpose and to create an environment where our people feel valued, respected, and able to contribute to their full potential. We believe employee engagement and the power of our employee voices is foundational to strong performance. We have transparent and regular communication channels with our employees consisting of many forms – including all employee meetings, regular communication messages from executive leadership, top leadership forums, pulse check feedback mechanisms and engagement surveys. Our employee feedback survey is designed to help us measure overall employee engagement and we consistently achieve participation rates between 80 to 90%. We consistently have high levels of engagement measured by feelings of connection to our mission, Jazz as a great place to work where their well-being is supported and they feel valued and included. It also provides important insight into the areas where we need to focus in the year ahead for several key components of our company objectives, such as decision-making, opportunities for development, and DEI. Our survey informs programmes and activities aligned with achieving our corporate objectives and achieving our goal of evolving our operating culture for agility and scalability. Our Community Beat teams are employee volunteers and representatives that promote company culture and create a sense of belonging and camaraderie among our employees. They foster programmes and engagement activities on a local level to draw better connections to employees with the company strategy and business milestones, give back through community service, and promote different health and well-being initiatives.

14 Growth, Development and Total Rewards We understand that empowering people to find new and better ways of doing things, to gain new experiences and to development new capabilities can also support our growth and achievements as a company. The exciting opportunities within our business provide rich and ample learning opportunities and experiences for career growth. Our talent strategy is focused on attracting the best talent, recognising and rewarding the performance of our employees as defined by both what they accomplished and how they accomplished it, and continually developing our talent through new experiences and learning opportunities. We recently launched a new performance management system to support our culture of learning, feedback, and continual growth. We encourage all employees to have an individual development plan to outline learning and growth interests and focus areas. We invest in manager and leadership development that emphasises the important behaviours and values to successfully lead others and promote our culture. We offer tuition reimbursement in our major markets aimed at growth and career development. Our management and leadership teams place significant focus and attention to diversity, capability development, and succession planning for critical roles. We regularly review talent development and succession plans for each of our functions to successfully maintain business operations and develop a pipeline of talent. We have goals concerning employee retention, diversity, and talent development. We provide our employees with what we believe to be market competitive and locally relevant compensation and benefits that support our overarching strategy to attract, retain and reward highly talented employees in an extremely competitive and dynamic industry. We strive to create a culture of health and well-being throughout the organisation by offering a diverse and customisable set of programmes focusing on employee experience, self-care, work-life balance, flexibility and early intervention. In addition to traditional employee benefits, Jazz supports employees and their families through access to a suite of innovative programmes that are designed to enhance their physical, financial, emotional and social well-being. Workplace Safety & Employee Care During COVID-19 Workplace safety is always a top priority for Jazz. To create and sustain a safe and healthy workplace, we have implemented initiatives designed to address risk evaluation, education and training of employees, use of appropriate personal protective equipment, and compliance with relevant national and international health and safety standards. In response to COVID-19, we launched a new employee support framework focused on Care, Connection, Continuity and Consciousness (our “4Cs”) to enable our employees to live into our values and support one another while doing everything we can to deliver on our patient mission. Important to this framework were new leader expectations and tools given the rise and complexity of emerging employee demands and needs – including more flexibility to address personal needs, a greater connection to understand the whole person and their lives, and more active support surrounding social injustice. For example, we provided productivity and collaboration tools and resources for employees working remotely, including training and toolkits to help leaders effectively lead and manage remote teams; increased flexibility within work schedules and leave programmes to support employees caring for children and others; expanded employees assistance and mindfulness programmes to help employees and their families manage anxiety, stress, and overall wellbeing; and increased investment in resources focused on inclusion and belonging. Anti-corruption, Anti-bribery and Human Rights We are committed to conducting our business with integrity and the pursuit of excellence in all that we do. Our management team and our Board of Directors are committed to honesty and compliance with all laws, rules, regulations and corporate policies that apply to our business, and we expect the same commitment from our employees, consultants, business partners and service providers. In particular, we are committed to acting responsibly, safely and with transparency in our interactions with patients, doctors and other stakeholders in the healthcare system. We have adopted a Comprehensive Compliance Programme (“CCP”). Under the CCP, it is the role of the Chief Compliance Officer to develop a plan for auditing and monitoring compliance with the CCP, with the purpose of those audits being to identify potential or existing problem areas and to take corrective measures in an effort to prevent a recurrence of non-compliance. To the best of our knowledge, as of 1 July 2020, we were in compliance with the CCP and our good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402. For more information, please see https://www.jazzpharma.com/our-purpose/ethical-standards/. Our Code of Conduct is another element of our efforts to ensure lawful and ethical conduct by us, our employees and directors. It is part of a larger process that includes compliance by all our employees and directors with our corporate policies and procedures, open communication, and the use and expectation of the highest integrity and good judgment.

15 Every year, all our employees and our directors are trained on and agree to abide by our Code of Conduct. Please see https://www.jazzpharma.com/code-of-conduct/ for the complete text of our Code of Conduct. A number of our policies and standard operating procedures complement the Code of Conduct, and where appropriate, these policies and standard operating procedures form part of our employees’ training plans, which we routinely evaluate. It is our policy and commitment to conduct our business in a manner designed to maintain a culture of honesty and opposition to fraud and corruption. We are committed to complying with all applicable anti-corruption and anti-bribery laws, including the Foreign Corrupt Practices Act and the United Kingdom Bribery Act. To help ensure compliance with these laws, all employees and directors of the company, its subsidiaries and affiliates, and third party vendors and other agents acting on our behalf are trained on and agree to abide by our global Anti-Corruption Policy. For more information, please see https://www.jazzpharma.com/our-purpose/ethical-standards/. We have a well-established vendor due diligence, risk assessment and on-boarding process for supply chain and partner markets. We comply with the Modern Slavery Act 2015 and the Californian Transparency in Supply Chain Acts to help tackle slavery and human trafficking. In particular, as set out in our Slavery and Human Trafficking Statement – 2020, we have adopted procedures for assessing suppliers that provide materials for use in our tangible goods for sale and have enhanced these procedures to include steps for evaluating whether our product suppliers comply with applicable laws related to eradication of human trafficking, slavery and illegal child labour. Our Supply Chain and Quality Assurance teams oversee these verification procedures using an internally-developed multi-part assessment. In addition, we have adopted written Standards of Conduct for Supply Chain and request that our product suppliers certify that they comply with applicable laws concerning human trafficking, slavery and illegal child labour in the countries in which they do business. For more information, please see https://www.jazzpharma.com/our-purpose/ethical-standards/. We have also established various methods of confidential communication for our employees, vendors and others to report suspected violations of laws, rules, regulations or company policies, including our Compliance Hotline. For more information, please see https://www.jazzpharma.com/about/corporate-ethics/. Where permitted by local laws, anonymous reporting is also available. Environment, health and safety Our operations are subject to complex and increasingly stringent environmental, health and safety laws and regulations in the countries where we operate and, in particular, in Italy and Ireland where we have manufacturing facilities. Our manufacturing activities involve the controlled storage, use and disposal of chemicals and solvents. Environmental and health and safety authorities in Italy and Ireland administer laws governing, among other matters, the emission of pollutants into the air (including the workplace), the discharge of pollutants into bodies of water, the storage, use, handling and disposal of hazardous substances, the exposure of persons to hazardous substances, and the general health, safety and welfare of employees and members of the public. We seek to operate our manufacturing facilities in an environmentally responsible way to protect our people, our business, our environment and the local communities in which we operate. In light of the potential impact of our business on the environment, we have adopted a number of internal environmental policies and management systems designed to manage our operations in compliance with applicable laws, directives and regulations on environmental protection and in support of environmental sustainability and local biodiversity. Our environmental policies and management systems include procedures for assessing compliance with applicable environmental laws and regulations and reporting incidents of non-compliance to applicable governmental authorities. For example, we have environmental policies governing both of our manufacturing facilities in Athlone, Ireland and Villa Guardia (Como), Italy, which demonstrate our commitment to environmental sustainability and require us to minimise resource use (e.g., energy and water) and waste generation, optimise the use of raw materials, and undertake continuous improvement in environmental performance, with an emphasis on pollution prevention.

16 Directors’ and secretary’s interests The names of the directors and the secretary are set out on page 1. None of the directors, the secretary or members of their immediatefamilieshad anyinterest in sharesordebentures of any subsidiary. Directors’ emolumentsisset forth in Note 10 to theconsolidatedfinancial statements. The interests of the directors and secretary, in office as at 31 December2020, in theordinary share capital of Jazz Pharmaceuticals plcare shown in the table below:

Ordinary Shares (1) As at 1January 2020 Ordinary Shares (1) (or date of appointment,iflater) As at 31 December 2020 Deferred Deferred Shares Shares OptionsRSUs SharesShares OptionsRSUs Directors: Bruce C. Cozadd 198,338 —692,924 102,800 210,832 —816,029 116,650 Paul L. Berns 6,046 4,691 31,085 1,920 7,035 —37,850 2,705 Jennifer Cook ———— —— —— PatrickG.Enright 15,743 9,929 8,540 1,920 17,663 —15,305 2,705 Peter Gray7,395 —30,085 1,920 9,315 —36,850 2,705 Heather Ann McSharry6,717 —30,085 1,920 7,628 —36,850 2,705 Seamus Mulligan 1,100,868 —31,085 1,920 1,152,788 —37,850 2,705 KennethW.O’Keefe 8,169 22,249 26,585 1,920 15,962 —33,350 2,705 Anne O'Riordan——11,905 4,760 2,867 18,670 4,598 Norbert G. Riedel, Ph.D. 5,765 —30,085 1,920 6,754 —36,850 2,705 ElmarSchnee5,277 —23,785 1,920 7,197 —30,550 2,705 MarkD.Smith, M.D. ———— —— —— Catherine A. Sohn, Pharm.D. 6,928 —34,585 1,920 7,917 —28,850 2,705 Rick EWinningham2,504 —22,085 1,920 3,493 —28,850 2,705 Secretary: Aislinn Doody 44 —9,925 2,632 27 —9,925 3,431 ______(1) Allinterests declaredare in theordinary shares of $0.0001 par value of Jazz Pharmaceuticals plc. Political donations The Group made no politicaldonations during 2020 or 2019 thatwouldrequire disclosure under theElectoral Act, 1997. Accounting records The directors believe thatthey have compliedwith therequirements of Sections 281 to 285 of the Companies Act 2014 with regard to maintaining adequate accounting records by employing personnel with appropriate expertise and by providing adequateresources to thefinancialfunction. The accounting records are maintained by theparent company at its officeat5th Floor, Waterloo Exchange,Waterloo Road, Dublin4,D04 E5W7, Ireland. Going concern The directors, having made enquiries, believe thatthe Group and parent company have adequate resourcesto continue in operationalexistencefor theforeseeable future and that it is appropriate to continue to adopt the going concern basis in preparing theGroup and parent company financialstatements. Subsequent events Detailsofmaterial events subsequent to thereporting dateare setout in Note 30 to the consolidated financial statements.

17 Audit committee We have an audit committee which acts on behalf of the directors of Jazz Pharmaceuticals plc in fulfilling the directors’ oversight responsibilities with respect to the company’s corporate accounting and financial reporting processes, the systems of internal control over financial reporting and audits of financial statements, as well as the quality and integrity of the company’s financial statements and reports and the qualifications, independence and performance of the firm or firms of external auditors engaged as the company’s independent registered auditors for the purpose of preparing or issuing an audit report or performing audit services and the performance of the company’s internal audit function. Disclosure of information to auditors The directors believe that they have taken all steps necessary to make themselves aware of any relevant audit information and have established that the Group’s statutory auditors are aware of that information. In so far as they are aware, there is no relevant audit information of which the Group’s statutory auditors are unaware. Directors' compliance statement We acknowledge that we are responsible for securing the company’s compliance with its relevant obligations as defined in Section 225 of the Companies Act 2014. We confirm that: •Acompliance policy statement has been drawn up setting out the company’s policies; •Appropriate arrangements and structures that are, in our opinion, designed to secure material compliance with the company’s relevant obligations, have been put in place; and •Areview has been conducted, during the financial year, of the arrangements and structures that have been put in place to secure the company’s compliance with its relevant obligations. Independent auditor In accordance with Section 383 (2) of the Companies Act 2014, KPMG, Chartered Accountants will continue in office.

On behalf of the board

Peter Gray Heather Ann McSharry 4 May 2021 Director Director

18 Jazz Pharmaceuticals plc Statement of Directors' Responsibilities in respect of the Directors’ Report and the Financial Statements

The directors are responsible for preparing the directors’ report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the Group financial statements in accordance with International Financial Reporting Standards, or IFRS, as adopted by the EU, and have elected to prepare the parent company financial statements in accordance with IFRS as adopted by the EU and applied in accordance with the Companies Act 2014.

Under company law, the directors must not approve the group and parent company financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the group and parent company and of the profit or loss for that year and otherwise comply with the Companies Act 2014. In preparing these financial statements, the directors are required to: •select suitable accounting policies and then apply them consistently; •make judgements and estimates that are reasonable and prudent; •state whether applicable Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; •assess the Group and parent company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and •use the going concern basis of accounting unless they either intend to liquidate the Group or parent company or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the Group and parent company and enable them to ensure that the financial statements comply with the Companies Act 2014. They are responsible for such internal controls as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Group and the parent company and to prevent and detect fraud and other irregularities. The directors are also responsible for preparing a directors’ report that complies with the requirements of the Companies Act 2014.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the Republic of Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

On behalf of the board

Peter Gray Heather Ann McSharry 4 May 2021 Director Director

19 Independent auditor’s report to the members of Jazz Pharmaceuticals plc Report on the audit of the financial statements Opinion We have audited the financial statements of Jazz Pharmaceuticals Plc (“the Parent Company”, “the Company”) and its consolidated undertakings (together, “the Group”) for the year ended 31 December 2020 , which comprise the consolidated income statement, the consolidated statement of comprehensive income, the consolidated and parent company balance sheets, the consolidated and parent company statements of cash flows, the consolidated and parent company statements of changes in shareholders’ equity and the related notes, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and International Financial Reporting Standards (“IFRS”) as adopted by the European Union and, as regards the Parent Company financial statements, as applied in accordance with the provisions of the Companies Act 2014. In our opinion: ▪ the financial statements give a true and fair view of the assets, liabilities and financial position of the Group and Parent Company as at 31 December 2020 and of the Group’s profit for the year then ended; ▪ the Group financial statements have been properly prepared in accordance with IFRS as adopted by the European Union; ▪ the Parent Company financial statements have been properly prepared in accordance with IFRS as adopted by the European Union, as applied in accordance with the provisions of the Companies Act 2014; and ▪ the Group and Parent Company financial statements have been properly prepared in accordance with the requirements of the Companies Act 2014. Basis for opinion We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We have fulfilled our ethical responsibilities under, and we remained independent of the Group in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (“IAASA”), as applied to listed entities. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Conclusions relating to going concern In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Our evaluation of the director’s assessment of the entity’s ability to continue to adopt the going concern basis of accounting included: –Evaluating the Group’s existing access to sources of financing, including undrawn committed bank facilities; –Comparing forecasted sales to recent historical financial information; –Evaluating the Group’s disclosures on going concern against the requirements of IAS 1. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group’s or the Parent Company’s ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

20 Independent auditor’s report to the members of Jazz Pharmaceuticals plc (continued) Key audit matters: our assessment of risks of material misstatement Key audit matters are those matters that, in our professional judgement, were of most significance in the audit of the financial statements and include the most significant assessed risks of material misstatement (whether or not due to fraud) identified by us, including those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing the efforts of the engagement team. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In arriving at our audit opinion above, the key audit matters, in decreasing order of audit significance, were as follows: 1. Assessment of the carrying value for the Vyxeos intangible asset, $960.8 million (2019 - $1.2 billion) Refer to note 2 (accounting policy), note 3 (critical accounting policy) and note 13 (financial disclosures) The key audit matter The Group reviews finite-lived intangible assets for impairment when events or circumstances indicate that the carrying value of such assets may not be recoverable. The recoverability of the carrying values of intangible assets is contingent on estimated discounted future cash flows. There is a risk that the assets will be impaired if actual cash flows do not meet the Group’s expectations. The Vyxeos intangible asset balance as at 31 December 2020 was $960.8 million. As disclosed in note 13, the Group recorded an impairment charge of $163.1 million in 2020 relating to Vyxeos, which reflects a reassessment of the estimated future cash flows associated with this product. We identified the assessment of the carrying value of the Vyxeos intangible asset as a key audit matter due to the high degree of subjectivity involved in assessing the significant assumptions upon which the estimated discounted future cashflows are dependent, specifically certain revenue forecasts, the impact of the expiry of patents and the selection of discount rates. How the matter was addressed in our audit We undertook, amongst others, the following procedures: •We evaluated the design and tested the operating effectiveness of certain internal controls over the Vyxeos intangible asset impairment review process, including the Group’s control related to the development of the revenue forecasts for Vyxeos; •We evaluated the reasonableness of management’s revenue forecasts for Vyxeos by comparing significant assumptions to (1) company-specific operational information and management’s communications to the Board of Directors and (2) available industry or other third-party reports on expected market opportunities; •We assessed the Group’s ability to accurately forecast revenues by comparing historical forecasted revenues for Vyxeos to actual results; and •We performed a sensitivity analysis over Vyxeos estimated undiscounted future cash flows to assess the impact of changes to those forecasts on the Group’s determination of the carrying value of Vyxeos. As a result of our work, we determined that the impairment charge of $163.1 million relating to Vyxeos was reasonable. We found that the judgements made by management were supported by reasonable assumptions and that the Group’s disclosures were appropriate.

21 Independent auditor’s report to the members of Jazz Pharmaceuticals plc (continued) 2. Recoverability of U.S. deferred tax assets (“DTAs”), $719.8 million (2019 - $529.7 million). Refer to note 2 (accounting policy), note 3 (critical accounting policy) and note 11 (financial disclosures) The key audit matter We focused on the recoverability of the U.S. DTAs related to tax benefits arising from U.S. net operating losses (“NOLs”) and tax credits carried forward. Management prepares forecasts of future taxable income to assess recoverability of the U.S DTAs. There is a risk that the assets will be impaired if the future taxable income does not meet the Group’s expectations. We identified the recoverability of the U.S. deferred tax assets as a key audit matter due to the extent of specialised skills or knowledge needed and the subjectivity involved in assessing the Group’s forecast of sufficient future taxable income. The future taxable income forecasts generated by the Group contain a number of significant judgements and estimates including revenue forecasts, the success of new product launches, the timing of generics entering the market in respect of existing products following patent expiry, profit margins, and discount rates. In particular, evaluating the Group’s U.S. revenue forecasts involved a high degree of management judgement. How the matter was addressed in our audit We undertook, amongst others, the following procedures: •We evaluated the design and tested the operating effectiveness of certain internal controls over the Group’s deferred tax asset valuation allowance process including controls related to the development of U.S. revenue forecasts; •We evaluated the reasonableness of management’s revenue forecasts for products sold in the U.S. by comparing significant assumptions to (1) company-specific operational information and management’s communication to the Board of Directors and (2) available industry or other third-party reports on expected market opportunities; •We involved income tax professionals with specialised skills and knowledge, who assisted in performing a technical assessment of the Group’s tax positions, application of relevant tax regulations and utilisation of NOLs and tax credits; and •To assess the Group’s ability to forecast, for products sold in the U.S., we compared the Group’s historical forecasted revenues to actual historic outcomes. As a result of our work, we found that the judgements made by management were supported by reasonable assumptions and that the Group's disclosures were appropriate. 3. Parent Company key audit matters Due to the nature of the Parent Company’s activities, there are no key audit matters that we are required to communicate in accordance with ISAs (Ireland). Our application of materiality and an overview of the scope of our audit Materiality for the Group financial statements as a whole was set at $19.5 million (2019: $30 million). This has been calculated with reference to a benchmark of profit before taxes. Materiality represents 4.5% of this benchmark adjusted for the Vyxeos impairment charge, Priority Review Voucher amortisation and Immunogen impairment charge (2019: 4.5%). We report to the Audit Committee all corrected and uncorrected misstatements we identified through our audit with a value in excess of $0.7 million (2019: $1.4 million), in addition to other audit misstatements below that threshold that we believe warranted reporting on qualitative grounds. Of the Group’s five (2019: five) reporting components, we subjected two (2019: two) to full scope audits for group purposes and three (2019: three) to audits of account balances and specified risk-focused audit procedures. The latter were not individually financially significant enough to require a full scope audit for Group purposes but did present specific individual risks that needed to be addressed or were included in the scope of our Group reporting work in order to provide further coverage over the Group’s results. Materiality for the Parent Company financial statements as a whole was set at $19.5 million (2019: $28 million). This was determined with reference to a benchmark of net assets, of which it represents 0.7% (2019: 1.2%). We reported to the Audit Committee any corrected or uncorrected identified misstatements exceeding $0.7 million (2019: $1.4 million), in addition to other identified misstatements that warranted reporting on qualitative grounds.

22 Independent auditor’s report to the members of Jazz Pharmaceuticals plc (continued) We applied Group and Parent Company materiality to assist us determine the overall audit strategy for the Group and Parent Company, what risks were significant risks and determine the audit procedures to be performed. Other information The directors are responsible for the other information presented in the Annual Report together with the financial statements. The other information comprises the information included in the directors’ report. The financial statements and our auditor’s report thereon do not comprise part of the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except as explicitly stated below, any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether, based on our financial statements audit work, the information therein is materially misstated or inconsistent with the financial statements or our audit knowledge. Based solely on that work we have not identified material misstatements in the other information. Based solely on our work on the other information undertaken during the course of the audit, we report that, in those parts of the directors' report specified for our consideration: ▪ we have not identified material misstatements in the directors’ report; ▪ in our opinion, the information given in the directors’ report is consistent with the financial statements; ▪ in our opinion, the directors’ report has been prepared in accordance with the Companies Act 2014. Our opinions on other matters prescribed by the Companies Act 2014 are unmodified We have obtained all the information and explanations which we consider necessary for the purpose of our audit. In our opinion, the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited and the Company’s financial statements are in agreement with the accounting records. We have nothing to report on other matters on which we are required to report by exception The Companies Act 2014 requires us to report to you if, in our opinion, •the disclosures of directors’ remuneration and transactions required by Sections 305 to 312 of the Act are not made. •the Company has not provided the information required by section 5(2) to (7) of the European Union (Disclosure of Non-Financial and Diversity Information by certain large undertakings and groups) Regulations 2017 for the year ended 31 December 2019 as required by the European Union (Disclosure of Non-Financial and Diversity Information by certain large undertakings and groups) (amendment) Regulations 2018. We have nothing to report in this regard. Respective responsibilities and restrictions on use Directors’ responsibilities As explained more fully in their statement set out on page 19, the directors are responsible for: the preparation of the financial statements including being satisfied that they give a true and fair view; such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error; assessing the Group and Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting unless they either intend to liquidate the Group or the Company or to cease operations, or have no realistic alternative but to do so. Auditor’s responsibilities for the audit of the financial statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

23 Independent auditor’s report to the members of Jazz Pharmaceuticals plc (continued) A fuller description of our responsibilities is provided on IAASA’s website at http://www.iaasa.ie/Publications/ Auditing-standards/International-Standards-on-Auditing-for-use-in-Ire/Description-of-the-auditor-s-responsibilities- for. The purpose of our audit work and to whom we owe our responsibilities Our report is made solely to the Company’s members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company’s members, as a body, for our audit work, for our report, or for the opinions we have formed.

Emer McGrath 4 May 2021 for and on behalf of KPMG Chartered Accountants, Statutory Audit Firm 1 Stokes Place, St. Stephen’s Green, Dublin 2

24 Jazz Pharmaceuticals plc ConsolidatedIncome Statement forthe year ended31December2020

Notes 2020 2019 (in thousands exceptper share data) Revenues-continuing activities Productsales,net $2,346,660 $2,135,601 Royaltiesand contractrevenues 16,907 26,160 Total revenues 52,363,567 2,161,761 Costofproductsales (575,473) (753,371) Gross margin1,788,094 1,408,390 Operating expenses: Selling, generaland administrative (852,394) (733,944) Researchand development (522,386) (410,871) Total operating expenses (1,374,780) (1,144,815) Operating profit413,314 263,575 Finance income 828,818 24,177 Finance expense 8(353,914) (129,578) Netfinanceexpense(325,096) (105,401) Share of loss of equity-accountedinvestees (2,962) (4,089) Profit before income taxes 85,256 154,085 Incometax benefit 11 28,769 156,947 Netprofitfor theyear$114,025 $311,032

Earnings perordinary share: Basic 12 $2.05 $5.48 Diluted12$ 2.00 $5.37

Weighted-average shares used in computing earnings pershare: Basic 12 55,712 56,749 Diluted1256,937 57,929 The accompanying notesform an integral part of these consolidated financialstatements.

25 Jazz Pharmaceuticals plc ConsolidatedStatementofComprehensive Income for theyearended31December2020

Notes 2020 2019 (in thousands) Netprofitfor theyear$114,025 $311,032 Othercomprehensive income (loss): Items that maybesubsequently reclassified to profit or loss: Foreign currencytranslation adjustments2491,293 (22,685) Netloss on cashflow hedges, net of tax24(1,142) (4,882) Othercomprehensive income (loss)90,151 (27,567) Total comprehensive income $204,176 $283,465 The accompanying notesform an integral part of these consolidated financialstatements.

26 Jazz Pharmaceuticals plc Consolidated Balance Sheet as at 31 December 2020

Notes 2020 2019 (in thousands) ASSETS Non-current assets: Goodwill and intangible assets 13 $3,251,267 $3,346,228 Property, plant and equipment 14 128,939 132,615 Right-of-use assets 23 122,959 136,086 Deferred tax assets 11 719,780 529,735 Non-current income tax receivable —19,173 Other non-current assets 16 43,159 123,367 Total non-current assets 4,266,104 4,287,204 Current assets: Inventories 17 95,621 78,833 Trade and other receivables, net 18 484,878 418,058 Income tax receivable 333 — Derivative financial instruments 15 11,907 2,508 Financial assets at fair value through profit or loss 26 —14,765 Cash and cash equivalents 19 1,057,769 637,344 Investments 19 1,075,000 440,000 Total current assets 2,725,508 1,591,508 Total assets $6,991,612 $5,878,712 LIABILITIES AND SHAREHOLDERS’EQUITY Current liabilities: Accounts payable $26,946 $45,732 Accruals and other current liabilities 20 348,563 267,920 Provisions 21 2,593 2,760 Loans and borrowings 22 243,635 33,387 Derivative financial instruments 15 3,625 1,037 Income tax payable25,149 10,801 Deferred revenue 2,546 4,720 Total current liabilities653,057 366,357 Non-current liabilities: Loans and borrowings 22 1,892,049 1,577,607 Lease liabilities, less current portion 23 140,035 151,226 Derivative financial instrument 15 424,469 84,627 Deferred tax liabilities 11 337,476 414,958 Income tax payable 99,928 107,851 Other non-current liabilities 20 1,220 862 Provisions 21 1,412 572 Deferred revenue 2,315 4,861 Total non-current liabilities 2,898,904 2,342,564 Total liabilities 3,551,961 2,708,921 Shareholders’ equity: Ordinary shares 24 66 Non-voting euro deferred shares 24 55 55 Other capital reserves24(1,018,499) (1,018,499) Share premium 24 18,908 870,380 Share-based compensation reserve 24 880,150 767,610 Other reserves 24 (134,523) (224,674) Retained earnings 3,693,554 2,774,913 Total shareholders’ equity 3,439,651 3,169,791 Total liabilities and shareholders’equity $6,991,612 $5,878,712 The accompanying notes form an integral part of these consolidated financial statements.

On behalf of the board

Peter Gray Heather Ann McSharry 4May 2021 Director Director

27 Jazz Pharmaceuticals plc ConsolidatedStatementofChangesinShareholders’ Equityfor theyearended31December2020

Non-votingEuro Share- Ordinary Shares Deferred based Compen- Total Other Capital Share sation Other Retained Shareholders’ Shares Amount Shares Amount Reserves Premium Reserve Reserves Earnings Equity (in thousands) Balance as at 1January 2019 57,504 $64,000 $55$(1,018,499) $812,548 $667,160 $(197,107) $2,765,403 $3,029,566 Cumulative effectadjustment from adoption of new accounting standards ———— ————(72) (72) Comprehensive income Profitfor theyear ———— ————311,032 311,032 Other comprehensive loss ———— ———(27,567) —(27,567) Total comprehensive income 283,465 Transactions with owners of the company, recogniseddirectly in equity: Contributions anddistributions: Issuance of ordinary shares 886 ——— —57,832 —— —57,832 Sharerepurchases (2,250) ——— ————(301,450) (301,450) Share-based compensation ———— ——114,096 ——114,096 28 Payment of withholding taxes ———— ——(16,739) ——(16,739) Excesstax benefit ———— ——3,093 ——3,093 Balance as at 31 December2019 56,140 64,000 55 (1,018,499) 870,380 767,610 (224,674) 2,774,913 3,169,791 Comprehensive income Profit for the year ———— ————114,025 114,025 Othercomprehensive income ———— ———90,151 —90,151 Total comprehensive income 204,176 Transactions with owners of the company, recogniseddirectly in equity: Contributions anddistributions: Issuance of ordinary shares 1,232 ——— —99,681 —— —99,681 Sharerepurchases (1,201) ——— ————(146,537) (146,537) Share-based compensation ———— ——124,838 ——124,838 Payment of withholding taxes ———— ——(16,877) ——(16,877) Excesstax benefit ———— ——4,579 ——4,579 Sharepremium reduction ———— —(951,153) ——951,153 — Balanceasat31December 2020 56,171 $64,000 $55$(1,018,499) $18,908 $880,150 $(134,523) $3,693,554 $3,439,651 The accompanying notesform an integral part of these consolidated financialstatements. Jazz Pharmaceuticals plc ConsolidatedStatementofCash Flows for theyearended31December2020 2020 2019 (in thousands) Operating activities Profit for the year $114,025 $311,032 Adjustments to reconcile profittonet cash provided by operating activities: Amortisation of intangible assets 374,544 258,895 Share-based payment expense 124,742 113,353 Impairment charges 238,052 503,467 Depreciation of property, plant and equipment 18,779 15,441 Depreciation of right-of-use assets 16,457 17,666 Distribution from equity-accounted investees 5,438 — Net interest expense 103,909 86,560 Loss on extinguishment of debt 17,706 — Fair value loss,net on embedded derivatives 200,209 13,029 Income tax benefit (28,769) (156,947) Provision for losses on accounts receivableand inventory 15,000 6,668 Other non-cash transactions 14,580 59 Changes in assetsand liabilities: Trade and other receivables (62,427) (105,618) Inventories (30,537) (32,790) Non-current assets 21,913 (18,919) Accounts payable, accruals and other liabilities 40,791 13,613 Deferred revenue (4,720) (5,414) Cash generated by operating activities 1,179,692 1,020,095 Interest paid (50,722) (51,588) Income taxespaid (226,823) (183,610) Net cash provided by operating activities 902,147 784,897 Investing activities Acquisition of investments (2,397,675) (917,100) Proceeds from maturityofinvestments 1,755,000 985,000 Purchase of intangibleassets (113,000) (80,500) Acquisition of in-process research and development (251,508) (87,700) Purchases of property, plant and equipment (15,004) (40,135) Interest received 11,125 20,460 Net proceeds from sale of assets 14,259 14,209 Asset acquisition, net of cash acquired —(55,074) Net cash used in investing activities (996,803) (160,840) Financing activities Gross proceeds from issuance of Exchangeable Senior Notes, due 2026 1,000,000 — Transaction costs related to issuance of Exchangeable Senior Notes, due 2026 (18,619) — Proceeds from revolving credit facility 500,000 — Proceeds from employee share purchases and exercise of share options 99,681 57,832 Share repurchases (146,537) (301,450) Payment of employee withholding taxes upon exercise of share-based awards (16,877) (16,739) Repayment of long-term debt (33,387) (33,387) Paymentsfor partial repurchase of Exchangeable Senior Notes, due 2021 and partial settlement of the associated embedded derivative (356,188) — Repaymentsunder revolving credit facility (500,000) — Repayment of lease liabilities (13,366) (2,957) Net cash provided by (used in) financing activities 514,707 (296,701) Effect of exchange rates on cash and cash equivalents 374 366 Net increase in cash and cash equivalents 420,425 327,722 Cash and cash equivalents, at beginning of year 637,344 309,622 Cash and cash equivalents, at end of year $1,057,769 $637,344 The accompanying notesform an integral part of these consolidated financialstatements.

29 Jazz Pharmaceuticals plc Parent Company BalanceSheet as at 31 December2020

31 December Notes 2020 2019 (in thousands) ASSETS Non-current assets: Investmentsinsubsidiaries 29(a) $2,905,315 $2,800,811 Right-of-useassets 29(d) 9,101 11,409 Amountsdue from group undertakings 18,675 6,019 Total non-current assets 2,933,091 2,818,239 Current assets: Cash and cash equivalents 129 183 Trade andotherreceivables 29(b) 72,109 185,175 Total current assets 72,238 185,358 Total assets$3,005,329 $3,003,597

LIABILITIESAND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable$227 $462 Accrualsand other current liabilities 29(c) 203,503 606,626 Total current liabilities203,730 607,088 Lease liabilities, less current portion 29(d) 8,732 10,291 Total liabilities 212,462 617,379 Shareholders’ equity: Ordinary shares2466 Non-voting euro deferredshares245555 Otherundenominatedcapital 24 472 472 Share premium 24 18,908 870,380 Share-basedcompensation reserve 24 743,355 635,394 Retainedearnings 2,030,071 879,911 Total shareholders’ equity 2,792,867 2,386,218 Total liabilities andshareholders’ equity $3,005,329 $3,003,597 The accompanying notesform an integral part of these parent company financial statements.

On behalfofthe board

PeterGray Heather Ann McSharry 4May 2021 Director Director

30 Jazz Pharmaceuticals plc ParentCompany StatementofChangesinShareholders’ Equity for theyearended31December2020

Non-votingEuro Ordinary Shares Deferred Other Share-based Total Number Number of Undenominated Share Compensation Retained Shareholders’ of Shares Amount Shares Amount Capital Premium Reserve Earnings Equity (in thousands) Balance as at 1January 2019 57,504 $6 4,000 $55$ 472 $812,548 $538,037 $456,784 $1,807,902 Comprehensive loss: Profitfor theyear —— —— —— —724,577 724,577 Total comprehensive income 724,577 Transactions with owners of the company, recognised directly in equity: Contributions anddistributions: Issuance of ordinary shares 886 ————57,832 ——57,832 Share repurchases

31 (2,250) ——————(301,450) (301,450) Share-basedcompensation —— —— ——114,096 —114,096 Payment of withholding taxes —— —— ——(16,739) —(16,739) Balance as at 31 December2019 56,140 64,000 55 472 870,380 635,394 879,911 2,386,218 Comprehensive income: Profitfor theyear —— —— —— —345,544 345,544 Total comprehensive income 345,544 Transactions with owners of the company, recognised directly in equity: Contributions anddistributions: Issuance of ordinary shares 1,232 ————99,681 ——99,681 Share repurchases (1,201) ——————(146,537) (146,537) Share-basedcompensation —— —— ——124,838 —124,838 Payment of withholding taxes —— —— ——(16,877) —(16,877) Sharepremium reduction —— —— —(951,153) —951,153 — Balanceasat31December 2020 56,171 $6 4,000 $55$ 472 $18,908 $743,355 $2,030,071 $2,792,867 The accompanying notesform an integral part of these parent company financial statements. Jazz Pharmaceuticals plc Parent Company StatementofCash Flows for theyearended31December2020

2020 2019 (in thousands) Operating activities Netprofitfor theyear $345,544 $724,577 Adjustmentstoreconcilenet incometonet cash generated by operating activities: Share-based payment expense 4,891 4,790 Netinterestexpense 505 591 Depreciation of right-of-use assets 2,297 2,263 Changes in assetsand liabilities: Accountspayable,accruals andotherliabilities (1,532) (140) Trade andotherreceivables (2,410) (212) Amountsdue fromsubsidiary undertakings, net (45,860) 8,638 Cash generated by operating activities 303,435 740,507 Interest paid (505) (591) Net cash providedbyoperating activities302,930 739,916 Investingactivities Return on investment in subsidiary undertakings 15,442 14,218 Net cash providedbyinvesting activities15,442 14,218 Financing activities Share repurchases (146,537) (301,450) Net movement in group cash pool 133,924 (132,986) Net repayment of loans to subsidiary undertakings (386,434) (358,676) Proceeds from employeeshare purchasesand exercise of share options 99,681 57,832 Payment of employeewithholding taxesupon exercise of share-basedawards (16,877) (16,739) Net repayment of leaseliabilities (2,183) (2,119) Net cash used in financing activities (318,426) (754,138) Net decrease in cash and cash equivalents (54) (4) Cash and cash equivalents at beginning of year183 187 Cash and cash equivalents at endofyear$129 $183 The accompanying notesform an integral part of these parent company financial statements.

32 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements

1. Description of Business, Statement of Compliance and Basis of Preparation

Description of the business Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercialising life-changing medicines that transform the lives of patients with serious diseases – often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Our lead marketed products are: •Xyrem® (sodium oxybate) oral solution, a product approved by the U.S. Food and Drug Administration, or FDA, and marketed in the U.S. for the treatment of both cataplexy and excessive daytime sleepiness, or EDS, in narcolepsy patients seven years of age and older; •Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product that contains 92% less sodium than Xyrem, approved by FDA and launched in the U.S. in November 2020 for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; •Sunosi® (solriamfetol), a product approved by FDA and marketed in the U.S. and in Europe to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea; •Zepzelca™ (lurbinectedin), a product approved by FDA in June 2020 and launched in July 2020 in the U.S. for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy; •Vyxeos® (daunorubicin and cytarabine) liposome for injection, a product approved in the U.S. and in Europe (where it is marketed as Vyxeos® liposomal 44 mg/100 mg powder for concentrate for solution for infusion) for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia, or AML, or AML with myelodysplasia-related changes; •Defitelio® (defibrotide sodium), a product approved in the U.S. for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, or VOD, also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Europe (where it is marketed as Defitelio® (defibrotide)) for the treatment of severe VOD in adults and children undergoing HSCT therapy; and •Erwinaze® (asparaginase Erwinia chrysanthemi), a treatment approved in the U.S. and in certain markets in Europe (where it is marketed as Erwinase®) for patients with acute lymphoblastic leukemia, who have developed hypersensitivity to E. coli-derived asparaginase. Our strategy to create shareholder value is focused on: •Strong execution driving revenue growth in our core therapy areas through leveraging our leading market position and expertise in sleep and new high-growth products in oncology that address significant unmet needs; •Expanding our pipeline with internal and external patient-centric innovation to achieve a balanced portfolio of durable, highly differentiated programme; •Continuing to build a flexible, efficient, and productive development engine for targeted therapeutic conditions to identify and progress early- and mid-stage assets; and •Investing in an efficient, scalable operating model and differentiated capabilities to enable successful partnerships and unlock further value through indication expansion and global markets. Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this report, all references to “ordinary shares” refer to Jazz Pharmaceuticals plc’s ordinary shares.

33 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Statement of compliance and basis of preparation The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as adopted by the European Union, or EU, and with those parts of the Companies Act 2014 applicable to companies reporting under IFRS. The parent company financial statements have been prepared in accordance with IFRS, as adopted by the EU, as applied in accordance with the provisions of the Companies Acts 2014 which permits a company that publishes its company and group financial statements together, to take advantage of the exemption in Section 304(2) of the Companies Act 2014 from presenting to its members both its company income statement and statement of comprehensive income and related notes which form part of the approved company financial statements. The profit for the 2020 financial year in the parent company was $345.5 million (2019: profit - $724.6 million). In addition to these consolidated financial statements, we also prepare consolidated financial statements and report them on an Annual Report on Form 10-K pursuant to the rules and regulations of the U.S. Securities and Exchange Commission, and in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. IFRS differs in certain significant respects from U.S. GAAP. For a discussion of the significant differences between IFRS and U.S. GAAP as they apply to our 2020 consolidated financial statements, please refer to “Appendix A - IFRS to U.S. GAAP Reconciliation” to this annual report. The consolidated and parent company financial statements are presented in U.S. dollars, the U.S. dollar being the functional currency of Jazz Pharmaceuticals plc. All values are rounded to the nearest thousand ($000), except when otherwise indicated. The financial statements are prepared on the historical cost basis, except for share-based compensation, derivative instruments and financial assets at fair value through profit or loss, which are stated at fair value. The preparation of the consolidated and parent company financial statements in conformity with IFRS as adopted by the EU requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The judgements, estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances. Actual results could differ materially from these estimates. The areas involving a high degree of judgement and the areas where estimates and assumptions are critical to the financial statements are discussed in Note 3. The consolidated and parent company financial statements were approved by the directors of Jazz Pharmaceuticals plc on 4 May 2021.

2. Accounting Policies

Basis of consolidation On 18 January 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction, in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc and we became the parent company of, and successor to, Jazz Pharmaceuticals, Inc. We refer to this transaction as the Azur Merger. This transaction was accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with Jazz Pharmaceuticals, Inc. treated as the acquiring company for accounting purposes. The following accounting treatment was applied in respect of the reverse acquisition: •The assets and liabilities of the legal subsidiary, Jazz Pharmaceuticals, Inc., were recognised and measured in the consolidated financial statements at their pre-combination carrying amounts, without any restatement to fair values; •The identifiable assets and liabilities of the legal parent, Jazz Pharmaceuticals plc, were recognised in accordance with IFRS 3 Business Combinations, or IFRS 3, at the acquisition date and goodwill was measured in accordance with IFRS 3; •The retained reserves recognised in the consolidated financial statements were those of the legal subsidiary immediately before the business combination; and •The equity structure reflects that of the legal parent, including the equity instruments issued under the share for share exchange to effect the business combination.

34 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

The consolidated financial statements comprise the financial statements of Jazz Pharmaceuticals plc and all of its subsidiaries as at 31 December 2020. The parent controls a subsidiary if it is exposed, or has rights, to variable returns from its involvement with the subsidiary and has the ability to affect those returns through its power over the subsidiary. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. All intercompany account balances, transactions, and any unrealised gains and losses or income and expenses arising from intercompany transactions have been eliminated in preparing the consolidated financial statements. Our subsidiary undertakings have the same financial year-end as Jazz Pharmaceuticals plc, except for two subsidiaries that have a different statutory financial year-end date for regulatory purposes. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

Business combinations Business combinations are accounted for using the acquisition method. The fair value of an acquisition is measured as the aggregate of the consideration transferred, measured at acquisition date fair value, and the amount of any noncontrolling interests in the acquiree. For each business combination, the Group elects whether to measure the noncontrolling interests in the acquiree at fair value or at the proportionate share of the acquiree’s identifiable net assets. Transaction costs, other than those associated with the issue of debt or equity securities, that we incur in connection with a business combination are expensed as incurred. Any contingent consideration payable is measured at fair value at the acquisition date. If the contingent consideration is classified as equity, then it is not remeasured and settlement is accounted for within equity. Otherwise, subsequent changes in the fair value of the contingent consideration are recognised in profit or loss. Goodwill is initially measured as the excess of the fair value of the aggregate of the consideration transferred over the fair value of the identifiable assets acquired and liabilities assumed.

Foreign currency Transactions and balances Transactions in foreign currencies are translated into the functional currency of the relevant company at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the relevant functional currency at exchange rates prevailing at the reporting date or on settlement. Resulting gains and losses are recorded in the income statement. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are retranslated to the functional currency at the exchange rate at the date that the fair value was determined. Non-monetary items that are measured based on historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Foreign operations On consolidation, the assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into U.S. dollars at the rate of exchange prevailing at the reporting date and at the average monthly exchange rates for revenue and expense accounts which are a reasonable approximation of the cumulative effect of the rates on the transaction dates. The exchange differences arising on translation for consolidation are recognised in other comprehensive income (loss). On disposal of a foreign operation, the component of other comprehensive income (loss) relating to that particular foreign operation is reclassified to the income statement. When the settlement of a monetary item receivable from or payable to a foreign operation is neither planned nor likely in the foreseeable future, foreign currency gains and losses arising from such items are considered to form part of the net investment in the foreign operation and are recognised in other comprehensive income (loss) and presented in the foreign currency translation reserve in equity.

Revenue recognition Our revenue comprises product sales, net and royalty and contract revenues. Revenues are recognised when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration

35 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) we expect to be entitled to in exchange for those goods or services. Prior to recognising revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Product sales, net Product sales revenue is recognised when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient. Reserves for variable consideration Revenues from sales of products are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established and which relate to returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government rebates, government chargebacks, coupon programmes and rebates under managed care plans and commercial payor contracts. Calculating certain of these reserves involves estimates and judgements, and we determine their expected value based on sales or invoice data, contractual terms, historical utilisation rates, new information regarding changes in these programmes’ regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilisation rates for these programmes and channel inventory data. These reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is highly probable that a significant reversal in the amount of the cumulative revenue recognised will not occur in a future period. We reassess our reserves for variable consideration at each reporting date. Historically, adjustments to estimates for these reserves have not been material. Reserves for returns, specialty distributor fees, wholesaler fees, government rebates, coupon programmes and rebates under managed care plans are included within current liabilities in our consolidated balance sheets. Reserves for government chargebacks and prompt payment discounts are shown as a reduction in accounts receivable. Details of the estimates and judgements involved in estimating these deductions are set out in Note 3. Royalties and contract revenues We enter into out-licensing agreements under which we license certain rights to our products or product candidates to third parties. If a licensing arrangement includes multiple goods or services, we consider whether the license is distinct. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognise revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If the license to our intellectual property is determined not to be distinct, it is combined with other goods or services into a combined performance obligation. We consider whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognising revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting date and, if necessary, adjust the measure of performance and related revenue recognition. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or that of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognise revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. For arrangements that include sales-based royalties and milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties and sales-based milestones relate, we

36 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) recognise revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty or sales-based milestone has been allocated has been satisfied (or partially satisfied).

Property, plant and equipment Items of property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. Any gain or loss on disposal of an item of property, plant and equipment (calculated as the difference between the net proceeds from disposal and the carrying amount of the item) is recognised in profit or loss for the year. Ongoing repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method to allocate the cost of property, plant and equipment to their estimated residual values over their estimated useful lives as follows:

Buildings 40 years Manufacturing equipment and machinery 5-10 years Computer equipment 3-7 years Fixtures and fittings 5 years Leasehold improvementsOver the shorter of life of the asset or the lease term Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. Construction in progress is not depreciated until the related asset is completed and placed in service. Land is not depreciated.

Goodwill and other intangible assets In a business combination, goodwill is capitalised at the acquisition date. Goodwill is initially measured at cost, being the excess of the aggregate of the fair value of the consideration transferred and the amount recognised for noncontrolling interests over the fair value of the net identifiable assets acquired and liabilities assumed. If this consideration is lower than the fair value of the net assets of the subsidiary acquired, the difference is recognised in profit or loss. The assets acquired and liabilities assumed in a business combination are measured at their fair values at the date of acquisition. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Where goodwill forms part of a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of in this circumstance is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained. Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets acquired in a business combination are measured on initial recognition at their fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangible assets, excluding capitalised development costs, are not capitalised and expenditure is reflected in the income statement in the year in which the expenditure is incurred. Intangible assets available for use consist primarily of purchased developed technology which are amortised on a straight-line basis over their estimated useful lives, which range from two to 18 years, and are assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life is reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the income statement in the expense category consistent with the function of the intangible assets. Intangible assets not yet ready for use comprise acquired in-process research & development, or IPR&D, assets. IPR&D assets are not amortised, but tested for impairment on an annual basis or when facts and circumstances warrant an impairment test. Any impairment charge on IPR&D assets is recognised within research and development expense. If and when development is complete, which generally occurs when regulatory approval to market a product is obtained, the associated assets would then be amortised over their estimated useful lives.

37 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Impairment of non-financial assets The carrying amounts of our depreciable non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. Non-depreciable intangible assets, which comprise assets not yet ready for use, and goodwill are tested annually for impairment and additionally if any indicators of impairment are identified. An impairment loss is recognised when the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. Impairment losses are recognised in the income statement in the expense category consistent with the function of the asset. The recoverable amount of assets is the greater of their fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash- generating unit to which the asset belongs. Impairment losses recognised in respect of the cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the cash-generating unit (or groups of units) and then, to reduce the carrying amount of the other assets in the unit (or group of units) on a pro rata basis. Impairment losses in respect of goodwill are not reversed. In respect of other assets, an impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

Current and deferred income tax Tax expense comprises current and deferred tax. Current and deferred tax is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in other comprehensive income. Current income tax Current tax is the expected tax payable on the taxable income for the year using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of the previous years. Deferred income tax Deferred tax is provided using the liability method providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities at rates expected to apply in the period when the liability is settled or the asset is recovered. A deferred tax asset is only recognised to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. Deferred tax assets are reduced to the extent that it is no longer probable that the related income tax benefit will be realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to either other comprehensive income (loss) or shareholders’ equity, in which case the deferred tax is also recorded in either other comprehensive income (loss) or shareholders’ equity, respectively. Deferred income tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to taxes levied by the same tax authority and the same taxable entity. Tax exposures In determining the amount of current and deferred income tax, we take into account the impact of uncertain tax positions and whether additional taxes and interest may be due. This assessment relies on estimates and assumptions and may involve a series of judgements about future events. New information may become available that causes us to change our judgement regarding the adequacy of existing tax liabilities; such changes to tax liabilities will impact tax expense in the period that such a determination is made.

38 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Leases We determine if an arrangement is a lease at inception. Leases are included in right-of-use assets, accrual and other current liabilities, and lease liabilities on our consolidated balance sheet and parent company balance sheet. Right-of-use assets and lease liabilities are recognised based on the present value of the future minimum lease payments over the lease term at commencement date. In determining the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The right- of-use asset also includes any lease payments made prior to commencement, reduced by lease incentives and increased by initial direct costs incurred. We recognise a depreciation charge for right-of-use assets on a straight- line basis over the lease term within selling, general administrative expenses, and an interest expense on lease liabilities within finance expenses in our consolidated income statement. Our lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We have lease agreements with lease and non-lease components, which are generally accounted for separately. For vehicle leases we account for the lease and non-lease components as a single lease component. We have elected the short-term lease exemption and, therefore, do not recognise a right-of-use asset or corresponding liability for lease arrangements with an original term of 12 months or less. Lease payments associated with short-term leases are recognised in our consolidated income statement on a straight-line basis over the lease term. We have elected the low value lease exemption and, therefore, do not recognise a right-of-use asset or corresponding liability for lease arrangements for which the underlying asset is of low value. Lease payments associated with these leases are recognised in our consolidated income statement on a straight-line basis over the lease term.

Research and development expenses Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is expensed as incurred. An internally generated intangible asset is recognised only if development costs are measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and we intend to, and have sufficient resources to, complete development and to use or sell the asset. We have determined that, to date, the regulatory, clinical or field trial risks inherent in the development of our products currently preclude us from capitalising any development costs.

Finance income and expense Finance income comprises interest income on funds invested, fair value gains on re-measurement of derivatives not designated as hedges, gains on cash flow hedges and reclassifications of net gains previously recognised in other comprehensive income (loss). Interest income is recognised as it accrues in profit or loss, using the effective interest method. Finance expense comprises interest expense on borrowings and on lease liabilities, fair value losses on re- measurement of derivatives not designated as hedges, losses on cash flow hedges, loss on extinguishment of debt and reclassifications of net losses previously recognised in other comprehensive income (loss). Foreign currency gains and losses on financial assets and financial liabilities are reported on a net basis as either finance income or finance expense depending on whether foreign currency movements are in a net gain or net loss position.

Inventories Inventories are stated at the lower of cost and net realisable value. Cost is calculated on a first-in, first-out basis and includes the expenditure incurred in acquiring inventories and bringing them to their existing location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

39 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Financial assets On initial recognition, a financial asset is classified as measured at amortised cost or fair value with any movement being reflected through other comprehensive income (loss) or the income statement. On initial recognition of an equity investment that is not held for trading, the Group may irrevocably elect to present subsequent changes in the investment’s fair value in other comprehensive income (loss). This election is made on an investment-by- investment basis.

Cash, cash equivalents and investments Cash and cash equivalents comprise cash balances, short-term deposits and money market funds with original maturities of three months or less and are readily convertible into known amounts of cash. Investments comprise time deposits with original maturities of greater than three months. They are held at amortised cost.

Trade and other receivables Trade receivables are recognised initially at fair value and then carried at amortised cost less allowance for impairment. The company applies the IFRS 9 Financial Instruments simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

Financial liabilities Financial liabilities are recognised initially on the trade date, which is the date that we become a party to the contractual provisions of the instrument. We derecognise a financial liability when our contractual obligations are discharged, cancelled or expire. Financial liabilities comprise loans and borrowings and trade and other payables. Such financial liabilities are recognised initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included in finance expense in the income statement. Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a pre-payment for liquidity services and amortised over the period to which the facility relates.

Derivatives and hedging activities We record the fair value of derivative instruments as either assets or liabilities on the consolidated balance sheet. Changes in the fair value of derivative instruments are recorded each period in profit or loss or other comprehensive income (loss), depending on whether a derivative instrument is designated as part of a hedging transaction and, if it is, the type of hedging transaction. For a derivative to qualify as a hedge at inception and throughout the hedged period, we formally document the nature and relationships between the hedging instruments and hedged item. We assess, both at inception and on an on-going basis, whether the derivative instruments that are used in cash flow hedging transactions are highly effective in offsetting the changes in cash flows of hedged items. We assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion of derivative instruments, if any, to profit or loss. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting and any related unrealised gain or loss on the derivative instrument is recognised in profit or loss. Derivatives that are not designated and do not qualify as hedges are adjusted to fair value through profit or loss. Embedded derivatives Derivatives embedded in host contracts are accounted for as separate derivatives and recorded at fair value if their economic characteristics and risks are not closely related to those of the host contracts and the host contracts are not held for trading or designated as fair value through profit or loss. These embedded derivatives are measured at fair value with changes in fair value recognised in profit or loss.

40 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares are recognised as a deduction from equity.

Share-based payments Share-based payment expense for equity-settled awards made to employees and directors is measured and recognised based on their estimated grant date fair values. These awards include employee share options, restricted stock units, or RSUs, and share purchases related to our employee share purchase plan, or ESPP. Share-based payment cost for RSUs awarded to employees and directors is measured based on the closing fair market value of the company’s shares on the date of grant. Share-based payment cost for share options awarded to employees and directors and shares issued under our ESPP is estimated at the grant date based on the fair value of the award as calculated using the Black-Scholes option pricing model. The value of awards expected to vest is recognised as an expense in profit or loss over the requisite service periods together with a corresponding increase in equity. When the terms of an equity-settled transaction award are modified, the minimum expense recognised is the expense as if the terms had not been modified and the original terms of the award were met. An additional expense is recognised for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee as measured at the date of modification. Where there is net share settlement of exercised share options or RSU releases and the company is required to pay the income withholding tax on behalf of employees, such transactions are classified in their entirety as equity- settled share-based payment transactions if they would have been so classified in the absence of the net share settlement feature. The dilutive effect of outstanding options is reflected as share dilution in the computation of diluted earnings per share. Further details are given in Note 12. The cost for equity awards granted to the parent company’s subsidiaries’ employees represents additional capital contributions by the company to its subsidiaries. An additional investment in subsidiaries has been recorded in respect of those awards granted to the company’s subsidiaries’ employees, with a corresponding increase in the company’s shareholders’ equity. The additional capital contribution is based on the fair value at the grant date of the award, allocated over the life of the underlying grant’s vesting period. Where share-based compensation recharge arrangements are in place with subsidiary undertakings, we recognise a related receivable in the parent company balance sheet over the vesting period.

Employee benefit plans We operate a number of defined contribution retirement plans. Obligations for contributions to defined contribution plans are recognised as an employee benefit expense in profit or loss in the periods during which related services are rendered by employees.

Provisions A provision is recognised in the balance sheet when we have a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefit will be required to settle the obligation and the amount of the obligation can be reliably estimated. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as a finance expense.

Debt financing costs Debt financing costs comprise transaction costs and original issue discount on borrowings. Debt financing costs are allocated to financial reporting periods over the term of the related debt using the effective interest rate method. The carrying amount of debt includes related unamortised debt financing costs.

41 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Investment in subsidiary undertakings The parent company holds investments in group companies, which are carried at cost less any impairments. Investments in group companies include a contribution for share-based compensation relating to share-based payments made to employees of subsidiary undertakings.

Changes in accounting policies - new and revised standards that were effective for annual periods beginning on or after 1 January 2020 We have applied the following standards from 1 January 2020: In October 2018, the International Accounting Standards Board, or IASB, issued amendments to the definition of a business in IFRS 3 Business Combinations to help entities determine whether an acquired set of activities and assets is a business or not. They clarify the minimum requirements for a business, remove the assessment of whether market participants are capable of replacing any missing elements, add guidance to help entities assess whether an acquired process is substantive, narrow the definitions of a business and of outputs, and introduce an optional fair value concentration test. These amendments had no impact on the consolidated financial statements of the group, but may impact future periods depending on the nature of our future acquisitions. In October 2018, the IASB issued amendments to the definition of material in IAS 1, Presentation of Financial Statements, and IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors, and how it should be applied in response to difficulties some companies were having in applying the old definition when judging whether information was material for inclusion in their financial statements. We adopted the amendments with effect from 1 January 2020. Adoption did not have a material impact on our consolidated financial statements. In September 2019, the IASB issued "Interest Rate Benchmark Reform (Amendments to IFRS 9, Financial Instruments, IAS 39, Financial Instruments: Recognition and Measurement, and IFRS 7, Financial Instruments: Disclosures)" as a first reaction to the potential effects the Interbank Offered Rate, or IBOR, reform could have on financial reporting. We adopted the amendments with effect from 1 January 2020. Adoption did not have a material impact on our consolidated financial statements. In March 2018, the IASB issued its revised "Conceptual Framework for Financial Reporting" which included revised definitions of an asset and a liability, as well as new guidance on measurement and derecognition, presentation and disclosure. We adopted the amendments with effect from 1 January 2020. Adoption did not have a material impact on our consolidated financial statements.

Prospective accounting changes, new standards and interpretations not yet adopted A number of new standards, amendments to standards and interpretations are effective for annual periods beginning on or after 1 January 2021, and have not been applied to these consolidated financial statements. Those which may be relevant to the group are set out below. In May 2020, the IASB issued "Amendment to IFRS 16 ‘COVID-19-Related Rent Concessions’". As a practical expedient, a lessee may elect not to assess whether a COVID-19 related rent concession from a lessor is a lease modification. A lessee that makes this election accounts for any change in lease payments resulting from the COVID-19 related rent concession the same way it would account for the change under IFRS 16, if the change were not a lease modification. The amendments are effective from 1 June 2020 and adoption is not expected to have a material impact on our consolidated financial statements. In August 2020, the IASB issued "Interest Rate Benchmark Reform – Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16)" with amendments that address issues that might affect financial reporting as a result of the reform of an interest rate benchmark, including the effects of changes to contractual cash flows or hedging relationships arising from the replacement of an interest rate benchmark with an alternative benchmark rate. The amendments provide practical relief from certain requirements in IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 relating to; changes in the basis for determining contractual cash flows of financial assets, financial liabilities and lease liabilities; and hedge accounting. The amendments are effective from 1 January 2021 and adoption is not expected to have a material impact on our consolidated financial statements. In May 2020, the IASB issued "Onerous Contracts – Cost of Fulfilling a Contract (Amendments to IAS 37)" amending the standard to specify the costs a company should include in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments are effective from 1 January 2022 to

42 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) contracts existing at the date when the amendments are first applied. At the date of initial application, the cumulative effect of applying the amendments is recognised as an opening balance adjustment to retained earnings or other components of equity, as appropriate. Adoption is not expected to have a material impact on our consolidated financial statements. In May 2020, the IASB issued "Amendments to IAS 16 ‘Property, Plant and Equipment: Proceeds before Intended Use". The amendment prohibits entities from deducting from the cost of an item of property, plant and equipment, any proceeds of the sale of items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling such items, and the costs of producing those items, in profit or loss. The amendments are effective from 1 January 2022 and adoption is not expected to have a material impact on our consolidated financial statements.

3. Critical Accounting Estimates and Judgements A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgements, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We believe the following accounting estimates and judgements to be critical.

Revenue recognition Revenues are recognised when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Product sales, net Product sales revenue is recognised when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient. A significant portion of our net product revenues is derived from sales of Xyrem. We sell Xyrem in the U.S. to a single central pharmacy, Express Scripts Specialty Distribution Services, Inc., or Express Scripts. In 2020, sales of Xyrem to Express Scripts accounted for 74% of our net product sales. We recognise revenues from sales of Xyrem within the U.S. when control has transferred to the customer, which occurs when Express Scripts removes product from our consigned inventory location at its facility for shipment directly to a patient. We do not accept returns of Xyrem from Express Scripts. Items deducted from gross product sales Revenues from sales of products are recorded net of government rebates and rebates under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt payment discounts, patient coupon programmes, and specialty distributor and wholesaler fees. Calculating certain of these items involves estimates and judgements based on sales or invoice data, contractual terms, historical utilisation rates, new information regarding changes in applicable regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilisation rates and channel inventory data. We review the adequacy of our provisions for sales deductions on a quarterly basis. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. Because we derive a significant portion of our revenues from sales of Xyrem in the U.S. to one specialty pharmacy customer, Express Scripts, we have a much higher level of knowledge about each prescription than if we sold the product through the normal pharmaceutical wholesaler channel as we do with most of our other products. The most significant items deducted from gross product sales where we exercise judgement are rebates, sales returns and chargebacks.

43 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Thefollowingtable presentsthe activityand ending balancesfor our sales-relatedaccruals and allowances(in thousands):

Discounts and Rebates Sales Returns Distributor payable Reserve Chargebacks Fees Total Balance at 31 December2018 $81,114 $2,510 $408 $5,457 $89,489 Provision, net153,930 5,519 41,864 56,041 257,354 Payments/credits (152,191) (4,567) (41,139) (47,378) (245,275) Balance at 31 December2019 82,853 3,462 1,133 14,120 101,568 Provision, net288,052 18,448 45,550 69,332 421,382 Payments/credits (260,020) (3,542) (41,390) (66,659) (371,611) Balance at 31 December2020 $110,885 $18,368 $5,293 $16,793 $151,339

The above accruals andallowancesare included withincurrent liabilities or shown as areduction in trade receivables on our consolidated balance sheet.

In 2020, total itemsdeducted from gross product saleswere15.2% (2019: 10.8%) of gross product sales. Included in these amounts areimmaterial adjustmentsrelated to prior yearsales due to changesinestimates. Such amounts represented less than1%ofnet product salesfor the years ended31December 2020 and 2019. Rebates We are subject to rebates on salesmadeundergovernmental and managed-care pricing programmes and commercial payor contractsinthe U.S.The largest of these rebates is associatedwith salescoveredbyMedicaid. We participate in stategovernment-managed Medicaid programmes as well as certain other qualifying federaland stategovernment programmes under thetermsofwhich discounts andrebatesare provided to participating government entities. We offerrebatesand discountstomanagedhealthcareorganisations and commercialpayors in the U.S. In estimating our provisions for rebates, we considerrelevant statutes with respect to governmentalpricing programmesand contractualsales terms with managed-care providers, commercialpayors and group purchasing organisations. We estimatethe rebateprovision based on historical utilisation rates, historicalpayment experience, new information regarding changes in regulations and guidelines thatwould impact the amount of theactual rebates, our expectations regarding future utilisation ratesand channel inventory data obtainedfrom our majorU.S. wholesalers in accordancewithour inventory management agreements. Estimating these rebates is complex, in part due to the time delay betweenthe dateofsaleand the actualsettlement of the liability. We believe thatthe methodology we use to estimaterebates on product salesmade under governmentaland managed-care pricing programmesisreasonableand appropriategiven current facts and circumstances. However, estimates mayvary from actual experience. Rebateswere$288.1 millionand $153.9 million, or 10.4% and 6.5% as apercentage of gross product sales, in 2020 and 2019, respectively. Salesreturns For certainproducts, we allow customers to return productwithin aspecifiedperiod before and afterthe applicableexpiration dateand issue creditswhich maybeappliedagainst existing or future invoices. We account for salesreturns as areduction in net revenue at thetimeasale is recognised by establishing an accrualinanamount equaltothe estimatedvalue of products expected to be returned. The salesreturn accrual is estimatedprincipally based on historical experience,the level and estimated shelflifeofinventory in thedistribution channel, our return policy andexpected marketeventsincluding genericcompetition. Salesreturns were $18.4 millionand $5.5 million, or 0.7% and 0.2% as apercentage of gross product sales, in 2020 and 2019, respectively. Chargebacks We participate in chargebackprogrammeswithanumberofentities, principally Federal Supply Schedule, Group Purchasing Organisations, and otherpublicparties, under whichpricing on products below wholesalers’ list prices is providedtoparticipating entities. These entitiespurchaseproductthrough wholesalers at the contractprice and thewholesalers charge backtousthe differencebetweentheir acquisition cost andthe lower negotiated price.

44 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

We record the difference as allowances against accounts receivable. We determine our estimate of the chargebacks provision primarily based on historical experience on a product and programme basis, current contract prices under the chargeback programmes and channel inventory data. Chargebacks were $45.6 million and $41.9 million, or 1.6% and 1.8% as a percentage of gross product sales, in 2020 and 2019, respectively. Discounts and distributor fees Discounts and distributor fees comprise prompt payment discounts, patient coupon programmes and specialty distributor and wholesaler fees. We offer customers a cash discount on gross product sales as an incentive for prompt payment. We estimate provisions for prompt pay discounts based on contractual sales terms with customers and historical payment experience. To help patients afford our products, we have various programmes to assist them, including patient assistance programmes, a free product voucher programme and co-pay coupon programmes for certain products. We estimate provisions for these programmes primarily based on expected programme utilisation, adjusted as necessary to reflect our actual experience on a product and programme basis. Specialty distributor and wholesaler fees comprise fees for distribution of our products. We estimate provisions for distributor and wholesaler fees primarily based on sales volumes and contractual terms with our distributors. Discounts and distributor fees were $69.3 million and $56.0 million, or 2.5% and 2.4% as a percentage of gross product sales, in 2020 and 2019, respectively.

Goodwill and intangible assets Goodwill Goodwill represents the excess of the fair value of the acquisition consideration over the fair value of assets acquired and liabilities assumed. We test goodwill for impairment annually in October and when events or changes in circumstances indicate that the carrying value may not be recoverable. For the purpose of impairment testing of goodwill, we have a single cash-generating unit. The recoverable amount of the cash-generating unit is based on fair value less costs to sell. We have determined the fair value of our single reporting unit to be equal to our market capitalisation, as determined by our traded share price, plus a control premium. The control premium used was based on a review of such premiums identified in recent acquisitions of companies of similar size and in similar industries. We performed our annual goodwill impairment test in October 2020 and concluded that goodwill was not impaired as the fair value of the cash-generating unit significantly exceeded its carrying amount, including goodwill. A 10% adverse change in our market capitalisation or in the control premium used would not cause the carrying value of the cash-generating unit to exceed its fair value. As at 31 December 2020, we had $958.3 million of goodwill (2019: $920.0 million) resulting from acquisitions accounted for as business combinations. Intangible assets We have acquired a number of intangible assets, including intangible assets related to currently marketed products (developed technology) and intangible assets related to product candidates (IPR&D). When significant identifiable intangible assets are acquired, we engage an independent third-party valuation firm to assist in determining the fair values of these assets as of the acquisition date. Discounted cash flow models are typically used in these valuations, which require the use of significant estimates and assumptions, including but not limited to: •estimating the timing of and expected costs to complete the in-process projects; •projecting regulatory approvals; •estimating future cash flows from product sales resulting from completed products and in-process projects; and •developing appropriate discount rates and probability rates by project. We believe the fair values that we assign to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates. No assurance can be given, however, that the underlying assumptions used to estimate expected cash flows will transpire as estimated. In addition, we are required to estimate the period of time over which to amortise the intangible assets, which requires significant judgement.

45 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Our ready for use intangible assets consist primarily of purchased developed technology which are amortised on a straight-line basis over their estimated useful lives, which range from two to 18 years. The estimated useful lives associated with intangible assets are consistent with the estimated lives of the products and may be modified when circumstances warrant. Intangible assets with finite lives are reviewed for impairment whenever events or circumstances indicate that the carrying value of an asset may not be recoverable. Events giving rise to impairment are an inherent risk in the pharmaceutical industry and cannot be predicted. Factors that we consider in deciding when to perform an impairment review include significant under-performance of a product in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. An impairment loss is recognised when the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. The impairment analysis is principally based on discounted estimated cash flows. Estimating future cash flows related to an intangible asset involves estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortisation expense. IPR&D is not amortised but is tested for impairment annually or when events or circumstances indicate that the recoverable amount may be below the carrying value of the asset. If the carrying value of the assets is not expected to be recovered, the assets are written down to their estimated recoverable amount. As at 31 December 2020, we had $2.1 billion of intangible assets ready for use (2019: $2.2 billion) and $0.2 billion of IPR&D assets (2019: $0.2 billion).

Income taxes Our most significant tax jurisdictions are Ireland and the U.S. Significant estimates are required in determining our income tax expense. Some of these estimates are based on management’s interpretations of jurisdiction-specific tax laws or regulations and the likelihood of settlement related to tax audit issues. Various internal and external factors may have favourable or unfavourable effects on our future effective income tax rate. These factors include, but are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, changes in estimates of prior years’ items, the impact of accounting for share- based compensation, changes in our international organisation, likelihood of settlement, and changes in overall levels of income before taxes. A deferred tax asset is only recognised to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. Realisation of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Significant judgement is required in determining whether it is probable that sufficient future taxable profits will be available against which the asset can be utilised. In evaluating our ability to recover our deferred tax assets, we consider all available positive and negative evidence, including cumulative income in recent fiscal years, our forecast of future taxable income exclusive of reversing temporary differences and significant risks and uncertainties related to our business. In determining future taxable income, we are responsible for assumptions utilised including the amount of Irish, U.S. state and federal, and other international pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgement about the forecasts of future taxable income and are consistent with the plans and estimates that we are using to manage our underlying business. Actual operating results and the underlying amount and category of income in future years could render our current assumptions of recoverability of net deferred tax assets inaccurate. We periodically evaluate the likelihood of the realisation of deferred tax assets and they are reduced to the extent that it is no longer probable that the related income tax benefit will be realised. This determination depends on a variety of factors, some of which are subjective, including our recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income, carryforward periods available to us for tax reporting purposes, various income tax strategies and other relevant factors. If we determine that the deferred tax assets are not realisable in a future period, we would record material changes to income tax expense in that period. In determining the amount of current and deferred income tax, we take into account the impact of uncertain tax positions and whether additional taxes and interest may be due. This assessment relies on estimates and assumptions and may involve a series of judgements about future events. New information may become available that causes us to change our judgement regarding the adequacy of existing tax liabilities; such changes to tax liabilities will impact tax expense in the period that such a determination is made. For additional information on our deferred tax balances, please see Note 11.

46 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

4. Asset Acquisitions and Collaborations

Asset acquisition and exclusive license agreement In October 2020, we entered into an asset purchase and exclusive license agreement with SpringWorks Therapeutics, Inc., or SpringWorks, under which we acquired SpringWorks’ fatty acid amide hydrolase, or FAAH, inhibitor program. Under the terms of the agreement, SpringWorks has assigned or exclusively licensed all assets relating to its FAAH inhibitor programme to us, including assignment of SpringWorks’ proprietary FAAH inhibitor PF-04457845, or PF-’845, now named JZP150 and its license agreement with Pfizer, Inc., or Pfizer, under which Pfizer exclusively licensed PF-’845 to SpringWorks in 2017. In addition to assuming all milestone and royalty obligations owed by SpringWorks to Pfizer, we made an upfront payment of $35.0 million to SpringWorks, of which $34.3 million was recorded as an acquired IPR&D intangible asset on our consolidated balance sheet and $0.7 million related to inventory for use in clinical trials was recognised within research and development expense, and may make potential milestone payments to SpringWorks of up to $375.0 million upon the achievement of certain clinical, regulatory and commercial milestones, and pay incremental tiered royalties to SpringWorks on future net sales of JZP150 in the mid- to high-single digit percentages.

License agreement In December 2019, we entered into an exclusive license agreement, or original license agreement, with Pharma Mar, S.A., or PharmaMar, for development and U.S. commercialization of Zepzelca. Zepzelca was granted orphan drug designation for relapsed SCLC by FDA in August 2018. In December 2019, PharmaMar submitted an NDA, to FDA for accelerated approval of Zepzelca for relapsed SCLC based on data from a Phase 2 trial, and in February 2020, FDA accepted the NDA for filing with priority review. In June 2020, FDA approved the NDA for Zepzelca for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum- based chemotherapy. Under the terms of the original license agreement, which became effective in January 2020 upon expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, we paid PharmaMar an upfront payment of $200.0 million, which was recorded as an acquired IPR&D intangible asset on our consolidated balance sheet. In June 2020, we made a milestone payment of $100.0 million to PharmaMar following FDA accelerated approval of Zepzelca, which was capitalised as an intangible asset on our consolidated balance sheet. PharmaMar is eligible to receive potential future regulatory milestone payments of up to $150.0 million upon the achievement of continued U.S. regulatory approval of Zepzelca following the successful completion of confirmatory trials within certain timelines. PharmaMar is also eligible to receive up to $550.0 million in potential U.S. commercial milestone payments, as well as incremental tiered royalties on future net sales of Zepzelca ranging from the high teens up to 30 percent. PharmaMar may receive additional payments on approval of other indications, with any such payments creditable against commercial milestone payment obligations. PharmaMar retains production rights for Zepzelca and will supply the product to us. In October 2020, we entered into an amendment and restatement of the original license agreement with PharmaMar, or the amended license agreement, which expanded our exclusive license to include rights to develop and commercialise Zepzelca in Canada.

Asset acquisition On 12 August 2019, we announced the acquisition of Cavion, Inc., or Cavion, a clinical-stage biotechnology company, for an upfront payment of $52.5 million with the potential for additional payments of up to $260.0 million upon the achievement of certain clinical, regulatory and commercial milestones, for a total potential consideration of $312.5 million. As a result of the acquisition, we added JZP385, a modulator of T-type calcium channels, for the potential treatment of essential tremor, to our clinical pipeline. The acquisition of Cavion was accounted for as an asset acquisition because it did not meet the definition of a business.

47 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Thefollowingtable summarisesthe total consideration for theacquisition andthe value of assets acquiredand liabilities assumed (inthousands):

Consideration Upfront payment for acquisition of Cavion's outstanding shares $52,500 Cash acquired 397 Working capital adjustment (255) Transaction costs 2,829 Total consideration $55,471

Assets Acquiredand LiabilitiesAssumed Cash $397 In-process researchand development 48,275 Deferredtax assets 7,995 Otherassetsand liabilities (1,196) Total net assets acquired $55,471

The value attributed to in-processresearchand development relatestoJZP385 andwas capitalisedasan acquiredIPR&D intangible asset.

Collaboration andlicense agreement On 2January 2019, we enteredinto astrategic collaboration agreement withCodiak BioSciences, Inc., or Codiak, focused on theresearch, development and commercialisation of exosome therapeutics to treatcancer. Codiakgranted us an exclusive, worldwide,royalty-bearing license to develop, manufacture and commercialise therapeuticcandidates directed at five targets to be developedusing Codiak's engEx™ precision engineering platform for exosome therapeutics. Under the terms of the agreement,Codiakisresponsible for the execution of preclinicaland early clinical development of therapeuticcandidates directed at allfive targetsthrough Phase 1/2 proof of concept studies. Following theconclusion of the applicablePhase1/2 study, we will be responsible for future development,potential regulatory submissions andcommercialisation for each product.Codiakhas the option to participateinco- commercialisation andcost/profit-sharing in the U.S. and Canada on up to two products. As part of theagreement, we paid Codiakanupfront payment of $56.0 million, whichwas recordedasan acquiredIPR&D intangible assetonour consolidatedbalancesheet. Codiakiseligible to receive up to $20 millioninpreclinicaldevelopment milestone payments. Codiakisalsoeligibletoreceive milestone paymentstotalling up to $200 million pertarget based on investigationalNDA acceptance, clinical and regulatory milestones,including approvals in theU.S., theEuropeanUnion and Japan, and certainsalesmilestones. Codiakis also eligibletoreceive tiered royaltiesonnet salesofeachapproved product. Collaboration and option agreement In 2017, we enteredintoacollaboration and option agreement withImmunoGen, Inc., or Immunogen, and we paidthemanon-refundable upfront payment of $75.0 million, which wasincludedwithinothernon-current assets on the consolidated balance sheet upon closing of the transaction. Thisagreement was amendedinNovember 2019. Under theamended agreement we hadthe right to opt into an exclusive, worldwide license to develop and commercialise IMGN632, aCD123-targetedantibody-drug conjugatefor hematological malignancies. In December2020, we exercised our opt-out rightswithrespect to IMGN632, thereby relinquishing our development and commercialisation option resulting in the impairment of the non-current asset of $75.0 million. The impairment charge was recognised withinresearch anddevelopment expense.

48 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

5. Revenues The following tablepresents asummary of totalrevenues(in thousands):

Year Ended 31 December 2020 2019 Xyrem $1,741,758 $1,642,525 Xywav 15,264 — Total Oxybate 1,757,022 1,642,525 Sunosi 28,333 3,714 Total Neuroscience 1,785,355 1,646,239 Zepzelca 90,380 — Vyxeos 121,106 121,407 Defitelio/defibrotide 195,842 172,938 Erwinaze/Erwinase 147,136 177,465 Total Oncology 554,464 471,810 Other6,841 17,552 Product sales, net2,346,660 2,135,601 Royaltiesand contract revenues 16,907 26,160 Total revenues $2,363,567 $2,161,761

The following tablepresents asummary of totalrevenuesattributed to geographic sources (in thousands):

Year Ended 31 December 2020 2019 UnitedStates$2,144,541 $1,964,161 Europe 175,208 150,201 All other43,818 47,399 Total revenues $2,363,567 $2,161,761 The following tablepresents asummary of thepercentage of totalrevenuesfrom customers thatrepresented more than10% of our total revenues:

Year Ended 31 December 2020 2019 Express Scripts74% 76 % McKesson Corporation andaffiliates 12 %14%

For detailsofthe concentration of our trade receivables balanceasat31December 2020, please refer to Note 26.

Financing andpayment

Our payment termsvarybythe type and location of our customer but payment is generallyrequired in aterm ranging from 30 to 45 days.

Contractliabilities -deferredrevenue The deferred revenue balanceasof31December 2020 and 31 December2019 primarilyrelated to deferred upfront fees received from Nippon Shinyaku Co., Ltd., or Nippon Shinyaku, in connection withtwo license, development and commercialisation agreementsgranting Nippon Shinyaku exclusive rightstodevelop and commercialise each of Defitelio andVyxeos in Japan. We recognised contractrevenuesof$4.7 million in 2020 (2019: $5.4 million) relating to these upfront payments. The deferred revenue balances are being recognised overan

49 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued) averageoffour years representing theperiod we expecttoperform our research anddevelopmentsobligations under each agreement. The following tablepresents areconciliation of our beginning and ending balancesincontract liabilities from contracts with customers for the yearended31December 2020 and 31 December2019 (inthousands):

2020 2019 Balance as of 1January $9,581 $14,995 Amount recognisedwithin royaltiesand contractrevenues(4,720) (5,414) Balance as of 31 December$4,861 $9,581

6. Operating Segment Our operating segment is reportedinamanner consistent with theinternal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chiefexecutive officer. TheCODM assessesthe performance of the business, and allocates resources, basedonthe consolidated results of the company. We are managedasasinglebusiness unit engagedinthe identification, development and commercialisation of meaningful pharmaceuticalproducts thataddress unmet medical needs. Accordingly, we operateinone operating segment. See Note 5for entity-wide revenue disclosures. The following table presentstotalnon-current assets by location (inthousands):

31 December 2020 2019 Ireland $787,154 $704,044 United States 1,624,508 1,728,348 Italy 673,134 679,919 France 216,999 290,332 Other201,370 212,286 Total non-current assets (1) $3,503,165 $3,614,929

______(1) Non-current assets consistofproperty, plant and equipment,right-of-use assets andgoodwill and intangible assets.

7. Statutoryand OtherInformation Operating profitisstated after charging (inthousands):

Year Ended 31 December 2020 2019 Amortisation of intangible assets (Note13) $374,544 $258,895 Impairment of intangible assets (Note 13) 163,052 503,467 Impairment of non-current assets (Note 4) 75,000 — Depreciation of property, plant andequipment (Note14) 18,779 15,441 Depreciation of right-of-use assets(Note23) 16,457 17,666

50 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

Auditor’s remuneration for 2020 and2019 wasasfollows (in thousands):

Year Ended 31 December 2020 2019 KPMG firms KPMG firms KPMG outside KPMG outside Ireland Ireland KPMG Total Ireland Ireland KPMG Total Audit fees $1,889 $186 $2,075 $2,306 $177 $2,483 Otherassurance fees115 —115 92 —92 Taxfees326 811 1,137 151 1,018 1,169 Othernon-auditfees—33—33 Total $2,330 $1,000 $3,330 $2,549 $1,198 $3,747

The fee for auditservices providedbyKPMG Ireland to theparent company was $20,400 in 2020 (2019: $20,000).

8. FinanceIncomeand FinanceExpense Finance income wasasfollows (in thousands):

Year Ended 31 December 2020 2019 Interestincomeonfinancialassets at amortisedcost$11,125 $20,460 Netgainonforeign currencyforward contracts (Note 15) 8,791 2,592 Reclassification adjustmentsoncashflow hedgesfrom othercomprehensive income —1,125 Fair value gainonembeddedderivatives(Note22) 8,902 — Total $28,818 $24,177

Finance expense wasasfollows (in thousands):

Year Ended 31 December 2020 2019 Interestexpenseonborrowings at amortisedcost$102,895 $99,559 Fairvalue loss on embedded derivatives (Note22) 209,111 13,029 Interestexpenseonlease liabilities (Note23) 8,252 8,586 Foreign currency exchange loss, net 12,063 8,404 Loss on extinguishment of debt (Note22) 17,706 — Reclassificationadjustmentsoncashflow hedgesfrom other comprehensive income3,887 — Total $353,914 $129,578

51 Jazz Pharmaceuticals plc Notestothe Consolidated Financial Statements (continued)

9. Staff Numbers and Costs The average numberofpersons, including executive directors, employed by theGroup, analysedbycategory, wasasfollows:

Year Ended 31 December 2020 2019 Costofproductsales 140 125 Selling, general and administrative 1,205 1,056 Research anddevelopment 353 259 Total 1,698 1,440

As at 31 December2020 we had1,819 employees (2019: 1,551 employees) worldwide. Total staff costs wereasfollows (in thousands):

Year Ended 31 December 2020 2019 Wages and salaries$384,550 $305,436 Social security costs 30,996 25,342 Contributions to defined contribution plans 10,459 8,159 Equity-settledshare-based payments -directors andemployees (Note 25) 124,742 113,353 Total $550,747 $452,290

The aggregatestaff costs above exclude an amount of $0.1 millionin2020 (2019: $2.3 million) which has beencapitalisedand included withinproperty, plant and equipment on the consolidated balance sheet. We maintainaqualified401(k) savings plan, in whichall U.S. basedemployees are eligible to participate, providedtheymeetthe requirementsofthe plan. We matchcertainemployeecontributions under the 401(k) savings planand we recordedanexpense of $6.3 millionin2020 (2019: $5.0 million). We also operateanumberofdefined contribution retirement plans for certain non-U.S. based employees. Expenses relatedtocontributions to suchplans were$4.2 millionin2020 (2019: $3.2 million).

10. Directors’ Emoluments Directors’ emolumentswereasfollows(in thousands):

Year Ended 31 December 2020 2019 Expense related to long-term incentive schemes (RSUs) $9,277 $8,596 Feesfor services as director 987 967 Gain on exercise of share options 2,912 — Otheremoluments2,480 2,332 Total $15,656 $11,895

Other emoluments represent amounts paid to executive directors in connection with themanagement of the affairs of the Group.

52 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

11. Income Taxes

Tax recognised in profit or loss The major components of theincometax benefitwereasfollows (in thousands):

Year Ended 31 December 2020 2019 Current taxexpense: Current year$249,294 $201,629 Adjustment for prior years (4,465) (25,642) Deferredtax benefit: Origination and reversal of temporary differences (273,147) (332,763) Recognition of previously unrecognisedtax losses, creditsand temporary differences(451) — Changes in taxrates —(171) Incometax benefitreportedinthe incomestatement $(28,769) $(156,947)

We recognisedanincometax benefitof$28.8 millionin2020 (2019: benefit of $156.9 million) relatedtotax arising on incomeinIreland, theU.S. and certainotherforeign jurisdictions, certainuncertain taxpositions and various expenses not deductiblefor taxpurposes. The income taxbenefit in 2020 includes adeferredtax benefit of $35.9 million relating to theimpairment charge recognised during theyearinrespectofVyxeos.

We are currentlypaying cash taxesinIreland, theU.S. and certain other jurisdictions where we have operations and eitherall netoperating loss carryforwards, or NOLs, have been utilised, or arerestrictedasaresult of the Azur Merger. Certainofour subsidiarieswereunderexamination by theFrenchtax authoritiesfor fiscal years 2012, 2013, 2015, 2016 and 2017. In theperiod from December2015 through to December2019, we received proposed taxassessment noticesfor eachofthe years under examination relating to certaintransfer pricing adjustments. The noticesprovided for additionalFrenchtax of approximately $45.9 millionfor 2012 and 2013 and approximately $13.1 millionfor 2015, 2016 and 2017, including interest andpenaltiesthrough the respective dates of the proposed assessment,translated at theforeign exchange rate at 31 December2020. Due to thesubjective nature of thetransfer pricing issuesinvolved, during 2020, thecompany reachedanagreement in principlewiththe French taxauthorities to settle theauditsfor all open years. The settlement requiredthe Company to pay incremental taxes, interest and penalties of $19.6 million, translatedatthe foreign exchange rateasof 31 December2020. The income taxexpense in 2020 includes the impactofthe settlement,which wasfinalised and paidin2021. In early2021, the Company received anotice from theFrenchtax authoritiesand certain of our French subsidiariesare underexamination by theFrenchtax authoritiesfor the year ended 31 December 2018 and 2019. Certainofour Italian subsidiariesare currently underexamination by theItalian taxauthoritiesfor the year ended31December2017. Certainofour Luxembourg subsidiariesare currently underexamination by the Luxembourg taxauthorities for the years ended 31 December 2017 and2018.

Tax recognisedinequity The income taxcredited directlytoequitywas as follows(in thousands):

Year Ended 31 December 2020 2019 Share-basedcompensation -excess tax benefits: Current tax$—$ 142 Deferredtax 4,579 2,951 Incometax benefitcrediteddirectly to equity $4,579 $3,093

53 Jazz Pharmaceuticals plc Notestothe Consolidated Financial Statements (continued)

Deferredtax chargedtoother comprehensive income (loss) Deferredtax related to itemsrecognisedinother comprehensive income (loss)during the yearwas as follows (in thousands):

Year Ended 31 December 2020 2019 Deferredtax benefit on net loss on cash flow hedges$(163) $(697) Deferredtax charged to othercomprehensive loss $(163) $(697)

Reconciliation of effective tax rate Areconciliationofincome taxatthe statutory ratetoour effective income taxrateisasfollows:

Year Ended 31 December 2020 2019 Statutory taxrate12.5 %12.5 % Foreign rate differential(51.0)% (10.9)% Financing costs 40.0 %(3.4)% Research andothertax credits(38.1)% (25.8)% Deductions on subsidiary equity(30.2)% (15.2)% Uncertaintax positions 19.1 %0.3 % Non deductibleofficers' compensation 10.1 %5.4 % Otherchange in unrecognisedtax losses, credits andtemporary differences 7.1 %9.6 % Share-based payment (3.8)% (0.7)% Change in estimates (3.4)% —% Non taxable/deductible exchange gains/losses2.1 %(0.3)% Covidreliefand other taxbenefits (2.0)% —% Investment in subsidiaries&equityinvestees 1.4 %(0.1)% Change in taxrates (0.6)% 0.8 % Non-deductible travel and transportation costs 0.4 %0.2 % Intra-entitytransfer of intellectualproperty assets —% (55.4)% Patent box incentive —% (20.5)% Other2.7 %1.6 % Effective income taxrate(33.7)% (101.9)%

The effective taxratefor 2020 was (33.7)% (2019: (101.9)%). Theeffective taxratefor 2020 waslower than the Irishstatutory rateof12.5% primarilydue to the impactoforiginating taxcreditsand deductions on subsidiary equity, partially offset by the disallowanceofcertaininterest deductions andprovision for thesettlement reached with theFrenchtax authorities.

54 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

Deferredtax assetsand liabilities Deferredtax assets andliabilities are attributable to thefollowing (in thousands):

Assets Liabilities Net As at 31 As at 31 As at 31 As at 31 As at 31 As at 31 December December December December December December 2020 2019 2020 2019 2020 2019 Property, plant and equipment $1,701 $1,211 $(7,820) $(4,508) $(6,119) $(3,297) Intangibleassets 72,720 76,972 (326,636) (410,389) (253,916) (333,417) Inventories199,173 59,200 ——199,173 59,200 Employeebenefits 12,865 10,191 ——12,865 10,191 Share-based payment transactions 43,381 29,540 ——43,381 29,540 Provisions 700 381 ——700 381 Taxloss carry-forwards 73,379 83,555 ——73,379 83,555 Researchand other taxcredits 208,934 185,038 ——208,934 185,038 Accruals, reservesand deferred revenue 56,713 45,929 (386) —56,327 45,929 Other items50,214 37,718 (2,634) (61) 47,580 37,657 Netdeferredtax assets $719,780 $529,735 $(337,476) $(414,958) $382,304 $114,777

The movement in deferred taxbalancesduring 2020 was as follows (in thousands):

As at 31 Recognised Foreign As at 31 December in profit or Recognised exchange December 2019 loss in equity and other 2020 Property, plant and equipment $(3,297) $(2,905) $— $83$(6,119) Intangibleassets (333,417) 89,515 —(10,014) (253,916) Inventories59,200 139,979 —(6) 199,173 Employeebenefits 10,191 2,674 ——12,865 Share-basedpayment transactions 29,540 9,263 4,579 (1) 43,381 Provisions 381 319 ——700 Taxloss carry-forwards 83,555 (10,407) —231 73,379 Research andothertax credits185,038 23,896 ——208,934 Accruals, reserves anddeferred revenue 45,929 10,235 —163 56,327 Otheritems 37,657 11,029 —(1,106) 47,580 Total $114,777 $273,598 $4,579 $(10,650) $382,304

55 Jazz Pharmaceuticals plc Notestothe Consolidated Financial Statements (continued)

Themovement in deferredtax balances during 2019 was as follows (in thousands):

As at 31 Acquired in Foreign As at 31 December asset Recognised in Recognised in exchange and December 2018 acquisition profit or loss equity other 2019 Property, plant and equipment $(21,420) $—$18,123 $—$—$(3,297) Intangibleassets (594,086) (1,370) 257,519 —4,520 (333,417) Inventories41,267 —17,933 ——59,200 Employeebenefits 7,438 —2,753 ——10,191 Share-basedpayment transactions 22,137 —4,452 2,951 —29,540 Provisions 322 —59——381 Taxloss carry-forwards 82,873 3,924 (3,242) ——83,555 Researchand other taxcredits 144,193 5,319 35,526 ——185,038 Accruals, reservesand deferred revenue 49,894 —(4,663) —698 45,929 Other items32,029 —4,474 —1,154 37,657 Total $(235,353) $7,873 $332,934 $2,951 $6,372 $114,777

As at 31 December2020, we hadtax losses and other carryforwards in theU.S. (federaland state), Ireland, Luxembourg, theUnited Kingdom and Malta. We also had certain taxcredits in the U.S. (federaland state) and Ireland. U.S.federaltax losseswillexpire, if not utilised, in thetax years 2021 to 2036, andthe U.S. federaltax creditswillexpire, if not utilised, in thetax years 2021 to 2040. U.S.state taxlosses willexpire,ifnot utilised, in the taxyears 2021 to 2040. U.S.state tax credits andtax losses and other carryforwards in Ireland, Luxembourg, the UnitedKingdom andMalta have no expiration period. We also had foreign taxcreditscarried forward in Ireland of $45.6 million as at 31 December 2020 (2019: $41.7 million), which mayonly be utilised against certainsources of income.The foreign taxcreditshave no expiration period. Utilisation of deferredtax assets of $107.3 million, relating to taxlossesand othertemporary differences arising in Ireland, is dependent on future taxableprofits in excess of profits arising from thereversal of existing taxabletemporary differences, and we have incurred lossesinthe current andpreceding periods in the trade to which the deferred taxassets relate. We concluded that availableevidence supported therecognition of these deferred tax assets after an assessment of the relative impactofall positive andnegative evidence thatexistedat 31 December2020, including an evaluation of future sourcesoftaxable income exclusive of reversing temporary differences, the factthat the taxlossesand othertemporary differences have no expiration period, andsignificant risks anduncertaintiesrelatedtoour business. As at 31 December 2020, no deferredtax liability (2019: Nil) for temporary differencesof$1.9 billion (2019: $1.6 billion) related to undistributedearnings of investeeshas been recognised because theparent is abletocontrol the timing of the reversal of thetemporary differencesand it is probablethat the temporary differences will not reverse in theforeseeable future. Deferredtax assets have not been recognised in respect of the following items(in thousands):

31 December 2020 2019 Deductibletemporary differences$13,614 $8,598 Taxlosses 14,366 12,300 Taxcredits49,362 45,409 Total $77,342 $66,307

Deferredtax assets have not beenrecognisedinrespect of certain U.S.state,Luxembourg andMalta tax losses and similar deductions, U.S.and foreign taxcreditsand otherforeign deductible temporary differences,becauseitis not probable thatfuture taxable profitswillbeavailable against which we canutilise thebenefits therefrom.

56 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

As at 31 December2020, we have establishedaliabilityof$146.6 million (2019: $124.3 million) for gross uncertain taxpositions which we judge maynot be sustained upon examination.

12. Earnings Per Share Basic earnings per ordinary shareiscalculated by dividing net profit attributable to owners of the parent company by theweighted-average numberofordinary shares in issue during theyear. Diluted earnings per ordinary share is calculated by dividing net profit attributable to owners of the parent company by the weighted-average numberofordinary shares outstanding and potentiallydilutive ordinary shares outstanding. Basic and diluted earnings per ordinary share were computed as follows(in thousands, except per share amounts):

Year Ended 31 December 2020 2019 Numerator: Netprofitfor theyear$114,025 $311,032 Denominator: Weighted average shares –basic55,712 56,749 Dilutive effect of employeeincentive plans and purchaseplans 1,225 1,180 Weighted average shares –diluted56,937 57,929 Earnings per share: Basic $2.05 $5.48 Diluted $2.00 $5.37

The following tablerepresentsthe weighted-average ordinary shares thatwereexcluded from the computation of dilutedearnings per ordinary share forthe periods presentedbecause including them would have an anti-dilutive effect (in thousands):

Year Ended 31 December 2020 2019 Options, RSUs and purchase plans 4,866 4,719 2021 Notes1,904 2,878 2024 Notes2,625 2,625 2026 Notes3,559 —

57 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

13. Goodwilland Intangible Assets Goodwill and intangibleassets consistedofthe following (inthousands):

Total Acquired Priority Manufacturing goodwill and developed review contracts / Acquired intangible Goodwill technologies voucher trademarks IPR&D assets Cost: As at 31 December2018 $927,630 $3,242,847 $111,101 $15,151 $364,822 $4,661,551 Additions —80,500 ——133,775 214,275 Transfers —138,534 ——(138,534) — Disposals —(36,000) ———(36,000) Foreign exchange (7,612) (20,862) —(237) (2,679) (31,390) As at 31 December 2019 920,018 3,405,019 111,101 14,914 357,384 4,808,436 Additions —113,000 ——251,508 364,508 Transfers —200,000 ——(200,000) — De-recognised—(429) (111,101) —(169,624) (281,154) Foreign exchange 38,285 100,107 —1,138 (3,448) 136,082 As at 31 December 2020 $958,303 $3,817,697 $—$16,052 $235,820 $5,027,872

Accumulatedamortisation and impairment: As at 31 December 2018 $—$687,543 $—$15,151 $37,919 $740,613 Amortisation charge —258,895 ———258,895 Impairment charge —367,266 ——136,201 503,467 Disposals —(36,000) ———(36,000) Foreign exchange —(7,655) —(237) 3,125 (4,767) As at 31 December 2019 —1,270,049 —14,914 177,245 1,462,208 Amortisation charge —263,443 111,101 ——374,544 Impairment charge —163,052 ———163,052 De-recognised —(429) (111,101) —(169,624) (281,154) Foreign exchange —60,265 —1,138 (3,448) 57,955 As at 31 December 2020 $—$1,756,380 $—$16,052 $4,173 $1,776,605

Netbook value: As at 31 December 2020 $958,303 $2,061,317 $—$—$231,647 $3,251,267 As at 31 December 2019 $920,018 $2,134,970 $111,101 $—$180,139 $3,346,228

In January 2020, we capitalised an upfront payment of $200.0 million to PharmaMar, in connection with our license agreement for Zepzelca, to acquiredIPR&D as an indefinite-lived intangibleasset. Upon FDA approval of ZepzelcainJune 2020, we reclassifiedthisacquired IPR&Dassettoacquireddevelopedtechnologiesfinite-lived intangible assets. The additions to acquireddevelopedtechnologiesin2020 reflectthe capitalisation of milestone paymentsof$100.0 million and $13.0 milliontriggeredbyFDA approval of ZepzelcainJune 2020 and European Marketing Authorization of Sunosi in January 2020, respectively. The additions to acquireddevelopedtechnologiesin2019 reflectthe capitalisation of milestone payments triggeredbyFDA approval of Sunosi in March2019 and subsequent U.S. Drug Enforcement Administration, or DEA, scheduling in June 2019. After receiving DEA scheduling we reclassified$138.1 million from acquired IPR&D to acquired developed technology finite-livedintangible assets. On 30 April 2018, we entered into an agreement with Spark Therapeutics, Inc., or Spark, to purchase arare pediatric disease PRVfrom Spark. In consideration for thePRV,wepaidSpark $110.0 million andwecapitalised

58 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) the acquisition cost, including direct transaction costs, as a finite-lived intangible asset upon closing of the transaction in May 2018. In January 2020, we redeemed the PRV in the submission of the NDA for Xywav, at which point the PRV intangible asset was amortised in full. Our acquired developed technology intangible assets are related to Vyxeos, Defitelio, Zepzelca, Sunosi, and Erwinaze/Erwinase. The carrying values of these assets as at 31 December 2020 were $960.8 million, $567.3 million, $282.8 million, $202.5 million and $47.9 million, respectively. The carrying values of Vyxeos, Defitelio, Sunosi and Erwinaze/Erwinase as at 31 December 2019 were $1.2 billion, $592.2 million, $208.8 million and $131.9 million, respectively. As at 31 December 2020, the remaining useful lives of the Vyxeos, Defitelio, Zepzelca, Sunosi and Erwinaze/Erwinase assets were 15 years, 9 years, 9 years, 10 years and 6 months, respectively. The weighted-average remaining useful life of acquired developed technologies as at 31 December 2020 was 11.6 years (2019: 12.7 years). The impairment charge within acquired developed technologies of $163.1 million recognised in 2020 relates to Vyxeos and reflects a reassessment of the estimated future cash flows associated with this product. The recoverable amount of $960.8 million as at 31 December 2020 was based on value in use. In determining value in use, the estimated future cash flows were discounted at a rate of 8% on a pre-tax basis. In 2019, we recorded an impairment charge of $367.3 million related to Vyxeos. The impairment charge within acquired IPR&D in 2019 of $136.2 million reflects the decision to stop enrolment in our Phase 3 clinical study of defibrotide for the prevention of VOD due to a determination that the study is highly unlikely to reach one of its primary endpoints. The amortisation of acquired developed technologies and the 2020 and 2019 impairment charges of acquired developed technologies are included in cost of product sales in the consolidated income statement. The amortization of the PRV intangible asset and the 2019 impairment charge recognised in relation to acquired IPR&D are included in research and development expenses in the consolidated income statement. In addition to the $200.0 million upfront payment to PharmaMar that was capitalised to acquired IPR&D, and subsequently reclassified to acquired developed technologies finite-lived intangible assets upon FDA approval of Zepzelca, the additions to acquired IPR&D during 2020 primarily reflect the capitalisation of an upfront payment to SpringWorks' of $35.0 million, net of certain inventory acquired of $0.7 million, and an upfront payment to Redx Pharma plc. of $10.0 million. Additions to acquired IPR&D during 2019 primarily relate to IPR&D acquired in the acquisition of Cavion and in the strategic collaboration with Codiak. Details of these transactions are set out in Note 4. In 2020, we de-recognised the cost and accumulated amortisation for a number of intangible assets that were fully amortised or impaired, as these assets are no longer in use and therefore there are no remaining future economic benefits. As at 31 December 2020 the carrying amount of intangible assets pledged as security under our amended credit agreement was $1.9 billion (2019: $1.9 billion). For the purpose of impairment testing of goodwill, we have a single cash-generating unit which corresponds to the operating segment level. The recoverable amount of the cash-generating unit is based on fair value less costs to sell. Our market capitalisation, as determined by our traded share price plus a control premium, has been used to calculate fair value. The control premium used was based on a review of such premia identified in recent acquisitions of companies of similar size and in similar industries (Level 2). We performed our annual goodwill impairment test in October 2020 and concluded that goodwill was not impaired as the fair value of the Group cash- generating unit significantly exceeded its carrying amount, including goodwill.

59 Jazz Pharmaceuticals plc Notestothe Consolidated Financial Statements (continued) 14. Property, Plant and Equipment Property, plant and equipment consisted of thefollowing (in thousands):

Manufacturing Construction in Computer Leasehold equipment& Fixtures & Land & progress equipment improvements machinery fittings buildings Total Cost: As at 31 December2018 $6,155 $32,746 $33,271 $26,853 $8,149 $47,150 $154,324 Additions 38,763 1,841 568 883 72842,090 Disposals (83) (5,626) (1,855) (192) (532) —(8,288) Transfers (39,983) 13,312 20,271 2,453 3,529 418 — Foreign exchange 7(11) 38 (138) (7) (43) (154) As at 31 December2019 4,859 42,262 52,293 29,859 11,146 47,553 187,972 Additions 8,833 2,882 137 1,994 238 71 14,155 Disposals (279) (7,135) (135) (273) (3) —(7,825) Transfers (6,628) 3,292 1,327 1,657 136 216 — Foreign exchange 190 234 490 1,227 75 214 2,430 As at 31 December2020 $6,975 $41,535 $54,112 $34,464 $11,592 $48,054 $196,732 60

Accumulateddepreciation: As at 31 December2018 $—$25,663 $7,934 $8,496 $2,710 $3,351 $48,154 Charged in year—5,486 4,081 2,936 1,698 1,240 15,441 Disposals —(5,582) (1,851) (178) (528) —(8,139) Foreign exchange —(17) 10 (77) (4) (11) (99) As at 31 December2019 —25,550 10,174 11,177 3,876 4,580 55,357 Charged in year—6,870 5,076 3,437 2,136 1,260 18,779 Disposals —(7,129) (106) (247) (3) —(7,485) Foreign exchange —193 288 543 39 79 1,142 As at 31 December2020 $—$25,484 $15,432 $14,910 $6,048 $5,919 $67,793

Netbook value: As at 31 December2020 $6,975 $16,051 $38,680 $19,554 $5,544 $42,135 $128,939 As at 31 December2019 $4,859 $16,712 $42,119 $18,682 $7,270 $42,973 $132,615

As at 31 December2020 thecarrying amount of property, plant and equipment pledged as security underour amendedcredit agreement was $109.4 million (2019: $118.1 million). For details of authorised capitalexpenditure,pleasesee Note 27. Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

15. Derivative Financial Instruments Derivative financialinstrumentsconsistedofthe following (inthousands):

31 December 2020 2019 Current assets: Foreign exchange forward contracts-not designatedashedges$11,907 $2,508 Current liabilities: Interestrateswaps -cash flow hedges2,835 855 Foreign exchange forward contracts-not designatedashedges 790 182 Total current liabilities3,625 1,037 Non-current liabilities: Embeddedderivatives-ExchangeableSenior Notes 424,469 83,967 Interest rate swaps -cash flow hedges —660 Total non-current liabilities424,469 84,627 Net liability arising on derivative financial instruments $416,187 $83,156

Foreign exchange forward contracts We enter into foreign exchange forward contracts, with durations of up to 365 days, designedtolimit the exposure to fluctuations in foreign exchange rates related to the translation of certainnon-U.S. dollardenominated liabilities, including intercompany balances. Hedge accounting is not applied to these derivative instrumentsas gains and losses on these hedge transactions are designed to offset gains and lossesonunderlying balancesheet exposures. As of 31 December2020 and 2019,the notional amount of foreign exchange contractswhere hedge accounting wasnot applied was $357.4 million and $180.9 million,respectively.

Interestrateswaps To achieve adesiredmix of floating and fixed interestrates on our variable ratedebt, we enteredinto interest rateswapagreementsinMarch2017 which mature on 12 July2021. These agreements hedge contractualterm loan interest rates. As of 31 December2020 and 2019, theinterestrateswapagreementshad anotionalamount of $300.0 million. As aresult of these agreements, the interest rate on aportion of our term loanborrowings wasfixed at 1.895%, plus the borrowing spread, until 12 July 2021. The effective portion of changes in thefairvalue of derivativesdesignated as and thatqualify as cash flow hedges is recorded in othercomprehensive loss and is subsequently reclassifiedintothe income statement in theperiod that the hedgedforecastedtransaction affects profit or loss.

Embedded derivatives The ExchangeableSenior Notes containembeddedderivatives, including theexchange option, that require separation as their economic characteristics and risks are not deemedtobeclosely relatedtothe host contract.The fairvalue of theembedded derivative liabilityisremeasured at each reporting period, with changesinfairvalue recognised in the consolidated incomestatement.

61 Jazz Pharmaceuticals plc Notes tothe ConsolidatedFinancial Statements(continued)

16. OtherNon-Current Assets Othernon-current assets consistedofthe following (inthousands):

31 December 2020 2019 Options acquired undercollaboration andoption agreements$12,200 $87,200 Other 30,959 36,167 Total $43,159 $123,367

In 2020, we exercisedour opt-out right on the collaboration andoption agreement with Immunogen, resulting in theimpairment of the non-current asset of $75.0 million. The impairment charge wasrecognised withinresearch and development expense.

17. Inventories Inventoriesconsisted of thefollowing (inthousands):

31 December 2020 2019 Rawmaterials$16,003 $13,595 Work in progress45,758 36,658 Finishedgoods 33,860 28,580 Total $95,621 $78,833

In 2020, the costofinventoriesincludedincost of product salesamounted to $50.6 million (2019: $45.2 million). In 2020, thewrite-downofinventories to netrealisable value amounted to $15.0 million (2019: $6.7 million).

18. Trade andOther Receivables Trade andotherreceivables consisted of thefollowing (in thousands):

31 December

2020 2019 Trade receivables$396,490 $355,987 Prepayments62,422 39,434 Otherreceivables 25,966 22,637 Total $484,878 $418,058

Our exposure to creditriskand impairment lossesrelated to trade and other receivablesisdisclosedin Note 26.

62 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

19. Cash, Cash Equivalents and Investments Cash and cash equivalents consistedofthe following (inthousands):

31 December

2020 2019 Cash $517,118 $333,172 Moneymarket funds 255,651 284,172 Time deposits-initial maturities threemonths or less 285,000 20,000 Total $1,057,769 $637,344

Investmentsconsistedofthe following (inthousands):

31 December

2020 2019 Time deposits-initialmaturitiesgreater than three months $1,075,000 $440,000

20. Accruedand OtherLiabilities Accruedand other current liabilities consistedofthe following (inthousands):

31 December 2020 2019 Rebates and other salesdeductions (Note3)$127,534 $96,860 Employeecompensation and benefits 102,601 80,531 Sales returns reserve (Note 3) 18,368 3,462 Royalties15,230 6,931 Current portion of leaseliabilities14,457 12,728 Inventory-related accruals9,809 7,816 Clinicaltrialaccruals9,108 3,141 Selling and marketing accruals 6,742 10,946 Consulting &professionalservices 6,660 7,665 Accrued interest 5,722 7,540 Accrued construction-in-progress 1,119 3,015 Accrued collaboration expenses 444 2,494 Otheraccruedliabilities 30,769 24,791 Total $348,563 $267,920

Other non-current liabilities consisted of thefollowing (in thousands):

31 December 2020 2019 Pension liability$1,203 $845 Other1717 Total $1,220 $862

63 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

21. Provisions Provisions consistedofthe following (in thousands):

Social security Onerous on share contract awards Total As at 31 December 2019 $1,314 $2,018 $3,332 Arising during the year408 1,822 2,230 Utilisedduring theyear(730) (827) (1,557) As at 31 December2020 $992 $3,013 $4,005 Analysedas: Current $545 $2,048 $2,593 Non-current 447 965 1,412 Total $992 $3,013 $4,005

Onerous contract Thisprovision is in relation to an onerous take-or-pay manufacturing contract.Itisexpectedthatthe provision will be paidin2022.

Social securityonshare awards The provision for social security contributions on share awards is calculatedbased on thenumber of awards outstanding at thereporting datethat are expected to be exercised, and using themarketprice of our ordinary shares at the reporting date as the best estimateofmarketprice at the dateofexercise. It is expected that the costs will be incurred during the exercise period of 1January 2021 to 31 December2030.

22. Loans and Borrowings Loans and borrowings consisted of thefollowing (inthousands):

31 December

2020 2019 Term loan $581,702 $613,981 2021 Notes210,248 518,844 2024 Notes497,086 478,169 2026 Notes846,648 — Total $2,135,684 $1,610,994 Analysedas: Current $243,635 $33,387 Non-current 1,892,049 1,577,607 Total $2,135,684 $1,610,994

64 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Thechange in liabilities arising from financing activities during 2020 was as follows (in thousands):

Reclassification Additions, and Amortisation of non-current foreign 1January of debt Changes in to currentloans currency 31 December 2020 Cash flows discount (1) fair value and borrowings adjustments (2) 2020 Current interest bearing loans and borrowings $33,387 $(33,387) $—$—$243,635 $—$243,635 Non-current interest bearing loans and borrowings 1,577,607 484,900 73,177 —(243,635) —1,892,049 Embedded derivatives (Note15) 83,967 140,293 —200,209 ——424,469 Leaseliabilities (Note23) 163,954 $(13,366) —— —3,904 154,492 Total liabilities from financing activities$1,858,915 $578,440 $73,177 $200,209 $—$3,904 $2,714,645

(1) Includes loss on extinguishment of debt during the yearof$17.7 million. (2) Includes leaseliabilitiesduring the yearof$3.0 million andthe impactofforeign exchange adjustmentsof $0.9 million. The change in liabilities arising from financing activities during 2019 was as follows (in thousands):

Reclassification Additions, Amortisation of non-current disposals and 1January of debt Changes in to currentloans foreign currency 31 December 2019 Cash flows discount fair value and borrowings adjustments (1) 2019 Current interest bearing loans and borrowings $33,387 $(33,387) $—$—$33,387 $—$33,387 Non-current interest bearing loans and borrowings 1,561,047 —49,947 —(33,387) —1,577,607 Embedded derivatives(Note 15) 70,938 ——13,029 ——83,967 Leaseliabilities (Note23) $162,879 $(2,957) —— —$ 4,032 $163,954 Total liabilities from financing activities$1,828,251 $(36,344) $49,947 $13,029 $—$4,032 $1,858,915

(1) Includes leaseliabilitiesduring theyearof$4.2 million, offsetbythe impact of foreign exchange adjustments of $0.2 million.

Creditfacility On 18 June 2015, Jazz Pharmaceuticals plc, as guarantor, and certainofour wholly ownedsubsidiaries, as borrowers, entered into acredit agreement,orthe 2015 credit agreement,thatprovided for a$750.0 million principal amount term loan, which wasdrawninfullatclosing, and a$750.0 million revolving credit facility, of which $160.0 million was drawnatclosing and subsequently repaid. We used the proceeds from initialborrowings under the 2015 credit agreement to repay in full the $893.1 million principal amount of term loans outstanding under the credit agreement thatweentered into in June 2012, as subsequently amended, which we refertoasthe previous

65 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) credit agreement, and to pay related fees and expenses. The previous credit agreement was terminated upon repayment of the term loans outstanding thereunder.

On 12 July 2016, we amended the 2015 credit agreement to provide for a revolving credit facility of $1.25 billion and a $750.0 million term loan facility. We used the proceeds of $1.0 billion of loans under the revolving credit facility, together with cash on hand, to fund the acquisition of Celator Pharmaceuticals Inc.

On 7 June 2018, we entered into a second amendment to the 2015 credit agreement to provide for a revolving credit facility of $1.6 billion, which replaced the existing revolving credit facility of $1.25 billion, and a new $667.7 million term loan facility, which replaced the $750.0 million term loan facility, of which $584.3 million (2019: $617.7 million) principal amount was outstanding as at 31 December 2020. We refer to the 2015 credit agreement as amended by the first and second amendments as the amended credit agreement.

Under the amended credit agreement, the term loan matures on 7 June 2023 and the revolving credit facility terminates, and any loans outstanding thereunder become due and payable, on 7 June 2023. Borrowings under the amended credit agreement bear interest, at our option, at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 1.375% to 1.750% per annum, based upon our secured leverage ratio, or (b) the prime lending rate, plus an applicable margin ranging from 0.375% to 0.750% per annum, based upon our secured leverage ratio. The revolving credit facility has a commitment fee payable on the undrawn amount ranging from 0.25% to 0.35% per annum based upon our secured leverage ratio. As at 31 December 2020, the interest rate on the term loan was 1.52% and the effective interest rate was 3.66%. As at 31 December 2020, we had undrawn amounts under our revolving credit facility totalling $1.6 billion. Jazz Pharmaceuticals plc and certain of our wholly owned subsidiaries are borrowers under the amended credit agreement. The borrowers’ obligations under the amended credit agreement and any hedging or cash management obligations entered into with a lender are guaranteed on a senior secured basis by Jazz Pharmaceuticals plc and certain of our subsidiaries (including the issuer of the Exchangeable Senior Notes as described below) and are secured by substantially all of Jazz Pharmaceuticals plc’s, the borrowers’ and the guarantor subsidiaries’ assets.

We may make voluntary prepayments of principal at any time without payment of a premium. We are required to make mandatory prepayments of the term loan (without payment of a premium) with (1) net cash proceeds from certain non-ordinary course asset sales (subject to other exceptions), (2) net cash proceeds from issuances of debt (other than certain permitted debt), and (3) casualty proceeds and condemnation awards (subject to other exceptions).

Principal repayments of the term loan, which are due quarterly, are equal to 5.0% per annum of the principal amount outstanding on 7 June 2018 of $667.7 million, with any remaining balance payable on the maturity date. The amended credit agreement contains financial covenants that require Jazz Pharmaceuticals plc and our restricted subsidiaries to not (a) exceed a maximum secured net leverage ratio or (b) fall below a cash interest coverage ratio. As at 31 December 2020, we were in compliance with these financial covenants.

Exchangeable Senior Notes Due 2026 In the second quarter of 2020, Jazz Investments I Limited, our wholly owned subsidiary, completed a private placement of $1.0 billion principal amount of the 2026 Notes. We used a portion of the net proceeds from this offering to repurchase for cash $332.9 million aggregate principal amount of the 2021 Notes through privately- negotiated transactions concurrently with the offering of the 2026 Notes. Interest on the 2026 Notes is payable semi-annually in cash in arrears on 15 June and 15 December of each year, beginning on 15 December 2020, at a rate of 2.00% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2026 Notes. The 2026 Notes mature on 15 June 2026, unless earlier exchanged, repurchased or redeemed. The holders of the 2026 Notes have the ability to require us to repurchase all or a portion of their 2026 Notes for cash in the event we undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2026 Notes include certain events of default after which the 2026 Notes may be due and payable immediately. Prior to 15 June, 2026, we may redeem

66 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) the 2026 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2026 Notes additional amounts as a result of certain tax-related events. We also may redeem the 2026 Notes on or after 20 June, 2023 and prior to 15 March, 2026, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption. The 2026 Notes are exchangeable at an initial exchange rate of 6.4182 ordinary shares per $1,000 principal amount of 2026 Notes, which is equivalent to an initial exchange price of approximately $155.81 per ordinary share. Upon exchange, the 2026 Notes may be settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal amount of the 2026 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2026 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2026 Notes who elect to exchange their 2026 Notes in connection with that make- whole fundamental change or during the related redemption period. Prior to 15 March, 2026, the 2026 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.

Exchangeable Senior Notes 2024 In the third quarter of 2017, we completed a private placement of $575.0 million principal amount of 2024 Notes. We used the net proceeds from this offering to repay $500.0 million in outstanding loans under the revolving credit facility and to pay related fees and expenses. We used the remainder of the net proceeds for general corporate purposes. Interest on the 2024 Notes is payable semi-annually in cash in arrears on 15 February and 15 August of each year, beginning on 15 February 2018, at a rate of 1.50% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2024 Notes. The 2024 Notes mature on 15 August 2024, unless earlier exchanged, repurchased or redeemed. The holders of the 2024 Notes have the ability to require us to repurchase all or a portion of their 2024 Notes for cash in the event we undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from The Nasdaq Global Select Market. Prior to 15 August 2024, we may redeem the 2024 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2024 Notes additional amounts as a result of certain tax-related events. We also may redeem the 2024 Notes on or after 20 August 2021, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption. The 2024 Notes are exchangeable at an initial exchange rate of 4.5659 ordinary shares per $1,000 principal amount of 2024 Notes, which is equivalent to an initial exchange price of approximately $219.02 per ordinary share. Upon exchange, the 2024 Notes may be settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal amount of the 2024 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2024 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2024 Notes who elect to exchange their 2024 Notes in connection with that make- whole fundamental change or during the related redemption period. Prior to 15 May 2024, the 2024 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.

Exchangeable Senior Notes Due 2021 In August 2014, we completed a private placement of $575.0 million principal amount of the 2021 Notes, resulting in net proceeds to us, after debt issuance costs, of $558.9 million. Interest on the 2021 Notes is payable semi-annually in cash in arrears on 15 February and 15 August of each year, beginning on 15 February 2015, at a

67 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) rate of 1.875% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2021 Notes. The 2021 Notes mature on 15 August 2021, unless earlier exchanged, repurchased or redeemed. The holders of the 2021 Notes have the ability to require us to repurchase all or a portion of their 2021 Notes for cash in the event Jazz Pharmaceuticals plc undergoes certain fundamental changes. Prior to 15 August 2021, we may redeem the 2021 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2021 Note additional amounts as a result of certain tax-related events. We also may redeem the 2021 Notes on or after 20 August 2018, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption. The 2021 Notes are exchangeable at an initial exchange rate of 5.0057 ordinary shares per $1,000 principal amount of 2021 Notes, which is equivalent to an initial exchange price of approximately $199.77 per ordinary share. Upon exchange, the 2021 Notes may be settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal amount of the 2021 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2021 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2021 Notes who elect to exchange their 2021 Notes in connection with that make- whole fundamental change or during the related redemption period. Prior to 15 February 2021, the 2021 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Concurrently with the offering of the 2026 Notes, we repurchased $332.9 million aggregate principal amount of the 2021 Notes. In the third quarter of 2020, we repurchased a further $23.3 million aggregate principal amount of the 2021 Notes. We recorded a loss on extinguishment of debt of $17.7 million in 2020, related to the partial repurchase of the 2021 Notes. As of 31 December 2020, the principal amount of the 2021 Notes remaining was $218.8 million. The Exchangeable Senior Notes were issued by Jazz Investments I Limited, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Exchangeable Senior Notes are senior unsecured obligations of the Issuer and are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the Exchangeable Senior Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted. The Exchangeable Senior Notes contain embedded derivatives, including the exchange option, that require separation as their economic characteristics and risks are not deemed to be closely related to the host contract. The initial fair values of the embedded derivative liability in the 2021 Notes, 2024 Notes and 2026 Notes were $180.5 million, $121.7 million and $148.1 million, respectively. The fair value of the embedded derivative liability is remeasured at each reporting period, with changes in fair value recognised in the consolidated income statement. The aggregate fair value of the embedded derivative liabilities as at 31 December 2020 was $424.5 million (2019: $84.0 million). We recognised a gain on the change in the fair value of the embedded derivative liability relating to the 2021 Notes of $8.9 million during the year ended 31 December 2020 (2019: loss of $4.0 million), a loss on the change in the fair value of the embedded derivative liability relating to the 2024 Notes of $2.4 million during the year ended 31 December 2020 (2019: loss of $9.0 million), and a loss on the change in the fair value of the embedded derivative liability relating to the 2026 Notes of $206.7 million during the year ended 31 December 2020.

68 Jazz Pharmaceuticals plc Notes tothe ConsolidatedFinancial Statements (continued)

23. Leases We have noncancellableleasesfor our office buildings andweare obligated to make payments under noncancellableleasesfor automobiles usedbyour salesforce. The amounts recognisedinthe profitorloss for which theGroup is lessee wereasfollows (in thousands):

Year Ended 31 December Lease Cost 2020 2019 Depreciation charge of right-of-useassets: Buildings $15,088 $16,445 Vehicles1,369 1,221 Interestexpense on leaseliabilities8,252 8,586 Short-term lease cost 4,031 2,613 Variable lease cost 10 7 Sublease income (224) (634) Netlease cost $28,526 $28,238

Supplementalbalance sheet information relatedtoleaseswas as follows (in thousands):

31 December Leases Classification 2020 2019 Assets Buildings $120,087 $134,533 Vehicles2,872 1,553 Total right-of-use assets Right-of-useassets $122,959 $136,086

Liabilities Current Accruedliabilities $14,457 $12,728 Non-current Lease liabilities, less current portion 140,035 151,226 Total lease liabilities$154,492 $163,954

Lease DiscountRate 1January 2020 1January 2019 Weighted-average discount rate -lease liabilities 5.3 %5.3 %

Other supplementalinformation related to leases wasasfollows (in thousands):

Year Ended 31 December 2020 2019 Cash paid for amountsincludedinthe measurement of leaseliabilities: Operating cash outflows from leaseliabilities$8,252 $8,586 Financing cash outflows from leaseliabilities13,426 8,480 Additions to right-of-use assets: Right-of-useassets obtained in exchange for lease liabilities (1) $1,763 $153,448

______(1) Includes the balances recognisedonJanuary 1, 2019 on adoption of IFRS16. Amaturityanalysisofour lease liabilities as at 31 December2020 has beendisclosedwithinNote 26.

69 Jazz Pharmaceuticals plc Notestothe Consolidated Financial Statements (continued)

24. ShareCapital and OtherReserves

Share capital As at 31 December2020 and2019, the authorised share capital of the parent company comprised300,000,000 ordinary shares of $0.0001 each and4,000,000 non-voting euro deferredshares of €0.01 each. Details of issued and fullypaid-up sharecapitalisset out in theparent company statement of changesinshareholders’ equity.

Share repurchase programme In November2016, our board of directors authorised ashare repurchase programme and as of 31 December2020 had authorised the repurchase of up to $1.5 billion, exclusive of any brokerage commissions. Under thisprogramme, whichhas no expiration date,wemay repurchase ordinary sharesfrom time to time on the open market. Thetiming andamount of repurchases will depend on avariety of factors, including theprice of our ordinary shares,alternative investment opportunities, restrictions under the amendedcredit agreement,corporate and regulatory requirementsand market conditions. The share repurchase programmemay be modified, suspended or discontinuedatany time without prior notice.In2020, we spent atotal of $146.5 million to purchase 1.2 million of our ordinary shares at an average totalpurchase price,including brokerage commissions, of $121.98 per share. In 2019, we spent atotal of $301.5 million to purchase 2.3 million of our ordinary sharesatanaverage total purchase price, including brokerage commissions, of $133.97 per share. All ordinary shares repurchased were cancelled. As of 31 December2020, the remaining amount authorised underthe share repurchase programme was $431.2 million (2019: $577.7 million).

Authorisedbut unissuedordinary shares We had reserved thefollowing sharesofauthorised but unissuedordinary shares (in thousands):

31 December

2020 2019 2011 Equity Incentive Plan 21,070 19,552 2007 EmployeeStock Purchase Plan 2,600 1,883 Amended andRestated2007 Non-Employee Directors Stock Award Plan 889 438 2007 Equity Incentive Plan 513 Amended andRestatedDirectors DeferredCompensation Plan —178 Total 24,564 22,064

Othercapital reserves Other capitalreserves consisted of thefollowing (in thousands):

Other Reverse Total other undenominated acquisition capital capital reserve reserves Balance as at 31 December2020 and 2019 $472 $(1,018,971) $(1,018,499)

Share premium The share premium account comprisesexcess moniesreceived in respectofshare capitaloverthe nominal value of shares issued. On 26 November2020, the Irish High Court approved thereduction of $951.2 millionofthe company’s share premium account withthe resulting reserve to be treatedasprofitsavailable for distribution. The High Court orderwas registered with the Companies Registration Officeon27November 2020. On 11 April 2013, theIrish High Court approved thereduction of $1.6 billion of thecompany’s share premium account with theresulting reserve to be treated as profits availablefor distribution. TheHigh Court order was registered with the CompaniesRegistration Officeon12April 2013.

70 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Otherreserves Otherreservesconsistedofthe following (inthousands):

Foreign currency Cash flow translation Total other hedge reserve reserve reserves Balance as at 31 December2018 $3,557 $(200,664) $(197,107) Other comprehensive loss before reclassifications (3,903) (22,685) (26,588) Reclassifications to income statement (979) —(979) Balance as at 31 December2019 (1,325) (223,349) (224,674) Othercomprehensive income (loss)before reclassifications (4,543) 91,293 86,750 Reclassifications to incomestatement 3,401 —3,401 Balance as at 31 December2020 $(2,467) $(132,056) $(134,523)

Nature and purpose of reserves Share-basedcompensation reserve:Thisreserveisusedtorecognise the value of equity-settledshare-based payment transactions providedtoemployeesaspartoftheirremuneration. For further details, please seeNote 25. Other undenominated capital:Thisreserveisrequiredtobecreated underIrishlaw to preserve permanent capital in theparent company. Reverse acquisition reserve:Following the Azur Merger, areverse acquisition reserve has beencreated to enable presentation of aconsolidated balance sheet thatcombines the equity structure of the legal parent withthe reservesofthe legalsubsidiary. Cashflow hedge reserve:The cash flow hedge reserve is usedtorecord theeffective portion of changesinthe fairvalue of derivatives designatedasand that qualify as cashflow hedgesand is subsequently reclassifiedintothe income statement in theperiod that the hedgedforecastedtransaction affects profit or loss. Foreign currency translation reserve:The foreign currency translation reserve is usedtorecord exchange differences arising from thetranslation of the financial statementsofforeign subsidiaries.

25. Share-Based Payments

2011 Equity Incentive Plan On 18 January 2012, thebusinessesofJazzPharmaceuticals, Inc. andAzur Pharma were combined in a merger transaction, or the Azur Merger. In connection with theAzur Merger, Jazz Pharmaceuticals, Inc.’s board of directors adoptedthe 2011 Equity Incentive Plan, or the2011 Plan, in October 2011 andits stockholders approved the 2011 Plan at thespecialmeeting of the stockholders heldinDecember 2011 in connection withthe Azur Merger. The 2011 Plan became effective immediately before theconsummation of the Azur Merger andwas assumed and adopted by us upon the consummation of theAzur Merger. The terms of the 2011 Plan provide for thegrant of stock options, stock appreciation rights, RSUs, other stockawards,and performance awards thatmay be settledin cash, shares, or otherproperty. All outstanding grantsunder the 2011 Plan were granted to employees and vest ratablyover service periods of four years and expire no more than10years afterthe dateofgrant. As of 31 December2020, atotalof29,538,645 of our ordinary shareshad beenauthorised for issuance under the2011 Plan. In addition, theshare reserve under the2011 Planwill automaticallyincrease on 1January of each year through 1January 2022, by the least of (a)4.5% of the total numberofordinary shares outstanding on 31 December of the preceding calendar year, (b) 5,000,000 shares, or (c) such lessernumberofordinary shares as determinedby our board of directors. On 1January 2021, theshare reserve under the2011 Planautomaticallyincreased by 2,526,437 ordinary shares pursuant to thisprovision.

2007 Equity Incentive Plan The 2007 Equity Incentive Plan, or the2007 Plan, which wasinitially adoptedbythe Jazz Pharmaceuticals, Inc. board of directors and approvedbythe Jazz Pharmaceuticals, Inc. stockholders in connection withits initial

71 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) public offering, was continued and assumed by us upon consummation of the Azur Merger. The 2007 Plan provided for the grant of stock options, RSUs, stock appreciation rights, performance stock awards and other forms of equity compensation to employees, including officers, non-employee directors and consultants. Prior to the consummation of the Azur Merger, all of the grants under the 2007 Plan were granted to employees and vest ratably over service periods of three to five years and expire no more than 10 years after the date of grant. Effective as of the closing of the Azur Merger on 18 January 2012, the number of shares reserved for issuance under the 2007 Plan was set to 1,000,000 ordinary shares. The share reserve under the 2007 Plan will not automatically increase. Since the Azur Merger, all of the new grants under the 2007 Plan were granted to non-employee directors, vest ratably over service periods of one to three years and expire no more than 10 years after the date of grant. The 2007 Plan expired in April 2017, and accordingly, no new grants can be awarded under the 2007 Plan. As of 31 December 2020, the number of shares reserved represents issuable shares from options granted but not yet exercised under the 2007 Plan.

2007 Employee Stock Purchase Plan In 2007, Jazz Pharmaceuticals, Inc.’s employees became eligible to participate in the ESPP. The ESPP was amended and restated by Jazz Pharmaceuticals, Inc.’s board of directors in October 2011 and approved by its stockholders in December 2011. The amended and restated ESPP became effective immediately prior to the effective time of the Azur Merger and was assumed by us upon the consummation of the Azur Merger. The amended and restated ESPP allows our eligible employee participants (including employees of any of a parent or subsidiary company if our board of directors designates such company as eligible to participate) to purchase our ordinary shares at a discount of 15% through payroll deductions. The ESPP consists of a fixed offering period of 24 months with four purchase periods within each offering period. The number of shares available for issuance under our ESPP during any six-month purchase period is 175,000 shares. As of 31 December 2020, a total of 5,263,137 of our ordinary shares had been authorised for issuance under the ESPP. The share reserve under the ESPP will automatically increase on 1 January of each year through 1 January 2022, by the least of (a) 1.5% of the total number of ordinary shares outstanding on 31 December of the preceding calendar year, (b) 1,000,000 shares, and (c) such lesser number of ordinary shares as determined by our board of directors or a duly-authorised committee thereof. On 1 January 2021, the share reserve under the ESPP automatically increased by 842,145 ordinary shares pursuant to this provision.

Amended and Restated 2007 Non-Employee Directors Stock Award Plan The Amended and Restated 2007 Non-Employee Directors Stock Award Plan, or the 2007 Directors Award Plan, which was initially adopted by the Jazz Pharmaceuticals, Inc. board of directors and approved by the Jazz Pharmaceuticals, Inc. stockholders in connection with its initial public offering, was continued and assumed by us upon the consummation of the Azur Merger. Until October 2011, the 2007 Directors Award Plan provided for the automatic grant of stock options to purchase shares of Jazz Pharmaceuticals, Inc.’s common stock to its non- employee directors initially at the time any individual first became a non-employee director, which vest over three years, and then annually over their period of service on its board of directors, which vest over one year. On 24 October 2011, Jazz Pharmaceuticals, Inc.’s board of directors amended the 2007 Directors Award Plan to eliminate all future initial and annual automatic grants so that future automatic grants would not be made that would be subject to the excise tax imposed by Section 4985 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, in connection with the Azur Merger. Accordingly, all future stock option grants under the 2007 Directors Award Plan will be at the discretion of our board of directors. Since the Azur Merger, all of the new grants under the 2007 Directors Award Plan were granted to non-employee directors and vest ratably over service periods of one to three years and expire no more than 10 years after the date of grant. In addition, the 2007 Directors Award Plan provides the source of shares to fund distributions made prior to 15 August 2010 under the Directors Deferred Compensation Plan described below. In August 2016, our shareholders approved our proposal to expand the types of stock awards that may be granted to our non-employee directors under the 2007 Directors Award Plan and eliminate the final automatic share reserve increase under the 2007 Directors Award Plan that was scheduled to occur on 1 January 2017. In July 2020, our shareholders approved our proposal to increase the number of ordinary shares authorised for issuance under the 2007 Directors Award Plan by 500,000 shares. As of 31 December 2020, a total of 1,403,938 of our ordinary shares had been authorised for issuance under the 2007 Directors Award Plan.

72 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Amended and Restated DirectorsDeferredCompensation Plan In May2007, the Jazz Pharmaceuticals, Inc.board of directors adoptedthe Directors DeferredCompensation Plan, or the Directors Deferred Plan, whichwas amendedinDecember2008 and was thenamendedand restatedin August 2010, and which was continued andassumedbyusupon consummation of theAzur Merger. The Directors DeferredPlanallows each non-employee director to electtodefer receipt of alloraportion of his or her annual retainer fees to afuture dateordates.Amounts deferredunder theDirectors DeferredPlanare credited as shares of Jazz Pharmaceuticals, Inc.’s common stock (or our ordinary shares following theAzur Merger) to aphantom stock account,the numberofwhich arebased on the amount of theretainerfeesdeferreddivided by themarketvalue of Jazz Pharmaceuticals, Inc.’s common stock(or our ordinary shares following the Azur Merger) on thefirst trading day of thefirst open window period following the datethe retainerfeesare deemed earned. On the 10thbusiness day following theday of separation from theboard of directors or the occurrence of achange in control,orassoon thereafteraspracticaloncethe non-employee director has providedthe necessary information for electronic deposit of the deferred shares, eachnon-employeedirector willreceive (or commence receiving, depending upon whether the director has electedtoreceive distributions from his or her phantom stock account in alump sum or in instalmentsover time)adistribution of hisorher phantom stockaccount,inour ordinary shares(i) reservedunder the 2007 Directors Option Planprior to 15 August 2010 and (ii) from anew reserve of 200,000 sharesset up under the Directors DeferredPlan on 15 August 2010. Since the consummation of theAzur Mergerwehave not permitted non-employeedirectors to defer anyannualretainerfeesunder the Directors DeferredPlan. On 31 October2019, our board of directors approvedthe termination of theDirectors DeferredPlan, andall outstanding phantom stock was distributed to each applicable non-employeedirector on 2November 2020. We recordednoexpense in 2020 and 2019 relatedtoretainerfeesearnedand deferred.

Share-based payments The table below shows, for allshare option grants, the weighted-average assumptions used in theBlack- Scholesoption pricing modeland the resulting weighted-average grant datefairvalue of share options granted in each of thepasttwo years:

Year Ended 31 December 2020 2019 Fair value at grant date$33.86 $41.50 Share price at grant date118.59 138.14 Exercise price118.59 138.14 Volatility33% 32 % Expected term (years) 4.4 4.4 Range of risk free interestrates 0.1-1.7% 1.3-2.6% Expected dividend yield —% —%

We rely on ablend of thehistorical and impliedvolatilities of our own ordinary shares to determine expected volatility for share option grants. In addition, we useasinglevolatilityestimate foreachshare option grant.The weighted-average volatilityisdeterminedbycalculating the weighted-average of volatilitiesfor all share options granted in agiven year. The expected term of share option grants represents the weighted-average period theawards areexpectedto remainoutstanding. For share options granted in 2020 and 2019, we estimated theweighted-average expected term based on historical exercise data. Therisk-free interest rate assumption was based on zero coupon U.S. Treasury instrumentswhose term was consistent withthe expected term of our share option grants. The expected dividend yield assumption was based on our history andexpectation of dividend payouts.

73 Jazz Pharmaceuticals plc Notes to theConsolidatedFinancial Statements (continued)

Equity-settledshare-basedpaymentsexpenserelated to share options, RSUs and grantsunder our ESPPwas as follows (in thousands):

Year Ended 31 December 2020 2019 Selling, generaland administrative $87,062 $80,461 Researchand development 30,170 26,035 Costofproductsales 7,510 6,857 $124,742 $113,353

Share options The following tablesummarisesinformation and activity relatedtoour share option plans:

2020 2019 Shares Shares Subject to Weighted- Subject to Weighted- Outstanding Average Outstanding Average Options Exercise Options Exercise (in thousands) Price (in thousands) Price Outstanding as at 1January 5,834 $131.57 5,280 $127.08 Options granted823 118.59 1,691 138.14 Options exercised(780) 111.47 (515) 90.27 Options forfeited (281) 137.73 (436) 139.56 Options expired(317) 159.41 (186) 159.59 Outstanding as at 31 December5,279 130.51 5,834 131.57 Exercisableasat31December 3,441 130.32 3,402 125.81

The options outstanding as at 31 December2020 had an exercise pricerange from $22.05 to $191.90 (2019: $7.98 to $191.90) andaweighted-average remaining contractual life of 6.3 years (2019: 6.6 years). The weighted- average share price at the dateofexercise for options exercisedin2020 was $145.31 (2019: $141.24).

74 Jazz Pharmaceuticals plc Notestothe Consolidated Financial Statements (continued)

Therange of exercise prices for options outstanding is further analysedbelow (in thousands):

31 December 2020 2019 $7.98 -$40.46 33 110 $41.67 -$59.13 532 641 $69.85 -$113.10 615 66 $114.38- $127.80 556 599 $128.51 -$136.18 645 898 $136.74 -$139.90 202 215 $140.03 -$140.03 850 1,054 $140.11 -$140.65 17 23 $140.67 -$140.67 604 785 $141.98 -$166.62 664 743 $166.74 -$191.90 561 700 Options outstanding at 31 December5,279 5,834

Restrictedstockunits In 2020, we granted RSUs covering an equal numberofour ordinary shares to employeeswithaweighted- average grant datefairvalue of $117.23 (2019: $138.11). Thefairvalue of RSUs is determined on thedateofgrant based on themarketprice of our ordinary shares as of thatdate. The fairvalue of theRSUs is recognised as an expense over thevesting period of four years.The weighted-average remaining contractualterm of RSUs outstanding as at 31 December 2020 was 1.5 years (2019: 1.4 years). In 2020, 423,000 RSUs were released (2019: 391,000 RSUs) with 290,000 ordinary shares issued(2019: 265,000 ordinary shares)and 133,000 ordinary shares withheld for taxpurposes (2019: 126,000 ordinary shares). The following table summarises information andactivityrelated to our RSUs:

2020 2019 Weighted- Weighted- Number of Average Number of Average RSUs Grant-Date RSUs Grant-Date (in thousands) Fair Value (in thousands) Fair Value Outstanding as at 1January 1,181 $139.32 1,102 $142.13 RSUs granted1,335 117.23 682 138.11 RSUs released (423) 137.50 (391) 144.34 RSUs forfeited (215) 130.21 (212) 140.76 Outstanding as at 31 December1,878 125.07 1,181 139.32

26. Financial RiskManagement We manage our financial risk exposures on agroup wide basis andseektoreducethe exposure of significant risks through aprocessofcontrolling, monitoring and reporting. Planning andbudgetary processes increase the opportunity for earlywarnings of financial risk. Monthlyfinancial reporting aids the identification of risk areasby management. Our approach to the management of these financialrisks is further describedfor each risk area below.

75 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

(a) Financial value hierarchy We use the following hierarchy for determining anddisclosing the fairvalue of financialinstruments by valuation technique: •Level 1: quoted (unadjusted) pricesinactive marketsfor identical assets or liabilities; •Level 2: other techniquesfor which allinputswhich have asignificant effect on the recorded fair value are observable, either directlyorindirectly; and •Level 3: techniqueswhich use inputs thathaveasignificant effectonthe recordedfairvalue that are not based on observable market data. We recognise transfers between levels of the fairvalue hierarchy at theend of the reporting period during which thechange has occurred.

(b) Financial instruments measured at fair value on arecurring basis The following table sets forth thefinancialinstruments measured at fair value on arecurring basis by level withinthe fairvalue hierarchy (inthousands):

31 December 2020 31 December 2019 Total Total Estimated Estimated Level 2Level 3 Fair Value Level 2Level 3 Fair Value Assets: Foreign exchange forward contracts $11,907 $—$11,907 $2,508 $—$2,508 Contingent consideration receivable ————14,765 14,765 Totals $11,907 $—$11,907 $2,508 $14,765 $17,273 Liabilities: Interestratecontracts $2,835 $—$2,835 $1,515 $—$1,515 Foreign exchange forward contracts 790 —790 182 —182 Embeddedderivatives —424,469 424,469 —83,967 83,967 Totals $3,625 $424,469 $428,094 $1,697 $83,967 $85,664

Our derivative assets andliabilities include interest rate and foreign exchange derivatives thatare measured at fairvalue using observable market inputssuch as forward rates, interest rates, our own creditriskaswellasan evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilitiesare classifiedwithinLevel 2ofthe fairvalue hierarchy. The fairvalue of contingent consideration receivable was determined using expectedcashinflowsbasedon the terms of the assetpurchase agreement withTerSera TherapeuticsLLC and our knowledge of thebusiness, as described below. The fairvalue of embedded derivative liabilitieswas determined using theMonte Carlosimulation. Thekey inputstothe Monte Carlosimulation were current share price, bond price,historicalvolatilityofour ordinary shares and risk-free interest rate. There were no transfers betweenany of thelevels of fairvalue measurements in 2020 or 2019.

76 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

Contingent consideration receivable The change in fairvalue of contingent consideration receivable wasestimatedasfollows (in thousands):

Level 3 Balance as at 31 December2019 $14,765 Receivedduring theyear(14,259) Fairvalue adjustment (506) Balance as at 31 December2020 $—

The total consideration for thePrialt assets soldtoTerSera was $80.0 million, of which $50.0 million was receivedatclosing and $15.0 million, less certainreimbursable expenses, wasreceived in December 2020 and December2019. The consideration was fullypaidasof31December 2020. Embeddedderivative liabilities The change in fairvalue of embedded derivative liabilitieswas estimated as follows(in thousands):

Level 3 Balance as at 31 December2018 $70,938 Fairvalue adjustment included in finance expense 13,029 Balance as at 31 December2019 83,967 Issuance of 2026 Notes148,117 Partialderecognition on repurchase of 2021 Notes (7,824) Fairvalue adjustment included in finance income (8,902) Fairvalue adjustment included in finance expense 209,111 Balance as at 31 December2020 $424,469

Anet fairvalue loss of $200.2 million wasrecognisedonthe embeddedderivativesin2020, primarily attributable to the2026 Notes anddrivenbyanincreaseinthe Jazz share price from $105.71 on thedateofissuance of the 2026 Notes to $165.05 as at 31 December 2020. Description of significant unobservable inputstovaluation The following table sets forth thesensitivity analysis on our shareprice volatility, whichisour mostsignificant unobservableinput. Thefairvalue measurementscategorised withinLevel 3ofthe fairvalue hierarchy, together with aquantitative sensitivityanalysis as at 31 December2020; below:

Fair Value Fair Value Share Price 10% change in Sensitivity to Sensitivity to Liability % Fair Value Estimated Estimated +10% -10% increase to Fair (in thousands) Volatility % Volatility +/- % (in thousands) (in thousands) Value of +/-10% 2021 Notes$ 4,310 29.9 3.0 $(1,697) $1,563 36.3 -39.4 2024 Notes65,360 31.9 3.2 (13,652) 13,216 20.2 -20.9 2026 Notes 354,799 34.9 3.5 (23,359) 23,944 6.6 -6.8 Total $424,469 $(38,708) $38,723

77 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

(c) Financial instruments measured at amortisedcostfor which fair value is disclosed(in thousands)

31 December 2020 31 December 2019

Carrying ValueFair Value Carrying ValueFair Value Term loans $581,702 $581,702 $613,981 $613,981 2021 Notes210,248 220,108 518,844 571,144 2024 Notes497,086 549,504 478,169 516,551 2026 Notes 846,648 952,109 —— Total liabilities $2,135,684 $2,303,423 $1,610,994 $1,701,676

Setout below are themajor methods andassumptions used in estimating the fairvalues of financial assets and liabilities.Fair value is theamount at which afinancial instrument could be exchangedinanarm’s length transaction betweeninformed andwilling parties, otherthaninaforcedliquidation or sale. Loans and borrowings The fairvalue of theExchangeable Senior Noteswas estimated in total using quotedmarket prices obtained from brokers (Level2), whichwas reducedbythe fairvalue of embedded derivatives to arrive at the fairvalue of a comparable instrument.The fairvalue of term loanborrowings approximates carrying value based on theborrowing rates currentlyavailablefor variable rateloans (Level 2). Cash, short-term deposits,trade and other receivables, trade payables and othercurrent financial liabilities The fairvalue of cash, short-term deposits,trade andotherreceivables, trade payables and other current financial liabilities approximate their carrying amounts largelydue to the short-term maturitiesoftheseinstruments.

(d) Derivative assets and liabilities designatedascash flow hedges The following table indicatesthe periods in whichthe cash flows associatedwith cash flow hedgesare expected to occur, impactprofitorloss and the carrying amountsofthe relatedhedging instruments.

31 December 2020 Expected cash flows /impact profit or loss Carrying More than amountTotal 1-3 months3-6 months6-12 months one year Interestrateswaps $(2,835) $(2,840) $(1,318) $(1,344) $(178) $—

31 December 2019 Expected cash flows /impact profit or loss Carrying More than amountTotal 1-3 months3-6 months6-12 months one year Interestrateswaps $(1,515) $(1,538) $(132) $(208) $(524) $(674)

78 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

(e) Offsetting financial assets and financial liabilities

Although we do not offsetderivative assets andliabilities withinour consolidated balance sheet,our InternationalSwapand Derivatives Association agreementsprovide for netsettlementoftransactions that are due to or from thesamecounterpartyupon early termination of the agreement due to an event of default or other termination event.

The following tablessummarise thepotentialeffectonour consolidatedbalancesheetofoffsetting our interest ratecontractsand foreign exchange forwardcontracts subjecttosuch provisions (in thousands):

31 December 2020 Net Amounts of Assets/ Liabilities Gross Amounts Not Offset in the Consolidated Gross Amounts Gross Amounts Presented in Balance Sheet of Recognised Offset in the the Derivative Cash Collateral Assets/ Consolidated Consolidated Financial Received Description Liabilities Balance Sheet Balance Sheet Instruments (Pledged) Net Amount Derivative assets $11,907 $—$11,907 $(2,207) $—$9,700 Derivative liabilities(3,625) —(3,625) 2,207 —(1,418)

31 December 2019 Net Amounts of Assets/ Liabilities Gross Amounts Not Offset in the Consolidated Gross Amounts Gross Amounts Presented in Balance Sheet of Recognised Offset in the the Derivative Cash Collateral Assets/ Consolidated Consolidated Financial Received Description Liabilities Balance Sheet Balance Sheet Instruments (Pledged) Net Amount Derivative assets $2,508 $—$2,508 $(596) $—$1,912 Derivative liabilities(1,697) —(1,697) 596 —(1,101)

(f) Market risk Interest raterisk -Investments The primary objectives of our investment policy, in order of priority, are as follows: safetyand preservation of principaland diversification of risk; liquidity of investmentssufficient to meet cash flow requirements; and competitive yield. Although our investments are subjecttomarket risk, our investment policyspecifiescredit qualitystandards for our investmentsand limits the amount of creditexposure from anysingle issue,issueror certain types of investment. Our investment policyallows us to maintainaportfolioofcashequivalents and short- term investmentsinavariety of securities, including U.S. federalgovernment andfederal agency securities, corporate bonds or commercialpaper issued by U.S. corporations, moneymarket instruments, certainqualifying moneymarket mutual funds, certainrepurchase agreements and tax-exempt obligations of U.S. states, agencies and municipalities. Our cash equivalentsand investments as at 31 December2020 and 2019 consisted of short-term time depositsand moneymarket funds which arenot subjecttosignificant interest rate risk. Interest rate risk -Loans and borrowings We are exposed to risks associatedwith changesininterest rates in connection with our term loanborrowings. As at 31 December 2020, $584.3 million(2019: $617.7 million) principalamount of term loan was outstanding. There were no borrowings outstanding under therevolving credit facilityasat31December2020 and 2019. To achieve adesiredmix of floating and fixed interest ratesonour term loan, we enteredintointerest rateswap agreementsinMarch 2017 that are designatedascashflow hedges. These derivative instrumentsare utilised for risk management purposes,and we do not use these derivativesfor speculative trading purposes.The interest rateswap agreementshave anotional amount of $300.0 millionand areeffective from 3March 2017 through 12 July 2021 and convert thefloating rate on aportion of our term loantoafixedrateof1.895%, plus the borrowing spread. The impactofahypotheticalincrease or decrease in interest rates on the fairvalue of our interest rate swapcontracts would be offset by achange in thevalue of the underlying liability. If interest rates were to increase or decrease by 100 basis points, interest expense in 2021 would increase or decrease by approximately $4.2 million, based on the unhedgedportion of our outstanding variable rateborrowings.

79 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

In 2014, we completed a private placement of $575.0 million aggregate principal amount of the 2021 Notes, of which we have repurchased $356.2 million of the aggregate principal amount. In 2017, we completed a private placement of $575.0 million aggregate principal amount of the 2024 Notes. In June 2020, we completed a private offering of an aggregate $1.0 billion principal amount of the 2026 Notes. The 2021 Notes, 2024 Notes and 2026 Notes have fixed annual interest rates of 1.875%, 1.50% and 2.00%, respectively, and we, therefore, do not have economic interest rate exposure on the Exchangeable Senior Notes. However, the fair values of the Exchangeable Senior Notes are exposed to interest rate risk. Generally, the fair values of the Exchangeable Senior Notes will increase as interest rates fall and decrease as interest rates rise. The fair values of the Exchangeable Senior Notes are also affected by volatility in our ordinary share price. As at 31 December 2020, the fair values of the 2021 Notes, the 2024 Notes and the 2026 Notes were estimated to be $220 million (2019: $571 million), $550 million (2019: $517 million) and $952 million, respectively. Foreign currency risk We have significant operations in Europe as well as in the U.S. The functional currency of each foreign subsidiary is generally the local currency. We are exposed to foreign currency exchange risk as the functional currency financial statements of foreign subsidiaries are translated to U.S. dollars. The assets and liabilities of our foreign subsidiaries having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive loss in shareholders’ equity. The reported results of our foreign subsidiaries will be influenced by their translation into U.S. dollars by currency movements against the U.S. dollar. Our primary currency translation exposure is related to our subsidiaries that have functional currencies denominated in the euro. A 10% strengthening or weakening in the rates used to translate the results of our foreign subsidiaries that have functional currencies denominated in the euro would have increased or decreased net income for the year ended 31 December 2020 by approximately $21 million (2019: $14 million). Transactional exposure arises where transactions occur in currencies other than the functional currency. Transactions in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction. The resulting monetary assets and liabilities are translated into the appropriate functional currency at exchange rates prevailing at the balance sheet date and the resulting gains and losses are reported in foreign currency loss in the consolidated income statement. As at 31 December 2020, our primary exposure to transaction risk related to euro net monetary liabilities held by subsidiaries with a U.S. dollar functional currency. We have entered into foreign exchange forward contracts to manage this currency risk. These foreign exchange forward contracts are not designated as hedges; gains and losses on these derivative instruments are designed to offset gains and losses on the underlying balance sheet exposures. As at 31 December 2020, we held foreign exchange forward contracts with notional amounts totalling $357.4 million (2019: $180.9 million). The net asset fair value of outstanding foreign exchange forward contracts was $11.1 million as at 31 December 2020 (2019: $2.3 million). Based on our foreign currency exchange rate exposures as at 31 December 2020, a hypothetical 10% adverse fluctuation in exchange rates would decrease the fair value of our foreign exchange forward contracts by approximately $31 million as at 31 December 2020 (2019: $15 million). The resulting loss on these forward contracts would be offset by a positive impact on the underlying monetary assets and liabilities. (g) Credit risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. All of our derivative instruments are utilised for risk management purposes, and we do not use derivatives for speculative trading purposes. As at 31 December 2020, we had foreign exchange forward contracts with notional amounts totalling $357.4 million (2019: $180.9 million). As at 31 December 2020, the net asset fair value of outstanding foreign exchange forward contracts was $11.1 million (2019: $2.3 million). As at 31 December 2020, we had interest rate swap contracts with notional amounts totalling $300.0 million (2019: $300.0 million). These outstanding interest rate swap contracts had a net liability fair value of $2.8 million as at 31 December 2020 (2019:

80 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

$1.5 million). Thecounterpartiestothesecontractsare large multinationalcommercialbanks, and we believe the risk of non-performanceisnot material. We are also subjecttocredit risk from our accounts receivablerelated to our productsales. We monitor our exposure within accounts receivableand record areserve against uncollectibleaccounts receivableasnecessary. We extend credittohospitals, pharmaceutical wholesaledistributors and specialty pharmaceuticaldistribution companies, primarily in the U.S., and to other internationaldistributors. Customercreditworthiness is monitored and collateralisnot required. We monitor deteriorating economic conditions in certain Europeancountrieswhich mayresult in variabilityofthe timing of cash receiptsand an increase in the average length of time that it takes to collect accountsreceivable outstanding. Historically, we have not experienced significant credit lossesonour accountsreceivable and we do not expect to have write-offs or adjustments to accounts receivablewhichwould have amaterial adverse effect on our financial position, liquidity or results of operations. As at 31 December 2020, two customers accounted for 80% of grossaccounts receivablebeing Express Scripts, which accountedfor 68% of gross accountsreceivable,and McKesson Corporation andaffiliates, or McKesson, which accountedfor 12% of gross accountsreceivable.Asat31December 2019, twocustomers accountedfor 89% of gross accounts receivablebeing Express Scripts, which accountedfor 77% of gross accounts receivable, andMcKesson, which accountedfor 12% of gross accounts receivable. As at 31 December 2020, trade receivables with an initial value of $0.1 million(2019: $0.1 million) were impaired andfullyprovidedfor. The movement in the allowancefor impairment in respect of trade receivableswas as follows (in thousands):

Impairment Provision As at 31 December 2018 $50 Charge for theyear9 Utilised during theyear(9) As at 31 December2019 50 Charge for theyear5 Utilised during the year(5) As at 31 December2020 $50

The ageing of trade receivables thatwerenot impaired was as follows (in thousands):

31 December 2020 2019 Not pastdue $389,021 $344,061 Pastdue 0-30 days 3,118 4,675 Pastdue 31-60 days 3,136 3,509 Pastdue 61-90 days 651 1,178 Pastdue greaterthan90days 564 2,564 Total $396,490 $355,987

The carrying amount of financial assets representsthe maximum creditexposure.

81 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

(h) Liquidity and capital management Liquidity risk is the risk that the Group will encounterdifficulty in meeting theobligations associatedwithits financial liabilities thatare settled by delivering cash or otherfinancial assets. We define liquidresourcesasthe total of our cash and cash equivalents andcurrent investment securities. We define capitalasour shareholders’equity. Our objectiveswhen managing our liquid resources are: •Tomaintainadequateliquidresourcestofund our ongoing operations andsafeguard our ability to continue as agoing concern; •Tohave availablethe necessary financial resourcestoallow us to invest in areasthat maydeliverfuture benefitsfor patientsand createvalue for shareholders; and •Tomaintainsufficient financial resourcestomitigateagainst risks and unforeseenevents. Liquid andcapital resourcesare monitored on thebasis of thetotalamount of such resourcesavailable and our anticipatedrequirementsfor the foreseeable future.Our liquidresourcesand shareholders’ equity were as follows (in thousands):

31 December

2020 2019 Cash and cash equivalents $1,057,769 $637,344 Total liquid resources $2,132,769 $1,077,344 Shareholders'equity$3,439,651 $3,169,791

As at 31 December2020, we hadcash, cashequivalentsand investmentsof$2.13 billion (2019: $1.08 billion), borrowing availability underour revolving creditfacilityof$1.60 billion (2019: $1.60 billion) and a long-term debt principalamount of $2.4 billion (2019: $1.8 billion). Our long-term debt comprised $584.3 million (2019: $617.7 million) aggregateprincipal amount term loan, $218.8 million (2019: $575.0 million) principal amount of the2021 Notes, $575.0 million (2019: $575.0 million) principalamount of the 2024 Notes and $1.0 billion (2019: Nil)principalamount of the 2026 Notes.During 2020, we generated cash flowsfrom operations of $902.1 million (2019: $784.9 million) andweexpect to continue to generatepositive cash flow from operations. As at 31 December2020, we had no outstanding borrowings (2019: Nil) underour revolving creditfacility. In April 2021, we andcertain of our wholly-owned subsidiaries, entered into Amendment No. 3toour Credit Agreement,dated as of 18 June 2015, or the Existing CreditAgreement, withthe lenders partytheretoand Bank of America,N.A., as administrative agent,collateral agent, letter of credit issuerand swing line lender. The Amendment No. 3amended theExisting CreditAgreement to permit the issuance of senior secured notes and made certain relatedchanges as set forththerein. In April 2021, our wholly-owned subsidiary, Jazz Securities Designated Activity Company, issued$1.5 billion in aggregate principalamount of 4.375% senior secured notes due 2029. Concurrentlywith theclosing of theGWAcquisition, we expect to enterintonew senior secured credit facilities, which is expectedtoconsist of a$500.0 millionrevolving creditfacilityand aterm loanBfacilityinan aggregateamount thatisexpectedtoequal approximately $3.85 billion. We expecttouse term loan Bborrowings under newsenior secured creditfacilitiesand thenet proceeds from the senior secured notes, togetherwith cash on hand to fund the cash consideration payable in connection with theGWAcquisition. We believe that our existing cash balances, cash we expect to generate from operations and funds available under our revolving credit facilitywill be sufficient to fund our operations and to meet our existing obligations for the foreseeablefuture, including our obligations under the amendedcredit agreement.

82 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements(continued)

Thetables below summarise the maturity profile of our financial liabilities (including the Exchangeable Senior Noteshost contracts) based on contractual undiscountedpayments, including estimated interestpayments, as at 31 December2020 and 2019 (inthousands):

Total Less than 1 1to3 3to5 More than 5 contractual Carrying At 31 December 2020 year years years years cash flows Value ExchangeableSenior Notes $251,540 $57,250 $623,625 $1,010,000 $1,942,415 $1,553,982 Term loan 45,019 562,597 ——607,616 581,702 Accruals andothercurrent liabilities 342,841 ———342,841 342,841 Leaseliabilities22,393 44,772 42,681 86,495 196,341 154,492 Accountspayable 26,946 ———26,946 26,946 Foreign exchange forward contracts 28,714 ———28,714 790 Revolving credit facility commitment fee 4,056 5,800 ——9,856 — Interestrateswaps 3,048 ———3,048 2,835 Total $724,557 $670,419 $666,306 $1,096,495 $3,157,777 $2,663,588 At 31 December 2019 ExchangeableSenior Notes $19,406 $603,031 $592,251 $—$1,214,688 $997,013 Term loan 54,028 104,532 525,014 —683,574 613,981 Accruals andothercurrent liabilities 260,380 ———260,380 260,380 Lease liabilities 21,315 42,243 45,365 104,655 213,578 163,954 Accountspayable 45,732 ———45,732 45,732 Foreign exchange forward contracts 15,916 ———15,916 182 Revolving credit facility commitment fee 4,067 8,111 1,744 —13,922 — Interest rateswaps5,780 3,048 ——8,828 1,515 Total $426,624 $760,965 $1,164,374 $104,655 $2,456,618 $2,082,757

During 2020 and 2019, we enteredinto foreign exchange forward contracts. The disclosedforeign exchange contracts arethe grossundiscounted cash flows.The following tableshowsthe inflows and outflows relating to these contracts (inthousands):

31 December 2020 2019 Outflows$(28,714) $(15,916) Inflows27,924 15,734 Net$(790) $(182)

27. Commitments and Contingencies

Indemnification In the normalcourse of business, we enter into agreements that containavariety of representations and warrantiesand provide for general indemnification, including indemnification associatedwith productliabilityor infringement of intellectual propertyrights. Our exposureunder these agreements is unknown because it involves future claims thatmay be made but have not yetbeenmade against us. To date, we have not paidany claims or been required to defend any action relatedtothese indemnification obligations..

83 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognise any liabilities relating to these obligations as of 31 December 2020 or 2019. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.

Other commitments As at 31 December 2020, we had $112.0 million (2019: $74.5 million) of noncancellable purchase commitments due within one year primarily related to agreements with third party manufacturers and for marketing campaigns. As at 31 December 2020, we had authorised capital expenditure of $26.0 million (2019: $21.0 million) of which $4.2 million (2019: $4.3 million) was contracted for.

Legal proceedings From June 2020 to March 2021, a number of class action lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement agreements we entered with Hikma and other ANDA filers violate state and federal antitrust and consumer protection laws, as follows: On 17 June 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by Blue Cross and Blue Shield Association, or BCBS, against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, or, collectively, the Company Defendants (hereinafter referred to as the BCBS Lawsuit). The BCBS Lawsuit also names Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA), Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceuticals, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc., or, collectively, the BCBS Defendants. On 18 June and 23 June 2020, respectively, two additional class action lawsuits were filed against the Company Defendants and the BCBS Defendants: one by the New York State Teamsters Council Health and Hospital Fund in the United States District Court for the Northern District of California, and another by the Government Employees Health Association Inc. in the United States District Court for the Northern District of Illinois (hereinafter referred to as the GEHA Lawsuit). On 18 June 2020, a class action lawsuit was filed in the United States District Court for the Northern District of California by the City of Providence, Rhode Island, on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc, and Roxane Laboratories, Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., and Hikma Pharmaceuticals plc, or, collectively, the City of Providence Defendants. On 30 June 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by UFCW Local 1500 Welfare Fund on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals Ireland Ltd., Jazz Pharmaceuticals, Inc., Roxane Laboratories, Inc., Hikma Pharmaceuticals plc, Eurohealth (USA), Inc. and West-Ward Pharmaceuticals Corp., or collectively the UFCW Defendants (hereinafter referred to as the UFCW Lawsuit). On 13 July 2020, the plaintiffs in the BCBS Lawsuit and the GEHA Lawsuit dismissed their complaints in the United States District Court for the Northern District of Illinois, and refiled their respective lawsuits in the United States District Court for the Northern District of California. On 14 July 2020, the plaintiffs in the UFCW Lawsuit dismissed their complaint in the United States District Court for the Northern District of Illinois and on 15 July 2020, refiled their lawsuit in the United States District Court for the Northern District of California. On 31 July 2020, a class action lawsuit was filed in the United States District Court for the Southern District of New York by the A.F. of L.-A.G.C Building Trades Welfare Plan on behalf of itself and all others similarly

84 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued) situated, against Jazz Pharmaceuticals plc (hereinafter referred to as the AFL Plan Lawsuit). The AFL Plan Lawsuit also names Roxane Laboratories Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceuticals Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc. On 14 August 2020, an additional class action lawsuit was filed in the United States District Court for the Southern District of New York by the Self-Insured Schools of California on behalf of itself and all others similarly situated, against the Company Defendants, as well as Hikma Pharmaceuticals plc, Eurohealth (USA) Inc., Hikma Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Roxane Laboratories, Inc., Amneal Pharmaceuticals LLC, Endo International, plc, Endo Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Lupin Inc., Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Holdings USA, Inc., Sun Pharmaceutical Industries, Inc., Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Watson Laboratories, Inc., Wockhardt Ltd., Morton Grove Pharmaceuticals, Inc., Wockhardt USA LLC, Mallinckrodt plc, and Mallinckrodt LLC (hereinafter the Self-Insured Schools Lawsuit). On 16 September 2020, an additional class action lawsuit was filed in the United States District Court for the Northern District of California, by Ruth Hollman on behalf of herself and all others similarly situated, against the same defendants named in the Self-Insured Schools Lawsuit. The plaintiffs in certain of these lawsuits are seeking to represent a class of direct purchasers of Xyrem, and the plaintiffs in the remaining lawsuits are seeking to represent a class of indirect purchasers of Xyrem. Each of the lawsuits generally alleges violations of U.S. federal and state antitrust, consumer protection, and unfair competition laws in connection with the Company Defendants’ conduct related to Xyrem, including actions leading up to, and entering into, patent litigation settlement agreements with each of the other named defendants. Each of the lawsuits seeks monetary damages, exemplary damages, equitable relief against the alleged unlawful conduct, including disgorgement of profits and restitution, and injunctive relief. It is possible that additional lawsuits will be filed against the Company Defendants making similar or related allegations. If the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In December 2020, these cases were centralised and transferred to the United States District Court for the Northern District of California, where the multidistrict litigation will proceed for the purpose of discovery and pre- trial proceedings. In January 2021, the Court issued a Case Management Order that schedules this case for trial in February 2023. On 18 March 2021, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota against the Company Defendants, Hikma Pharmaceuticals plc, Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA) Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc., raising similar allegations (the UHS Lawsuit). On 24 March 2021, the U.S. Judicial Panel on Multidistrict Litigation conditionally transferred the UHS Lawsuit to the United States District Court for the Northern District of California, where it was consolidated for discovery and pre-trial proceedings with the other cases. On 15 March 2021, GW filed a definitive proxy statement with the Securities and Exchange Commission in connection with the GW Acquisition (“Proxy Statement”). Since the filing of the Proxy Statement, Jazz Pharmaceuticals plc has been named in two lawsuits filed in state and federal courts in New York on 17 March 2021 by purported GW shareholders in connection with the GW Acquisition : the first was filed in the United States District Court for the Southern District New York by James Farrell (the “Farrell Litigation) and an additional suit was filed in New York state court by Brian Levy (the “Levy Litigation”). In addition to Jazz Pharmaceuticals plc, Jazz Pharmaceuticals UK Holdings Ltd., GW Pharmaceuticals plc, and the GW Board of Directors are named as defendants in the Farrell Litigation. In the Levy Litigation, GW Pharmaceuticals plc, the GW Board of Directors, Centerview Partners LLC, and Goldman Sachs & Co. LLC are named as defendants. In addition to the Farrell Litigation and the Levy Litigation, ten additional suits have been filed in New York, California, and Pennsylvania federal courts by purported GW shareholders against GW Pharmaceuticals plc and its Board of Directors, but which do not name any Jazz Pharmaceuticals parties (the “GW Litigation,” collectively with the Farrell Litigation and the Levy Litigation, the “Transaction Litigation”). In the Transaction Litigation, the plaintiffs allege that the Proxy Statement omitted material information and contained misrepresentations, and that the individual members of the GW Board of Directors breached their fiduciary duties, in violation of state and federal laws, including the Securities Exchange Act of 1934. The plaintiffs in the Transaction

85 Jazz Pharmaceuticals plc Notes tothe ConsolidatedFinancial Statements (continued)

Litigationsought various remedies, including injunctive relieftoprevent the consummation of theGWAcquisition unless certainallegedlymaterialinformation wasdisclosed, or in thealternative, rescissionordamages. On 14 April 2021, GW filedaForm 8-K containing supplemental disclosures related to the GW Acquisition. Pursuant to amemorandum of understanding betweenthe parties, the Levy Litigation was dismissedon14April 2021. Jazz does not believe any of GW’ssupplemental disclosures were material or required by law, and further believes thatthe claims in the Transaction Litigation are meritless. Jazz will continue to defend itselfinthe remaining Transaction Litigation. From time to time we areinvolvedinlegal proceedings arising in the ordinary course of business. We believe there is no otherlitigation pending thatcouldhave,individuallyorinthe aggregate,amaterialadverse effectonour resultsofoperations or financial condition.

28. RelatedParty Transactions The Group is controlledbyJazz Pharmaceuticals plc,the ultimateparent company. Thefollowing transactions were carried out with relatedparties.

Key management compensation Key management is definedasbeing the company’s directors, both executive and non-executive. The compensation paid or payabletokey management is shown below (in thousands):

Year Ended 31 December 2020 2019 Salariesand othershort term employee benefits$3,467 $3,299 Share-basedpayment expense -RSUs 9,277 8,596 Share-basedpayment expense -share options 6,035 6,369 Total $18,779 $18,264

The interests of key management in theordinary share capital of Jazz Pharmaceuticals plcare outlined in the directors' report on page 17.

Transactions withretirement benefit schemes We operate anumber of definedcontribution retirement plans. The costs of these plans are charged to the income statement in the period theyare incurred. For details of our transactions with thecompany’s retirement benefit schemes during theyear, please see Note9.

29. Notes to the Parent Company Financial Statements

(a) Investments Investmentsinsubsidiaries consisted of thefollowing (inthousands):

31 December 2020 2019 As at 1January $2,800,811 $2,705,723 Share-basedpayment 119,946 109,306 Return on investment (15,442) (14,218) As at 31 December$2,905,315 $2,800,811

Share-basedpayment represents capitalcontributions made to certain subsidiary undertakings to reflectthe amounts expensed by these subsidiary undertakings for share-based payment expenses.

86 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

Jazz Pharmaceuticals plchad the following subsidiary undertakings as at 31 December2020:

Registered CompanyNature of business office Jazz Pharmaceuticals Ireland Acquisition, development and commercialisation of (1) Limited pharmaceutical productsand research anddevelopment and management activities Jazz Pharmaceuticals, Inc. Acquisition, development, marketing, distribution and saleof (2) pharmaceutical productsand provision of researchand development and management services to relatedparties

Jazz Pharmaceuticals International Intra-group financing company (3) Limited Jazz Pharmaceuticals InternationalII Intra-group financing company (3) Limited Jazz Pharmaceuticals International Intra-group financing company (3) III Limited Jazz Pharmaceuticals France SAS Acquisition, development, marketing, distribution and saleof (4) pharmaceutical products Jazz Pharmaceuticals France Holding company (4) Holdings SAS Jazz Pharmaceuticals Europe Holding company (5) Holdings Limited Jazz Pharmaceuticals Lux S.à.r.l Holding company (6) JPI Commercial, LLCLicensing of intellectual property(2) Orphan Medical,LLC Dormant (2) Jazz Pharmaceuticals Holdings Inc. Holding company (2) AxCellBiosciences Corporation Dormant (2) Jazz Pharmaceuticals Netherlands Provision of support services to relatedparties(8) B.V. Jazz Pharmaceuticals Germany Marketing anddistribution of pharmaceutical products(9) GmbH Jazz Financing UK LimitedDormant (7) Jazz Pharmaceuticals UK LimitedMarketing anddistribution of pharmaceutical productsand (7) provision of management services to relatedparties Jazz Pharmaceuticals II SAS Licensing of intellectual property(4) Jazz Pharmaceuticals Canada Inc.Marketing anddistribution of pharmaceutical productsand (10) provision of support servicestorelated parties Jazz InvestmentsILimited Financing company (3) Jazz InvestmentsIILimited Intra-group financing company (3) Jazz Financing IDAC Group treasury, financing andholding company (1) Jazz Financing II LimitedIntra-group financing company (1) Jazz Securities DAC Financing company (1) Jazz CapitalLimited Holding company (1) Jazz Financing LuxS.à.r.l Intra-group financing company (11) Jazz Pharmaceuticals IberiaS.L. Marketing anddistribution of pharmaceutical products(12) Celator Pharmaceuticals Inc. Development of pharmaceuticalproducts, exploitation of (13) intellectual propertyand provision of support services to related parties Gentium S.r.l. Development andmanufacture of pharmaceutical products(14) Jazz Healthcare Italy S.r.l Marketing anddistribution of pharmaceutical products. (14) CelatorPharmaceuticals Corp Provision of research anddevelopment services to related (15) parties Jazz Pharmaceuticals Denmark, ApS Marketing anddistribution of pharmaceutical productsand (16) provision of support servicestorelated parties

87 Jazz Pharmaceuticals plc Notes tothe ConsolidatedFinancial Statements (continued)

Registered Company Nature of business office Jazz InvestmentsEurope LimitedIntra-group financing company (17) Jazz Pharmaceuticals Ireland Holding company (1) Holdings Unlimted Company Jazz Pharmaceuticals Research LLCLicensing of intellectualproperty (18) Rotalec IP Holdings LLCLicensing of intellectualproperty (18) Development of pharmaceuticalproducts, exploitation of intellectual propertyand provision of support services to Cavion, Inc. related parties (18) Jazz Financing Holdings Limited Holding company (1) Jazz Pharmaceuticals ANZ PTY Marketing anddistribution of pharmaceuticalproducts and Limited provision of support servicestorelated parties (19)

______(1) 5th Floor, Waterloo Exchange, Waterloo Road, Dublin4,D04 E5W7, Ireland (2) 3170 PorterDrive, PaloAlto, CA 94304, USA (3) HP House,21Laffan Street, Hamilton HM 09, Bermuda (4) City One, 84 Quai CharlesdeGaulle, 69006 Lyon, France (5) Hadfield House, Library Street,Gibraltar (6) 15 Boulevard F.W.Raiffeisen, L-2411 Luxembourg (7) Wing B, Building 5700, Spires House,John SmithDrive, Oxford Business Park South, Oxford, OX4 2RW, UK (8) Jonkerbosplein 52, 17thfloor, 6534ABNijmegen, TheNetherlands (9) Grillparzestr 18, Munich 81675, Germany (10) 2010 Winston ParkDr., Suite200, Oakville, Ontario, Canada, L6H5R7 (11) 1rue Hildegard von Bingen, L-1282 Luxembourg (12) CalleCaleruega 102, 7I28033, Madrid,Spain (13) 160 Greentree Drive, Suite 101, Dover, CountyofKent, DE 19904, USA (14) Villa Guardia (Como), PiazzaXXSettembren.2,Italy (15) 1959 UpperWater Street,Suite900, Halifax NS,Halifax NS B3J2X2, Canada (16) Regus Management Lautruphøj 12750 Ballerup Denmark (17) 93 MillStreet, Zone 5, Central Business District,Qormi CBD5090, Malta (18) 1209 Orange Street,CityofWilmington, Delaware 19801 (19) One InternationalTowers Sydney, Watermans Quay, Barrangaroo NSW 2000, Australia All shares heldare ordinary shares and allsubsidiary undertakings are wholly-ownedbythe parent company.

(b) Trade andotherreceivables Trade andotherreceivables consistedofthe following (in thousands):

31 December 2020 2019 Amounts owed from group undertakings $66,609 $184,235 Prepayments2,050 936 Otherreceivables 3,450 4 Total $72,109 $185,175

Amounts owed from group undertakings are interestfreeand repayableondemandapart from balances related to intra group cash pooling on whichinterest is receivable and interestrates vary based on currenciesheldinpooling account.There arenosignificant expected creditlossesonotherreceivables and no expectedcredit loss provision has beenrecognised.

88 Jazz Pharmaceuticals plc Notestothe ConsolidatedFinancial Statements (continued)

(c) Accrued and othercurrent liabilities Accruedand other current liabilities consistedofthe following (inthousands):

31 December

2020 2019 Amounts owed to group undertakings $200,226 $603,566 Accruedexpenses3,200 2,983 Othercurrent liabilities7777 Total $203,503 $606,626

Amounts owed to group undertakings are interestfreeand repayableondemandapart from balances related to intra group cash pooling on which interestispayableand interest ratesvarybased on currenciesheldinpooling account.

(d) Leases The below disclosures relates to thenoncancellable leasefor our office building at Waterloo Exchange, Waterloo Road, Dublin4,D04 E5W7, Ireland. The componentsofthe leaseexpense for the years ended 31 December2020 and2019 were as follows(in thousands):

Year Ended 31 December

Lease Cost 2020 2019 Depreciation charge of right-of-useassets: Buildings $2,297 $2,263 Interestexpenseonlease liabilities 505 591 Sublease income (224) (634) Netlease cost $2,578 $2,220

Supplementalbalance sheet information relatedtoleaseswas as follows (in thousands):

31 December Leases Classification 2020 2019 Assets Buildings Right-of-useassets $9,101 $11,409

Liabilities Current Accruedliabilities $2,261 $2,164 Non-current Leaseliabilities, less current portion 8,732 10,291 Total leaseliabilities$10,993 $12,455

31 December 2020 2019 Discount rate -lease liabilities 4.5 %4.5 %

89 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

Other supplementalinformation related to leases wasasfollows (in thousands):

Year Ended 31 December 2020 2019 Cash paid for amountsincludedinthe measurement of leaseliabilities: Financing cash outflowsfrom leaseliabilities$2,183 $2,112 Operating cash outflows from leaseliabilities505 591 Additions to right-of-use assets: Right-of-useassets obtained in exchange for leaseliabilities(1) $—$13,671

______(1) Includes the balances recognisedon1January 2019 on adoption of IFRS16. Amaturityanalysisofour lease liabilities as at 31 December2020 has beendisclosedwithinNote 29(e).

(e) Financial risk management The parent company’s financialriskexposures are predominantly relatedtoits investmentsinsubsidiariesand intercompany receivables and payables, therefore the parent company’s approachtofinancialriskmanagement is similar to the Group’s approachasdescribed in Note 26. Thefairvalue of cash and short-term deposits,trade and otherreceivables, accruedand other current financial liabilities approximate their carrying amounts largelydue to the short-term maturitiesoftheseinstruments. The tablesbelow summarises the maturity profile of the parent company's lease liabilities based on contractual undiscounted payments as at 31 December2020 (in thousands):

Total Less than 1 1to3 3to5 More than contractual Carrying At 31 December 2020 year years years 5years cash flows Value Leaseliabilities2,943 5,885 3,433 —12,261 10,993

The change in liabilities arising from financing activities during 2020 was as follows (in thousands):

Foreign exchange 1January 2020 Cash flows adjustments 31 December 2020 Leaseliabilities$12,455 $(2,183) $721 $10,993

(f) Contingentliabilities/guarantees The parent company has guaranteed theGroup’s borrowing under theamended creditagreement. As at 31 December2020, the principalamount of term loan outstanding was$584.3 million (2019: $617.7 million) and there werenoborrowings outstanding underour revolving creditfacility(2019: Nil). In addition, the Exchangeable Senior Notes are fullyand unconditionallyguaranteed on asenior unsecuredbasisbythe parent company.

(g) Relatedparty transactions As part of itsnormal operating activities, the parent company enters intotransactions with othergroup undertakings. Amounts due to andfrom group undertakings arerepayable on demand. Detailsoftransactions with keymanagement personnel aredescribedinNote 28. The share-based payment expense incurred by theparent company relatestoshare-based awards to non-executive directors of the company.

90 Jazz Pharmaceuticals plc Notes to the Consolidated Financial Statements (continued)

30. Subsequent Events Pending GW Acquisition The respective obligations of GW and us to consummate the GW Acquisition are subject to the satisfaction or waiver of a number of customary conditions, including obtaining certain regulatory approvals and obtaining sanction of the Scheme of Arrangement by the High Court of Justice of England and Wales. Certain conditions have been satisfied, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the approval by GW’s shareholders of the Scheme of Arrangement. The GW Acquisition is not subject to approval by our shareholders, nor is the GW Acquisition subject to a financing contingency. The GW Acquisition is expected to close in the first half of May 2021, subject to the satisfaction or waiver of the conditions set forth in the GW Transaction Agreement. In February 2021, in connection with the execution of the GW Transaction Agreement, we entered into a commitment letter with BofA Securities, Inc., Bank of America, N.A. and JPMorgan Chase Bank, N.A. pursuant to which the commitment parties have committed to provide us with a senior secured revolving credit facility in an aggregate principal amount of up to $500.0 million, a senior secured term loan B facility in an aggregate principal amount of up to $3,150.0 million and a senior secured bridge loan facility in an aggregate principal amount of up to $2,200.0 million to, among other things, finance our obligations in respect of the GW Acquisition. The effectiveness of such credit facilities is subject to the occurrence of customary closing conditions, including the consummation of the GW Acquisition. In April 2021, we and certain of our wholly-owned subsidiaries, entered into Amendment No. 3 to our Credit Agreement, dated as of 18 June 2015, or the Existing Credit Agreement, with the lenders party thereto and Bank of America, N.A., as administrative agent, collateral agent, letter of credit issuer and swing line lender. The Amendment No. 3 amended the Existing Credit Agreement to permit the issuance of senior secured notes and made certain related changes as set forth therein. In April 2021, our wholly-owned subsidiary, Jazz Securities Designated Activity Company, issued $1.5 billion in aggregate principal amount of 4.375% senior secured notes due 2029. Concurrently with the closing of the GW Acquisition, we expect to enter into new senior secured credit facilities, which is expected to consist of a $500.0 million revolving credit facility and a term loan B facility in an aggregate amount that is expected to equal approximately $3.85 billion. We expect to use term loan B borrowings under new senior secured credit facilities and the net proceeds from the senior secured notes, together with cash on hand to fund the cash consideration payable in connection with the GW Acquisition. The senior secured notes have a mandatory redemption clause that will be triggered under certain circumstances, including failure to complete the GW Acquisition within the time period outlined in the GW Transaction Agreement or the termination of the GW Acquisition.

91 APPENDIX A-IFRSTOU.S. GAAP RECONCILIATION The consolidated financialstatementsset out on pages25to92havebeenpreparedinaccordancewithInternationalFinancial Reporting Standards,orIFRSas adopted by theEuropeanUnion which differ in certain significant respectsfrom U.S. generallyacceptedaccounting policies, or U.S. GAAP. Areconciliation from our IFRStoour U.S.GAAP financialstatementsispresented below (inthousands): ConsolidatedIncome Statement for the year ended 31 December 2020

Share- based Acquired Amortisation Exchangeable payments Taxation IPR&D /Impairment Senior Notes Leases Other IFRS (A) (B) (C) (D) (E) (F) (G) U.S. GAAP Revenues Productsales,net $2,346,660 $—$—$—$—$—$—$—$2,346,660 Royaltiesand contractrevenues 16,907 ——— ————16,907 Total revenues 2,363,567 ——— ————2,363,567 Costofproductsales (575,473) 198 ——426,495 ——(137) (148,917) Gross margin1,788,094 198 ——426,495 ——(137) 2,214,650 Operating expenses: Selling, general and administrative (852,394) 3,373 106 —— —(5,318) —(854,233) Research anddevelopment (522,386) 1,168 —(258) 186,101 ———(335,375) Acquiredin-process research and 92 development —— —(251,250) ————(251,250) Intangibleassetamortisation —— ——(259,580) ———(259,580) Intangibleassetimpairment —— ——(136,139) ———(136,139) Total operating expenses (1,374,780) 4,541 106 (251,508) (209,618) —(5,318) —(1,836,577) Operating profit 413,314 4,739 106 (251,508) 216,877 —(5,318) (137) 378,073 Finance income 28,818 ——— —(8,902) —(12,063) 7,853 Finance expense (353,914) ——— —222,767 8,253 12,063 (110,831) Net finance expense (325,096) ——— —213,865 8,253 —(102,978) Share of loss of equity-accountedinvestees (2,962) ——— ————(2,962) Profit before income taxes 85,256 4,739 106 (251,508) 216,877 213,865 2,935 (137) 272,133 Incometax benefit(expense)28,769 —(62,286) —— ———(33,517) Net profit for the year$114,025 $4,739 $(62,180) $(251,508) $216,877 $213,865 $2,935 $(137) $238,616 ConsolidatedIncome Statement forthe year ended 31 December2019

Share- based Acquired Amortisation Exchangeable payments Taxation IPR&D /Impairment Senior Notes Leases Other IFRS (A) (B) (C) (D) (E) (F) (G) U.S. GAAP Revenues Productsales,net $2,135,601 $—$—$—$—$—$—$—$2,135,601 Royaltiesand contractrevenues 26,160 ——— ————26,160 Total revenues 2,161,761 ——— ————2,161,761 Costofproductsales (753,371) 257 ——626,160 ——(976) (127,930) Gross margin1,408,390 257 ——626,160 ——(976) 2,033,831 Operating expenses: Selling, general and administrative (733,944) 2,197 98 —— —(5,293) —(736,942) Research anddevelopment (410,871) 944 —(26,000) 136,201 ———(299,726) Acquiredin-process research and development —— —(109,975) ————(109,975) Intangibleassetamortisation —— ——(354,814) ———(354,814) Total operating expenses (1,144,815) 3,141 98 (135,975) (218,613) —(5,293) —(1,501,457) Operating profit 263,575 3,398 98 (135,975) 407,547 —(5,293) (976) 532,374 93 Finance income 24,177 ——— ————24,177 Finance expense (129,578) ——— —18,743 8,586 —(102,249) Net finance expense (105,401) ——— —18,743 8,586 —(78,072) Share of loss of equity-accountedinvestees (4,089) ——— ————(4,089) Profit before income taxes 154,085 3,398 98 (135,975) 407,547 18,743 3,293 (976) 450,213 Incometax benefit156,947 —(83,793) —— ———73,154 Net profit for the year$311,032 $3,398 $(83,695) $(135,975) $407,547 $18,743 $3,293 $(976) $523,367 ConsolidatedBalanceSheet as at 31 December2020

Share-based Acquired Amortisation Exchangeable payments Taxation IPR&D /Impairment Senior Notes Leases Other IFRS (A) (B) (C) (D) (E) (F) (G) U.S. GAAP ASSETS Non-current assets: Goodwill and intangible assets $3,251,267 $—$—$(674,354) $576,441 $—$—$—$3,153,354 Property, plant and equipment 128,939 (206) (798) —— —— —127,935 Right-of-use assets 122,959 —— —— —6,210 —129,169 Deferred tax assets 719,780 —(464,864) —— —— —254,916 Other non-current assets 43,159 ——(87,200) 75,000 —— —30,959 Total non-current assets 4,266,104 (206) (465,662) (761,554) 651,441 —6,210 —3,696,333 Current assets: Inventories 95,621 (225) —— ————95,396 Trade and other receivables, net 484,878 —114,285 —— ——11,907 611,070 Income tax receivable 333 —— —— —— —333 Derivative financial instruments 11,907 —— —— ——(11,907) — Cash and cash equivalents 1,057,769 —— —— —— —1,057,769 Investments 1,075,000 —— —— —— —1,075,000 Total current assets 2,725,508 (225) 114,285 —— —— —2,839,568 Total assets $6,991,612 $(431) $(351,377) $(761,554) $651,441 $—$6,210 $—$6,535,901

LIABILITIES AND SHAREHOLDERS'EQUITY Current liabilities: Accounts payable $26,946 $—$—$—$—$—$—$(1) $26,945 94 Accruals and other current liabilities 348,563 —— —— ——4,169 352,732 Provisions 2,593 (2,048) —— ———(545) — Loans and borrowings 243,635 —— ——2,687 ——246,322 Derivative financial instruments 3,625 —— —— ——(3,625) — Income tax payable25,149 —51— ————25,200 Deferred revenue 2,546 —— —— —— —2,546 Total current liabilities 653,057 (2,048) 51 ——2,687 —(2) 653,745 Non-current liabilities: Loans and borrowings 1,892,049 —— ——(43,533) ——1,848,516 Lease liabilities, less current portion 140,035 —— —— —— —140,035 Derivative financial instrument 424,469 —— ——(424,469) —— — Deferred tax liabilities 337,476 —(207,079) —— —— —130,397 Income tax payable99,928 —— —— —— —99,928 Other non-current liabilities 1,220 —— —— —— —1,220 Provisions 1,412 (965) —— ———(447) — Deferred revenue 2,315 —— —— —— —2,315 Total non-current liabilities 2,898,904 (965) (207,079) ——(468,002) —(447) 2,222,411 Total liabilities 3,551,961 (3,013) (207,028) ——(465,315) —(449) 2,876,156 Total shareholders’ equity 3,439,651 2,582 (144,349) (761,554) 651,441 465,315 6,210 449 3,659,745 Total liabilities and shareholders’ equity $6,991,612 $(431) $(351,377) $(761,554) $651,441 $—$6,210 $—$6,535,901 ConsolidatedBalanceSheet as at 31 December2019

Share-based Acquired Amortisation Exchangeable payments Taxation IPR&D /Impairment Senior Notes Leases Other IFRS (A) (B) (C) (D) (E) (F) (G) U.S. GAAP ASSETS Non-current assets: Goodwill and intangible assets $3,346,228 $—$—$(422,846) $437,613 $—$—$—$3,360,995 Property, plant and equipment 132,615 (206) (903) —— ———131,506 Right-of-use assets 136,086 —— —— —3,299 —139,385 Deferred tax assets 529,735 —(308,332) —— ———221,403 Non-current income tax receivable 19,173 —— —— ———19,173 Other non-current assets 123,367 ——(87,200) ————36,167 Total non-current assets 4,287,204 (206) (309,235) (510,046) 437,613 —3,299 —3,908,629 Current assets: Inventories 78,833 (225) —— ————78,608 Trade and other receivables, net 418,058 —38,985 —— ——17,273 474,316 Derivative financial instruments 2,508 —— —— ——(2,508) — Financial assets at fair value through profit or loss 14,765 —— —— ——(14,765) — Cash and cash equivalents637,344 —— —— ———637,344 Investments 440,000 —— —— ———440,000 Total current assets 1,591,508 (225) 38,985 —— ———1,630,268 Total assets $5,878,712 $(431) $(270,250) $(510,046) $437,613 $—$3,299 $—$5,538,897

LIABILITIES AND SHAREHOLDERS'EQUITY Current liabilities: 95 Accounts payable $45,732 $—$—$—$—$—$—$—$45,732 Accruals and other current liabilities 267,920 —— —— ——1,766 269,686 Provisions 2,760 (1,446) —— ———(1,314) — Loans and borrowings 33,387 —— —— ———33,387 Derivative financial instruments 1,037 —— —— ——(1,037) — Income tax payable10,801 —164 —— ———10,965 Deferred revenue 4,720 —— —— ———4,720 Total current liabilities 366,357 (1,446) 164 —— ——(585) 364,490 Non-current liabilities: Loans and borrowings 1,577,607 —— ——(3,737) ——1,573,870 Lease liabilities, less current portion 151,226 —— —— ———151,226 Derivative financial instrument 84,627 —— ——(83,966) —(661) — Deferred tax liabilities 414,958 —(190,863) —— ———224,095 Income tax payable107,851 —— —— ———107,851 Other non-current liabilities 862 —— —— ——661 1,523 Provisions 572 (572) —— ———— — Deferred revenue 4,861 —— —— ———4,861 Total non-current liabilities 2,342,564 (572) (190,863) ——(87,703) ——2,063,426 Total liabilities 2,708,921 (2,018) (190,699) ——(87,703) —(585) 2,427,916 Total shareholders’ equity 3,169,791 1,587 (79,551) (510,046) 437,613 87,703 3,299 585 3,110,981 Total liabilities and shareholders’ equity $5,878,712 $(431) $(270,250) $(510,046) $437,613 $—$3,299 $—$5,538,897 The principal differences between IFRS and U.S. GAAP, as they apply to our financial statements, are as follows:

A. Share-based payments Our accounting policy under U.S. GAAP is to treat each grant with a service condition as a single unit of accounting. The total compensation expense related to a specific grant with a service condition is recognised on a straight-line basis over the vesting period of such grant. Under IFRS, we are required to account for each tranche as a separate unit of accounting with expense recognised using the graded vesting method. Accordingly, the share- based payments expense recognition is accelerated under IFRS such that a higher proportion of the expense is recognised in the early years of grants which vest in installments.

B. Taxation There are different rules under IFRS and U.S. GAAP in relation to the recognition of deferred tax assets, or DTAs, associated with share-based compensation. DTAs are only recognised under IFRS and U.S. GAAP in relation to jurisdictions where tax deductions are available to the employer for equity grants given to employees (relevant employee equity awards). Under U.S. GAAP, a DTA may be recognised for relevant employee equity awards only to the extent that a compensation expense has previously been recorded in relation to those awards. In contrast, under IFRS, a DTA is recognised in relation to the tax effect of the full intrinsic value at the reporting date of all relevant employee equity awards expected to be exercised. Accordingly, the total DTA recognised under IFRS is higher than under U.S. GAAP. There are also different rules regarding the treatment of intercompany transfers of inventory. Under IFRS, any tax impacts to the seller are recognised as incurred. Deferred taxes resulting from intercompany transfers of inventory are recognised at the buyer’s tax rate. Under U.S. GAAP, any tax impacts to the seller are deferred and the buyer is prohibited from recognising a deferred tax asset resulting from the difference between the tax basis and consolidated carrying amount of the inventory.

C. Acquired In-Process Research and Development Under IFRS, upfront, option and development milestone payments related to in-process research and development, or IPR&D, assets that are separately acquired are capitalised on our balance sheet. If and when development is complete, which generally occurs when regulatory approval to market a product is obtained, the associated assets would then be amortised over their estimated useful lives. Under U.S. GAAP, upfront, option and development milestone payments related to IPR&D assets acquired in an asset acquisition are expensed if the assets have no alternative future use.

D. Intangible Asset Amortisation and Impairment Charges Under IFRS, intangible asset amortisation and impairment charges are classified by function i.e. primarily included in cost of product sales. Under U.S. GAAP, we present our intangible asset amortisation and impairment charges as a separate line item on the face of our consolidated income statement. On 30 April 2018, we entered into an agreement with Spark Therapeutics, Inc., or Spark, to purchase a rare pediatric disease priority review voucher, or PRV, from Spark for $111.1 million inclusive of transaction costs. This was capitalised as an intangible asset under both IFRS and U.S. GAAP. In October 2019 we notified the Food and Drug Administration, or FDA, of our intent to redeem the PRV in connection with the Xywav new drug application submission. The PRV was redeemed in January 2020, at which point the PRV intangible asset was amortised to the income statement. Under U.S. GAAP the cost of the PRV was amortised to the income statement in 2019 upon notification to FDA of our intent to redeem it. Under IFRS, a one-step impairment test is used when assessing impairment related to long-lived assets held for use. The carrying amount of an asset is compared with its recoverable amount. The recoverable amount is the higher of the asset’s fair value less costs of disposal or its value in use. Under U.S. GAAP, a two-step impairment test and measurement model is required. The carrying amount of an asset is first compared with the estimated undiscounted cash flows expected to result from the use of the asset. If the carrying amount is lower than the undiscounted cash flows, no impairment loss is recognised. If the carrying amount is higher than the undiscounted cash flows, an impairment loss is measured as the difference between the carrying amount and fair value. In 2020 and 2019, under IFRS, we recognised impairment charges of $163.1 million and $367.3 million, respectively,

96 related to the Vyxeos intangible asset where the carrying amount of the asset was in excess of its recoverable amount. There were no related impairment charges under U.S. GAAP in 2020 or 2019 as the carrying amount of the asset was lower than the estimated undiscounted cash flows. In 2019, under IFRS we recorded an Acquired IPR&D asset impairment charge of $136.2 million following the decision to stop enrollment in our Phase 3 clinical study of defibrotide for the prevention of VOD due to a determination that the study is highly unlikely to reach one of its primary endpoints. Due to the timing of when this decision was made, this impairment charge was recorded in 2020 under U.S. GAAP. In 2020, under IFRS, we recorded an other non-current asset impairment charge of $75.0 million following the decision to exercise our opt-out rights with respect to IMGN632 under the collaboration and option agreement with ImmunoGen, Inc., thereby relinquishing our development and commercialisation option. Under U.S. GAAP, the $75.0 million upfront payment was recorded as acquired IPR&D expense in the consolidated income statement in 2017.

E. Exchangeable Senior Notes In August 2014, we completed a private placement of $575.0 million principal amount of the 2021 Notes. In the third quarter of 2017, we completed a private placement of $575.0 million principal amount of the 2024 Notes. In the second quarter of 2020, we completed a private placement of $1.0 billion principal amount of the 2026 Notes. We used a portion of the net proceeds from this offering to repurchase for cash $332.9 million aggregate principal amount of the 2021 Notes through privately-negotiated transactions concurrently with the offering of the 2026 Notes. Under IFRS, the equity exchange, and certain other features, within the Exchangeable Senior Notes host contracts are considered to be embedded derivatives. Such embedded derivatives were bifurcated from the host debt contracts on initial recognition and are subsequently measured at fair value, with changes in fair value recognised in the income statement. Under U.S. GAAP, the Exchangeable Senior Notes were bifurcated into an exchange option, which is recognised in equity, and a host contract, which is recognised as a liability and measured at amortised cost.

F. Leases Under IFRS, we recognise a depreciation charge for right-of-use assets on a straight-line basis over the lease term within selling, general and administrative expenses, and an interest expense on lease liabilities within finance expenses in our consolidated income statement. Under U.S. GAAP, a single expense for lease payments is recognised on a straight-line basis over the lease term within selling, general and administrative expenses.

G. Other Adjustments The other reconciling items primarily relate to the reclassification of our derivative financial instruments, which are included within our other current assets, accrued liabilities or other non-current liabilities under IFRS, but which are disclosed separately on our balance sheet under IFRS.

97 APPENDIX B - RISK FACTORS Risks Related to the GW Acquisition and the Combined Company Upon Completion of the Acquisition We may not realize the anticipated benefits and synergies from our proposed acquisition of GW Pharmaceuticals. On February 3, 2021, we announced that we have entered into a definitive agreement with GW Pharmaceuticals under which our indirect wholly-owned subsidiary, Jazz Pharmaceuticals UK Holdings Limited, agreed to acquire GW Pharmaceuticals. While we and GW Pharmaceuticals will continue to operate independently until the completion of the acquisition, the success of the acquisition will depend, in part, on our ability to realize the anticipated benefits from successfully combining our and GW Pharmaceuticals’ businesses and we plan on devoting substantial management attention and resources to integrating our business practices and operations with GW Pharmaceuticals’ so that we can fully realize the anticipated benefits of the acquisition. Nonetheless, the products and technologies acquired may not be successful or continue to grow at the same rate as when operated independently or they may require significantly greater resources and investments than originally anticipated. The transaction could also result in the assumption of unknown or contingent liabilities. In addition, difficulties may arise during the process of combining the operations of our companies that could result in the failure to achieve the synergies or free cash flow that we anticipate, the failure to integrate operations and internal systems, programs and controls, the loss of key employees that may be difficult to replace in the very competitive pharmaceutical field, the failure to harmonize both companies’ corporate cultures, the disruption of each company’s ongoing businesses or inconsistencies in standards, controls, procedures and policies that adversely affect our ability to maintain relationships with customers, suppliers, distributors, collaboration partners, clinical trial investigators or managers of our clinical trials. As a result, the anticipated benefits of the acquisition may not be realized fully within the expected timeframe or at all or may take longer to realize or cost more than expected, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. The pending acquisition of GW Pharmaceuticals may not be completed on the currently contemplated timeline or terms, or at all; and regulatory bodies could impose certain requirements upon the combined company as a condition to approval that could reduce the anticipated benefits of the transaction. Consummation of the acquisition is conditioned on, among other things, obtaining necessary shareholder and regulatory approvals and the sanction of the High Court of Justice of England and Wales. In addition, the ongoing COVID-19 pandemic could delay the receipt of certain regulatory approvals and the court sanction. If any condition to the acquisition is not satisfied, it could delay or prevent the acquisition from occurring, which could negatively impact the price of our ordinary shares and future business and financial results. Further, as a condition to their approval of the acquisition, regulatory bodies may impose requirements, limitations or costs or require divestitures or place restrictions on the conduct of the combined business after the closing. These requirements, limitations, costs, divestitures or restrictions could jeopardize or delay the consummation of the acquisition or may reduce the anticipated benefits of the transaction. In addition, changes in laws and regulations could adversely impact our post-acquisition profitability and financial results. Failure to complete the acquisition of GW Pharmaceuticals could have a material and adverse effect on us. Either we or GW Pharmaceuticals may terminate the transaction agreement in certain circumstances. If the transactions contemplated by the transaction agreement are not completed, our ongoing business may be adversely affected and, without realizing any of the benefits of having completed the transactions, we will be subject to a number of risks, including the following: •the market price of our ordinary shares could decline; •we will be required to pay our costs relating to the transactions, such as legal, accounting, financial advisory and printing fees, whether or not the transactions are completed; •if the transaction agreement is terminated and our board of directors seeks another acquisition, our shareholders cannot be certain that we will be able to find a party willing to enter into a transaction as attractive to us as the acquisition of GW Pharmaceuticals; •we could be subject to litigation related to any failure to complete the acquisition or related to any enforcement proceeding commenced against us to perform our obligations under the transaction agreement;

98 •we will not realize the benefit of the time and resources, financial and otherwise, committed by our management to matters relating to the acquisition that could have been devoted to pursuing other beneficial opportunities; and •we may experience negative reactions from the financial markets or from our customers, suppliers or employees. Any of these risks could materially and adversely affect our business, financial condition, results of operations and growth prospects. Similarly, delays in the completion of the acquisition could, among other things, result in additional transaction costs, loss of revenue or other negative effects associated with delay and uncertainty about completion of the acquisition and could materially and adversely affect our business, financial condition, results of operations and growth prospects. The indebtedness of the combined company following the consummation of the acquisition will be substantially greater than our indebtedness on a standalone basis and greater than the combined indebtedness of Jazz Pharmaceuticals and GW Pharmaceuticals prior to the announcement of the acquisition. This increased level of indebtedness could adversely affect the combined company’s business flexibility and increase its borrowing costs. We expect that the cash consideration due to GW Pharmaceuticals’ shareholders under the transaction agreement will be approximately $6.5 billion. In addition to using cash on hand, we expect to incur significant acquisition-related debt financing, including secured term loans and senior secured notes. This substantially increased indebtedness and higher debt to equity ratio following the consummation of the acquisition may have the effect of, among other things, reducing the flexibility of the combined company to respond to changing business and economic conditions, lowering the credit ratings of the combined company, increasing the borrowing costs of the combined company and/or requiring the combined company to reduce or delay investments, strategic acquisitions and capital expenditures or to seek additional capital or restructure or refinance its indebtedness. Risks Related to Our Lead Products and Product Candidates

Our inability to maintain or increase sales from our neuroscience therapeutic area would have a material adverse effect on our business, financial condition, results of operations and growth prospects. Our business has been substantially dependent on Xyrem® (sodium oxybate) oral solution, and our financial results have been significantly influenced by sales of Xyrem. Our future plans assume that our newly launched oxybate product, Xywav™, with 92%, or approximately 1,000 to 1,500 milligrams per day, less sodium than Xyrem, depending on the dose, absence of a sodium warning and dosing titration option, will become the treatment of choice for patients who can benefit from oxybate treatment, current Xyrem patients, and patients who previously were not prescribed Xyrem, including those patients for whom sodium content is a concern. Our ability to successfully commercialize Xywav will depend on, among other things, our ability to obtain and maintain adequate coverage and reimbursement for Xywav and acceptance of Xywav by payors, physicians and patients. Our ability to maintain or increase oxybate product sales and realize the anticipated benefits from our investment in Xywav is subject to a number of additional risks and uncertainties as discussed in greater detail below, including those related to the introduction of authorized generic and generic versions of sodium oxybate and/or new products for treatment of cataplexy and/or excessive daytime sleepiness, or EDS, in narcolepsy in the U.S. market; the current and potential impacts of the COVID-19 pandemic, including the current and expected future negative impact on demand for our products and the uncertainty with respect to our ability to meet commercial demand in the future; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors; and challenges to our intellectual property around Xyrem and/or Xywav. While we expect that our business will continue to be substantially dependent on oxybate product sales from both Xyrem and Xywav, there is no guarantee that we can maintain oxybate sales at or near historical levels, or that oxybate sales will continue to grow. A significant decline in oxybate sales could cause us to reduce our operating expenses or seek to raise additional funds, which would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business. As for other products and product candidates in our neuroscience therapeutic area, we obtained approval of Sunosi® (solriamfetol) in 2019 in the U.S. and in January 2020 in the European Union, or EU, for the treatment of EDS associated with narcolepsy or obstructive sleep apnea, or OSA. Our ability to realize the anticipated benefits from our investment in Sunosi is subject to a number of risks and uncertainties, including the potential impacts of the continuing COVID-19 pandemic on the successful commercialization in the U.S. and the rolling launch in Europe, which are at an early stage; market acceptance of Sunosi; our ability, in a competitive retail pharmacy

99 market, to differentiate Sunosi from other products that are prescribed to treat excessive sleepiness in patients with OSA or EDS in patients with narcolepsy; adequate coverage and reimbursement by government programs and other third party payors, including the impact of future coverage decisions by payors; restrictions on permitted promotional activities based on any additional limitations on the labeling for the product that may be required by the U.S. Food and Drug Administration, or FDA, or the European Commission, or the EC, or other regulatory authority in the future; and our ability to satisfy FDA’s post-marketing requirements. If we are unable to successfully commercialize Sunosi in the U.S. and EU, or if sales of Sunosi do not reach the levels we expect, our anticipated revenue from Sunosi will be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. The introduction of new products in the U.S. market that compete with, or otherwise disrupt the market for, our oxybate products and product candidates would adversely affect sales of our oxybate products and product candidates. While Xyrem and Xywav are currently the only products approved by FDA and marketed in the U.S. for the treatment of both cataplexy and EDS in both adult and pediatric patients with narcolepsy, new treatment options for EDS in narcolepsy have launched, and in the future, other products may be launched that are competitive with or disrupt the market for our oxybate products. For example, in the future, we expect Xyrem and Xywav to face competition from authorized generic and generic versions of sodium oxybate. Nine companies have sent us notices that they had filed abbreviated new drug applications, or ANDAs, seeking approval to market a generic version of Xyrem, and we have filed and settled patent lawsuits with all nine companies. To date, FDA has approved or tentatively approved four of these ANDAs, and we believe that it is likely that FDA will approve or tentatively approve some or all of the others. In our patent litigation settlement with the first filer, West-Ward Pharmaceuticals Corp. (a wholly owned subsidiary of Hikma Pharmaceuticals PLC and now known as Hikma in the U.S.), or Hikma, we granted Hikma the right to sell an authorized generic product, or AG Product, with royalties back to us, in the U.S. beginning on January 1, 2023, or earlier under certain circumstances. Hikma has a right to elect to continue to sell the Hikma AG Product for a total of up to five years. We also granted Hikma a license to launch its own generic sodium oxybate product as early as six months after it has the right to sell the Hikma AG Product, but if it elects to launch its own generic product, Hikma will no longer have the right to sell the Hikma AG Product. In our settlements with Amneal Pharmaceuticals LLC, or Amneal, Lupin Inc., or Lupin, and Par Pharmaceutical, Inc., or Par, we granted each party the right to sell a limited volume of an AG Product in the U.S. beginning on July 1, 2023, or earlier under certain circumstances, and ending on December 31, 2025, with royalties back to us. AG Products will be distributed through the same risk evaluation and mitigation strategy, or REMS, as Xyrem and Xywav. We also granted each of Amneal, Lupin and Par a license to launch its own generic sodium oxybate product under its ANDA on or after December 31, 2025, or earlier under certain circumstances, including the circumstance where Hikma elects to launch its own generic product. If Amneal, Lupin or Par elects to launch its own generic product under such circumstance, it will no longer have the right to sell an AG Product. In our settlements with each of the other five ANDA filers, we granted each a license to launch its own generic sodium oxybate product under its ANDA on or after December 31, 2025, or earlier under certain circumstances, including circumstances where Hikma launches its own generic sodium oxybate product. The actual timing of the launch of an AG Product or generic sodium oxybate product is uncertain because the launch dates of the AG Products and generic sodium oxybate products under our settlement agreements are subject to acceleration under certain circumstances. Any ANDA holder launching an AG Product or another generic sodium oxybate product will independently establish the price of the AG Product and/or its own generic sodium oxybate product. Generic competition often results in decreases in the prices at which branded products can be sold. After any introduction of a generic product, whether or not it is an AG Product, a significant percentage of the prescriptions written for Xyrem will likely be filled with the generic product. Certain U.S. state laws allow for, and in some instances in the absence of specific instructions from the prescribing physician mandate, the dispensing of generic products rather than branded products when a generic version is available. This would result in reduction in sales of, and revenue from, Xyrem, although we would continue to receive royalties and other revenue based on sales of an AG Product in accordance with the terms of our settlement agreements. It is possible that additional companies may file ANDAs seeking to market a generic version of Xyrem which could lead to additional patent litigation or challenges with respect to Xyrem. Such patent litigation or challenges could potentially trigger acceleration of the launch dates in our settlement agreements if, for example, our patents covering Xyrem were invalidated. Alternatively, the launch dates in our settlement agreements could be accelerated

100 if a new ANDA filer were to obtain FDA approval for its sodium oxybate product, and launch its generic product through a generic sodium oxybate REMS before the entry dates specified in our settlement agreements. It is also possible that we could enter into a settlement agreement with a future ANDA filer that would permit such filer to enter the market on or prior to the launch date(s) in our settlement agreements. If a company launches a generic or authorized generic sodium oxybate product in any of these scenarios, except in limited circumstances related to an “at risk” launch, the launch date for Hikma’s AG Product would be accelerated to a date on or prior to the date of such entry, which could lead to acceleration of the other settling ANDA filers’ AG Product and generic sodium oxybate product launch dates as described above. Another circumstance that could trigger acceleration of Hikma’s launch date for an AG Product, which would also accelerate Amneal, Lupin and Par’s launch dates for their AG Products and ultimately could lead to acceleration of the other settling ANDA filers’ launch dates for their generic sodium oxybate products, is a substantial reduction in Xyrem net sales. Such a reduction could occur under various circumstances, including from our sales of Xywav or if a third party introduces a product to treat EDS or cataplexy in narcolepsy that leads to a substantial decline in Xyrem net sales. Accordingly, our strategy to drive revenue growth in our key franchises through, among other things, rapid adoption and broad access of Xywav in the U.S. could lead to the acceleration of such launch dates. Other companies may develop a sodium oxybate product for treatment of narcolepsy, using an alternative formulation or a different delivery technology, and seek approval in the U.S. using a new drug application, or NDA, approval pathway under Section 505(b)(2) and referencing the safety and efficacy data for Xyrem. In December 2020, Avadel Pharmaceuticals plc, or Avadel, filed a NDA for an extended-release formulation of sodium oxybate which uses its proprietary technology for the treatment of EDS and cataplexy in patients with narcolepsy. Xyrem may also face increased competition from new branded entrants to treat EDS in narcolepsy such as pitolisant. Other companies have announced that they have product candidates in various phases of development to treat the symptoms of narcolepsy, such as Axsome Therapeutics, Inc.’s reboxetine, and various companies are performing research and development on orexin agonists for the treatment of sleep disorders. We expect that Xywav will face competition similar to that described above for Xyrem, including from generic or authorized generic sodium oxybate products or new branded entrants in narcolepsy. For example, Avadel has announced that it has obtained an orphan drug designation from FDA for its extended-release sodium oxybate formulation. To obtain approval with orphan drug exclusivity, Avadel will have to show clinical superiority to Xyrem and Xywav. We cannot predict the timing or approvability of Avadel’s sodium oxybate product candidate or how FDA will evaluate any clinical superiority arguments that either we or Avadel may make, but in any event, we expect to face competition from Avadel, if its product candidate is approved. Moreover, non-oxybate products intended for the treatment of EDS or cataplexy in narcolepsy, including new market entrants, even if not directly competitive with Xyrem or Xywav, could have the effect of changing treatment regimens and payor or formulary coverage of Xyrem or Xywav in favor of other products, and indirectly materially and adversely affect sales of Xyrem and Xywav. Examples of such new market entrants include our product, Sunosi, and pitolisant, a drug that was approved by FDA in 2019 for the treatment of EDS in adult patients with narcolepsy and recently approved by FDA in October 2020 pursuant to a complete response resubmission for an adult cataplexy indication in the U.S. Pitolisant has also been approved and marketed in Europe to treat adult patients with narcolepsy with or without cataplexy, and a marketing authorization application is pending with the European Medicines Agency, or EMA, for approval of pitolisant in the treatment of EDS in OSA. In addition, we are also aware that prescribers often prescribe branded or generic medications for cataplexy, before or instead of prescribing oxybate therapy in Xyrem and Xywav, and that payors often require patients to try such medications before they will cover Xyrem or Xywav, even if they are not approved for this use. We expect that the approval and launch of an AG Product or other generic version of Xyrem could have a material adverse effect on our sales of and revenues from Xyrem and Xywav and on our business, financial condition, results of operations and growth prospects. We also expect that sales of Xywav will, and the approval and launch of any other sodium oxybate (including Avadel’s extended-release sodium oxybate formulation) or alternative product that treats narcolepsy could, have a material adverse effect on our sales of and revenues from Xyrem, which could have the additional impact of potentially triggering acceleration of market entry of AG Products or other generic sodium oxybate products under our patent litigation settlement agreements.

101 The distribution and sale of our oxybate products are subject to significant regulatory restrictions, including the requirements of a REMS, and these regulatory requirements subject us to risks and uncertainties, any of which could negatively impact sales of Xyrem and Xywav. The active pharmaceutical ingredient, or API, of Xyrem and Xywav, is a form of gamma-hydroxybutyric acid, or GHB, a central nervous system depressant known to be associated with facilitated sexual assault as well as with respiratory depression and other serious side effects. As a result, FDA requires that we maintain a REMS with elements to assure safe use, or ETASU, for Xyrem and Xywav to help ensure that the benefits of the drug in the treatment of cataplexy and EDS in narcolepsy outweigh the serious risks of the drug. The REMS imposes extensive controls and restrictions on the sales and marketing of Xyrem and Xywav that we are responsible for implementing. Any failure to demonstrate our substantial compliance with our REMS obligations, including as a result of business or other interruptions resulting from the evolving effects of the COVID-19 pandemic, or a determination by FDA that the REMS is not meeting its goals, could result in enforcement action by FDA, lead to changes in our REMS obligations, negatively affect sales of Xyrem or Xywav, result in additional costs and expenses for us and/or require us to invest a significant amount of resources, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects. FDA has stated that it will evaluate the Xywav and Xyrem REMS on an ongoing basis and will require modifications as may be appropriate. We cannot predict whether FDA will request, seek to require or ultimately require modifications to, or impose additional requirements on, the Xywav and Xyrem REMS, including in connection with the submission of new oxybate products or indications, the introduction of authorized generics, or to accommodate generics, or whether FDA will approve modifications to the Xywav and Xyrem REMS that we consider warranted. Any modifications approved, required or rejected by FDA could change the safety profile of Xywav or Xyrem, and have a significant negative impact in terms of product liability, public acceptance of Xywav or Xyrem as a treatment for cataplexy and EDS in narcolepsy, and prescribers’ willingness to prescribe, and patients’ willingness to take, Xywav or Xyrem, any of which could have a material adverse effect on our oxybate business. Modifications approved, required or rejected by FDA could also make it more difficult or expensive for us to distribute Xywav or Xyrem, make distribution easier for oxybate competitors, disrupt continuity of care for Xywav or Xyrem patients and/or negatively affect sales of Xywav or Xyrem. We depend on outside vendors, including Express Scripts Specialty Distribution Services, Inc., the central certified pharmacy, to distribute Xywav and Xyrem in the U.S., provide patient support services and implement the requirements of the Xywav and Xyrem REMS. If the central pharmacy fails to meet the requirements of the Xywav and Xyrem REMS applicable to the central pharmacy or otherwise does not fulfill its contractual obligations to us, moves to terminate our agreement, refuses or fails to adequately serve patients, or fails to promptly and adequately address operational challenges or challenges in implementing REMS modifications, whether due to business or other interruptions resulting from the evolving effects of the COVID-19 pandemic or otherwise, the fulfillment of Xywav or Xyrem prescriptions and our sales would be adversely affected. If we change to a new central pharmacy, new contracts might be required with government payors and other insurers who pay for Xywav or Xyrem, and the terms of any new contracts could be less favorable to us than current agreements. In addition, any new central pharmacy would need to be registered with the U.S. Drug Enforcement Administration, or DEA, and certified and would also need to implement the particular processes, procedures and activities necessary to distribute under the Xywav and Xyrem REMS. Transitioning to a new pharmacy could result in product shortages, which would negatively affect sales of Xywav and Xyrem, result in additional costs and expenses for us and/or take a significant amount of time, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects. In its approval of Hikma’s ANDA, FDA waived the requirement of a single shared REMS between the brand drug and generic versions, approving Hikma’s ANDA with a generic sodium oxybate REMS separate from the Xywav and Xyrem REMS, except for the requirement that the generic sodium oxybate REMS program pharmacies contact the Xywav and Xyrem REMS by phone to verify and report certain information. The generic sodium oxybate REMS was approved with the condition that it be open to all future sponsors of ANDAs or NDAs for sodium oxybate products. A sodium oxybate distribution system that is less restrictive than the Xywav and Xyrem REMS, such as the generic sodium oxybate REMS, which provides that generic sodium oxybate products and potentially new sodium oxybate products approved under a Section 505(b)(2) NDA approval pathway could be distributed through multiple pharmacies, could increase the risks associated with oxybate distribution. Because patients, consumers and others may not differentiate generic sodium oxybate from Xyrem or differentiate between the different REMS programs, any negative outcomes, including risks to the public, caused by or otherwise related

102 to a separate sodium oxybate REMS, could have a significant negative impact in terms of product liability, our reputation and good will, public acceptance of Xywav or Xyrem as a treatment for cataplexy and EDS in narcolepsy, and prescribers’ willingness to prescribe, and patients’ willingness to take, Xywav or Xyrem, any of which could have a material adverse effect on our oxybate business. We may face pressure to further modify the Xyrem and Xywav REMS or to license or share intellectual property pertinent to that REMS, including proprietary data required for the safe distribution of sodium oxybate, in connection with FDA’s approval of the generic sodium oxybate REMS or another oxybate REMS that may be submitted or approved in the future. Our settlement agreements with ANDA filers do not directly impact FDA’s waiver of the single shared system REMS requirement, any other ANDA or NDA filer’s ability to develop and implement the generic sodium oxybate REMS for its sodium oxybate product, or our ability to take any action with respect to the safety of the generic sodium oxybate REMS. We cannot predict the outcome or impact on our business of any future action that we may take with respect to FDA’s waiver of the single shared system REMS requirement, its approval and tentative approval of generic versions of sodium oxybate or the consequences of distribution of sodium oxybate through the generic sodium oxybate REMS approved by FDA or another separate REMS. REMS programs have increasingly drawn public scrutiny from the U.S. Congress, the Federal Trade Commission, or FTC, and FDA, with allegations that such programs are used as a means of improperly blocking or delaying competition. In December 2019, as part of the Further Consolidated Appropriations Act of 2020, the U.S. Congress passed legislation known as the Creating and Restoring Equal Access To Equivalent Samples Act, or CREATES. CREATES is intended to prevent companies from using REMS and other restricted distribution programs as a means to deny potential competitors access to product samples that are reasonably necessary to conduct testing in support of an application that references a listed drug or biologic, and provides such potential competitors a potential private right of action if the innovator fails to timely provide samples upon request. CREATES also grants FDA additional authority regarding approval of generic products with REMS. It is possible that the FTC, FDA or other governmental authorities could claim that, or launch an investigation into whether, we are using our REMS programs in an anticompetitive manner or have engaged in other anticompetitive practices. The Federal Food, Drug and Cosmetic Act further states that a REMS ETASU shall not be used by an NDA holder to block or delay generic drugs or drugs covered by an application under Section 505(b)(2) from entering the market. In its 2015 letter approving the Xyrem REMS, FDA expressed concern that we were aware that the Xyrem REMS is blocking competition. Between June and September 2020, we were served with a number of class action complaints that included allegations that we had used the Xyrem REMS to delay approval of generic sodium oxybate. In December 2020, these cases were centralized and transferred to the United States District Court for the Northern District of California, where the multidistrict litigation will proceed for the purpose of discovery and pre-trial proceedings. For additional information on these class action complaints, see Note 27, Commitments and Contingencies-Legal Proceedings of the Notes to Consolidated Financial Statements included in this Annual Report. It is possible that additional lawsuits will be filed against us making similar or related allegations. We cannot predict the outcome of these or potential additional lawsuits; however, if the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Pharmaceutical companies, including their agents and employees, are required to monitor adverse events occurring during the use of their products and report them to FDA. The patient counseling and monitoring requirements of the Xywav and Xyrem REMS provide more extensive information about adverse events experienced by patients taking Xywav and Xyrem, including deaths, than is generally available for other products that are not subject to similar REMS requirements. As required by FDA and other regulatory agencies, the adverse event information that we collect for Xywav and Xyrem is regularly reported to FDA and could result in FDA requiring changes to Xywav and/or Xyrem labeling, including additional warnings or additional boxed warnings, or requiring us to take other actions that could have an adverse effect on patient and prescriber acceptance of Xywav and Xyrem. As required by FDA, Xywav’s and Xyrem’s current labeling includes a boxed warning regarding the risk of central nervous system depression and misuse and abuse. Any failure to demonstrate our substantial compliance with the REMS or any other applicable regulatory requirements to the satisfaction of FDA or another regulatory authority could result in such regulatory authorities taking actions in the future which could have a material adverse effect on oxybate product sales and therefore on our business, financial condition, results of operations and growth prospects.

103 While we expect our oxybate products, Xyrem and our newly approved Xywav, to remain the largest part of our business, our success also depends on our ability to effectively commercialize products in our oncology therapeutic area. In addition to Xyrem, Xywav and our other neuroscience products and product candidates, we are commercializing a portfolio of products, including our other lead marketed products, Zepzelca, Vyxeos, Defitelio and Erwinaze. An inability to effectively commercialize Zepzelca, Vyxeos and Defitelio and to maximize their potential where possible through successful research and development activities, whether due to the evolving effects of the COVID-19 pandemic or otherwise, and an inability to replace the future product sales we will lose from Erwinaze, would have a material adverse effect on our business, financial condition, results of operations and growth prospects. Zepzelca Our ability to realize the anticipated benefits from our investment in Zepzelca® (lurbinectedin) is subject to a number of risks and uncertainties, including our ability to successfully commercialize Zepzelca in the U.S.; adequate supply of Zepzelca to meet demand; availability of favorable pricing and adequate coverage and reimbursement; the limited experience of, and need to educate, physicians in the use of Zepzelca for the treatment of metastatic small cell lung cancer, or SCLC; the potential for negative trial data read-outs in ongoing or future Zepzelca clinical trials; our and Pharma Mar, S.A., or PharmaMar’s ability to maintain accelerated approval or obtain FDA’s agreement as to a confirmatory study of Zepzelca; and the impact of the evolving effects of the COVID-19 pandemic on our ability to educate health care providers about Zepzelca in the treatment of relapsed, metastatic SCLC in the U.S. Vyxeos Our ability to realize the anticipated benefits from our investment in Vyxeos® (daunorubicin and cytarabine) liposome for injection by successfully and sustainably growing sales is subject to a number of risks and uncertainties, including our ability to differentiate Vyxeos from other liposomal chemotherapies and generically available chemotherapy combinations with which physicians and treatment centers are more familiar; acceptance by hospital pharmacy and therapeutics committees in the U.S., the EU and other countries; the increasing complexity of the acute myeloid leukemia, or AML, landscape requiring changes in patient identification and treatment selection, including diagnostic tests and monitoring that clinicians may find challenging to incorporate; the use of new and novel compounds in AML that are either used off-label or are only approved for use in combination with other agents and that have not been tested in combination with Vyxeos; the increasing use of venetoclax, which received full FDA approval in October 2020 for AML treatment; the limited size of the population of high-risk AML patients who may potentially be indicated for treatment with Vyxeos, particularly as a result of the shift of healthcare resources toward less intensive outpatient AML treatments in the U.S. in light of the COVID-19 pandemic which is directly negatively impacting, or delaying, the use of Vyxeos, as well as the suspension of in-person interactions with healthcare professionals due to the COVID-19 pandemic; the availability of adequate coverage, pricing and reimbursement approvals, competition from new and existing products and potential competition from products in development; and delays or problems in the supply or manufacture of Vyxeos. Although we saw some recovery in demand for Vyxeos beginning in the end of the second quarter of 2020, due to the ongoing impacts of the COVID-19 pandemic, we continue to expect a negative impact on demand for and utilization of Vyxeos compared to historical periods. If sales of Vyxeos do not reach the levels we expect, our anticipated revenue from the product would be negatively affected, which would have a material adverse effect on our business, financial condition, results of operations and growth prospects. Defitelio Our ability to maintain and grow sales and to realize the anticipated benefits from our investment in Defitelio® (defibrotide sodium) is subject to a number of risks and uncertainties, including continued acceptance by hospital pharmacy and therapeutics committees in the U.S., the EU and other countries; the continued availability of favorable pricing and adequate coverage and reimbursement; the limited experience of, and need to educate, physicians in recognizing, diagnosing and treating hepatic veno-occlusive disease, or VOD, particularly in adults; the possibility that physicians recognizing VOD symptoms may not initiate or may delay initiation of treatment while waiting for those symptoms to improve, or may terminate treatment before the end of the recommended dosing schedule; and the limited size of the population of VOD patients who are indicated for treatment with Defitelio (particularly if changes in hematopoietic stem cell transplantation treatment protocols reduce the incidence of VOD diagnosis and demand for Defitelio).

104 We announced in April 2020 that we stopped enrollment in our Phase 3 trial evaluating defibrotide in the prevention of VOD due to a determination that the study is highly unlikely to reach one of its primary endpoints. Although we do not expect this outcome to impact clinicians’ use of Defitelio in the treatment of VOD, it may result in delays in the initiation of treatment for some patients as clinicians wait for definitive signs and symptoms of VOD. Although we saw a resurgence in demand for Defitelio in the U.S. and outside the U.S. beginning in the end of the second quarter of 2020, due to the evolving effects of the COVID-19 pandemic, the reprioritization of healthcare resources and related delays, postponements or suspensions of certain medical procedures such as stem cell transplants, we continue to expect a negative impact on demand for and utilization of Defitelio. If sales of Defitelio do not reach the levels we expect, our anticipated revenue from the product would be negatively affected and our business, financial condition, results of operations and growth prospects would be materially adversely affected. In addition, because VOD is an ultra-rare disease, we have experienced inter-quarter variability in our Defitelio sales, which makes Defitelio sales difficult to predict from period to period. As a result, Defitelio sales results or trends in any period may not necessarily be indicative of future performance. Erwinaze Erwinaze® (asparaginase Erwinia chrysanthemi), which is approved to treat a limited population of patients with acute lymphoblastic leukemia, or ALL, who have developed hypersensitivity to E. coli-derived asparaginase, is licensed from, and manufactured by, a single source, Porton Biopharma Limited, or PBL, a company that is wholly owned by the UK Department of Health and Social Care. Our license and supply agreement with PBL, which included an exclusive right to market, sell or distribute Erwinaze, an exclusive license to Erwinaze trademarks, and a non-exclusive license to PBL’s manufacturing know-how, expired on December 31, 2020. In April 2020, PBL announced that it had entered into an agreement with a new partner to commercialize and distribute Erwinaze. Under our agreement with PBL, we have the right to sell certain Erwinaze inventory for a post-termination sales period of 12 months and retain ownership of certain data, know-how and other property interests, including the biologics license application, or BLA, for Erwinaze in the U.S. and marketing authorizations for Erwinase in several other countries. Subject to successful receipt, release and FDA approval for the batches from PBL, we expect to distribute available Erwinaze supply during the first half of 2021. If we are unable to replace the future product sales we will lose from Erwinaze with our existing or future products, our business, financial condition, results of operations and growth prospects would be materially adversely affected. In the past, a significant challenge to maintaining sales of Erwinaze and a barrier to increasing sales was PBL’s inability to consistently supply product that meets specifications in quantities that are adequate to meet market demand. Other challenges facing Erwinaze include the limited population of patients with ALL, and the incidence of hypersensitivity reactions to E. coli-derived asparaginase within that population; the development and/ or approval of new asparaginase treatments or treatment protocols for ALL that may not include asparaginase- containing regimens and prescribers’ use of alternate methods to address hypersensitivity reactions; difficulties with obtaining and maintaining favorable pricing and reimbursement arrangements; and potential competition from future biosimilar products. We face substantial competition from other companies, including companies with larger sales organizations and more experience working with large and diverse product portfolios. Our products compete, and our product candidates may in the future compete, with currently existing therapies, including generic drugs, product candidates currently under development by us and others and/or future product candidates, including new chemical entities that may be safer or more effective or more convenient than our products. Any products that we develop may be commercialized in competitive markets, and our competitors, which include large global pharmaceutical companies and small research-based companies and institutions, may succeed in developing products that render our products obsolete or non-competitive. Many of our competitors, particularly large pharmaceutical and life sciences companies, have substantially greater financial, operational and human resources than we do. Smaller or earlier stage companies may also prove to be significant competitors, particularly through focused development programs and collaborative arrangements with large, established companies. In addition, many of our competitors deploy more personnel to market and sell their products than we do, and we compete with other companies to recruit, hire, train and retain pharmaceutical sales and marketing personnel. If our sales force and sales support organization are not appropriately resourced and sized to adequately promote our products, the commercial potential of our current and any future products may be diminished. In any event, the commercial potential of our current products and any future products may be reduced or eliminated if our competitors develop or acquire and commercialize generic or branded products that are safer or more effective, are more convenient or are less expensive than our products.

105 Adequate coverage and reimbursement from third party payors may not be available for our products and we may be unable to successfully contract for coverage from pharmacy benefit managers and group purchasing organizations, which could diminish our sales or affect our ability to sell our products profitably; conversely, to secure coverage from these organizations, we may be required to pay rebates or other discounts or other restrictions to reimbursement that could diminish our sales. In both U.S. and non-U.S. markets, our ability to successfully commercialize and achieve market acceptance of our products depends in significant part on adequate financial coverage and reimbursement from third party payors, including governmental payors (such as the Medicare and Medicaid programs in the U.S.), managed care organizations and private health insurers. Without third party payor reimbursement, patients may not be able to obtain or afford prescribed medications. In addition, reimbursement guidelines and incentives provided to prescribing physicians by third party payors may have a significant impact on the prescribing physicians’ willingness and ability to prescribe our products. The demand for, and the profitability of, our products could be materially harmed if the Medicaid program, Medicare program, other healthcare programs in the U.S. or elsewhere, or third party commercial payors in the U.S. or elsewhere deny reimbursement for our products, limit the indications for which our products will be reimbursed, or provide reimbursement only on unfavorable terms. In particular, we cannot predict to what extent the evolving effects of the COVID-19 pandemic may disrupt global healthcare systems and access to our products or result in a widespread loss of individual health insurance coverage due to unemployment, a shift from commercial payor coverage to government payor coverage, or an increase in demand for patient assistance and/or free drug programs, any of which could adversely affect net revenue. As part of the overall trend toward cost containment, third party payors often require prior authorization for, and require reauthorization for continuation of, prescription products or impose step edits, which require prior use of another medication, usually a generic or preferred brand, prior to approving coverage for a new or more expensive product. Such restrictive conditions for reimbursement and an increase in reimbursement-related activities can extend the time required to fill prescriptions and may discourage patients from seeking treatment. We cannot predict actions that third party payors may take, or whether they will limit the access and level of reimbursement for our products or refuse to provide any approvals or coverage. From time to time, third party payors have refused to provide reimbursement for our products, and others may do so in the future. Third party payors increasingly examine the cost-effectiveness of pharmaceutical products, in addition to their safety and efficacy, when making coverage and reimbursement decisions. We may need to conduct expensive pharmacoeconomic and/or clinical studies in order to demonstrate the cost-effectiveness of our products. If our competitors offer their products at prices that provide purportedly lower treatment costs than our products, or otherwise suggest that their products are safer, more effective or more cost-effective than our products, this may result in a greater level of access for their products relative to our products, which would reduce our sales and harm our results of operations. In some cases, for example, third party payors try to encourage the use of less expensive generic products through their prescription benefit coverage and reimbursement and co-pay policies. Because some of our products compete in a market with both branded and generic products, obtaining and maintaining access and reimbursement coverage for our products may be more challenging than for products that are new chemical entities for which no therapeutic alternatives exist. Third party pharmacy benefit managers, or PBMs, group purchasing organizations, or GPOs, and payors can limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication, and to exclude drugs from their formularies in favor of competitor drugs or alternative treatments, or place drugs on formulary tiers with higher patient co-pay obligations, and/or to mandate stricter utilization criteria. Formulary exclusion effectively encourages patients and providers to seek alternative treatments, make a complex and time-intensive request for medical exemptions, or pay 100% of the cost of a drug. In addition, in many instances, certain PBMs, GPOs and third party payors may exert negotiating leverage by requiring incremental rebates, discounts or other concessions from manufacturers in order to maintain formulary positions, which could continue to result in higher gross to net deductions for affected products. In this regard, we have entered into agreements with PBMs and payor accounts to provide rebates to those entities related to formulary coverage for Xyrem, Xywav and Sunosi, but we cannot guarantee that we will be able to agree to coverage terms with other PBMs and other third party payors. We are seeking to secure payor coverage for Xywav that is similar to Xyrem and have implemented patient access programs for Xywav to support patients in obtaining access to Xywav during the launch period. However, payors could decide to exclude Xywav from formulary coverage lists, impose step edits that require patients to try alternative, including generic, treatments before authorizing payment for Xywav, limit the types of diagnoses for which coverage will be provided or impose a moratorium on coverage for

106 products while the payor makes a coverage decision. An inability to obtain or maintain adequate formulary positions could increase patient cost-sharing for Xywav and cause some patients to determine not to use Xywav. Any delays or unforeseen difficulties in obtaining access or reimbursement approvals could limit patient access, depress therapy adherence rates, and adversely impact our ability to successfully commercialize Xywav. If we are unsuccessful in obtaining broad coverage for Xywav, our anticipated revenue from and growth prospects for Xywav could be negatively affected. In many countries outside the U.S., procedures to obtain price approvals, coverage and reimbursement can take considerable time after the receipt of marketing authorization. Many European countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance funds in the EU member states will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some European countries, including some EU member states, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU member states, including those representing the larger markets. The HTA process, which is currently governed by the laws in these countries, is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU member states. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU member states, although a legislative proposal adopted by the EC in January 2018 concerning EU regulation governing HTA procedures may eventually lead to harmonization. If we are unable to maintain favorable pricing and reimbursement status in EU member states that represent significant markets, our anticipated revenue from and growth prospects for our products in the EU could be negatively affected. For example, the EC granted marketing authorization for Vyxeos in August 2018 and for Sunosi in January 2020, and, as part of our rolling launches of Vyxeos and Sunosi in Europe, we are making pricing and reimbursement submissions in European countries. Due to the evolving effects of the COVID-19 pandemic, we currently anticipate delays by certain European regulatory authorities in their pricing and reimbursement reviews. If we experience setbacks or unforeseen difficulties in obtaining favorable pricing and reimbursement decisions, including as a result of regulatory review delays due to the COVID-19 pandemic, planned launches in the affected EU member states would be delayed, which could negatively impact anticipated revenue from and growth prospects for Vyxeos and/or Sunosi. The pricing of pharmaceutical products has come under increasing scrutiny as part of a global trend toward healthcare cost containment and resulting changes in healthcare law and policy may impact our business in ways that we cannot currently predict, which could have a material adverse effect on our business and financial condition. Political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental changes, particularly given the current atmosphere of mounting criticism of prescription drug costs in the U.S. We expect there will continue to be legislative and regulatory proposals to change the healthcare system in ways that could impact our ability to sell our products profitably, as governmental oversight and scrutiny of biopharmaceutical companies is increasing. For example, we anticipate that the U.S. Congress, state legislatures, and regulators may adopt or accelerate adoption of new healthcare policies and reforms intended to curb healthcare costs, such as federal and state controls on reimbursement for drugs (including under Medicare, Medicaid and commercial health plans), new or increased requirements to pay prescription drug rebates and penalties to government health care programs, and additional pharmaceutical cost transparency policies that aim to require drug companies to justify their prices through required disclosures. There is also proposed legislation pending that would implement a Most Favored Nation, or MFN, pricing model. If a MFN pricing model were applied to any of our products, our revenues from U.S. sales of such products could decrease. Legislative and regulatory proposals that have recently been considered include legislative proposals to limit the terms of patent litigation settlements with generic sponsors, and proposals to define certain conduct around patenting and new product development as unfair competition. All such considerations may adversely affect our business and industry in ways that we cannot accurately predict. FDA recently issued a final regulation, as well as guidance for industry, permitting the importation of drugs into the U.S. from other countries under certain

107 circumstances, although it is currently unclear whether stakeholders will avail themselves of these pathways. Any of our products becoming subject to importation could negatively affect our business in ways that we cannot accurately predict. There is also ongoing activity related to health care coverage. The Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers. These changes impacted previously existing government healthcare programs and have resulted in the development of new programs, including Medicare payment-for-performance initiatives. The Affordable Care Act is currently subject to a broad legal challenge in California vs. Azar before the Supreme Court. Were the Supreme Court to invalidate the Affordable Care Act, that could have far-reaching consequences of an uncertain nature for our industry. However, the Biden administration and Democratically-controlled Congress are expected to take significant action to mitigate any ruling against the Affordable Care Act. Further, the administration and Congress are expected to take notable steps towards expanding health care coverage beyond the Affordable Care Act, which could have ramifications for the pharmaceutical industry. If healthcare policies or reforms intended to curb healthcare costs are adopted or if we experience negative publicity with respect to pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for our products, including Xyrem and Xywav, may be affected, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. We have periodically increased the price of Xyrem, most recently in January 2021, and there is no guarantee that we will make similar price adjustments to Xyrem and Xywav in the future or that price adjustments we have taken or may take in the future will not negatively affect Xyrem or Xywav sales volumes and revenues. We also have made and may in the future make price adjustments on our other products. There is no guarantee that such price adjustments will not negatively affect our reputation and our ability to secure and maintain reimbursement coverage for our products, which could limit the prices that we charge for our products, including Xyrem and Xywav, limit the commercial opportunities for our products and/or negatively impact revenues from sales of our products. If we become the subject of any future government investigation or U.S. Congressional oversight with respect to drug pricing or other business practices, we could incur significant expense and could be distracted from operation of our business and execution of our strategy. Any such investigation or hearing could also result in reduced market acceptance and demand for our products, could harm our reputation and our ability to market our products in the future, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We expect that legislators, policymakers and healthcare insurance funds in Europe will continue to propose and implement cost-containing measures to keep healthcare costs down. These measures could include limitations on the prices we will be able to charge for our products or the level of reimbursement available for these products from governmental authorities or third party payors. Further, an increasing number of European and other foreign countries use prices for medicinal products established in other countries as “reference prices” to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere. In addition to access, coverage and reimbursement, the commercial success of our products depends upon their market acceptance by physicians, patients, third party payors and the medical community. If physicians do not prescribe our products, we cannot generate the revenues we anticipate from product sales. Market acceptance of each of our products by physicians, patients, third party payors and the medical community depends on: •the clinical indications for which a product is approved and any restrictions placed upon the product in connection with its approval, such as a REMS or equivalent obligation imposed in a European or other foreign country, patient registry requirements or labeling restrictions; •the prevalence of the disease or condition for which the product is approved and its diagnosis; •the efficacy of the product in regular use; •the severity of side effects and other risks in relation to the benefits of our products; •unanticipated serious adverse events; •acceptance by physicians and patients of each product as a safe and effective treatment; •availability of sufficient product inventory to meet demand, particularly with respect to Erwinaze; •physicians’ decisions relating to treatment practices based on availability of product, particularly with respect to Erwinaze;

108 •perceived clinical superiority and/or advantages over alternative treatments; •relative convenience and ease of administration; •with respect to Xyrem and Xywav, physician and patient assessment of the burdens associated with obtaining or maintaining the certifications required under the Xyrem and Xywav REMS or equivalent obligation imposed in a European or other foreign country; •the cost of treatment in relation to alternative treatments, including generic products; and •the availability of financial or other assistance for patients who are uninsured or underinsured. Because of our dependence upon market acceptance of our products, any adverse publicity associated with harm to patients or other adverse events resulting from the use or misuse of any of our products or any similar products distributed by other companies, including generic versions of our products, could materially and adversely affect our business, financial condition, results of operations and growth prospects. For example, from time to time, there is negative publicity about illicit GHB and its effects, including with respect to illegal use, overdoses, serious injury and death. Because sodium oxybate, the API in Xyrem, is a derivative of GHB, Xyrem sometimes also receives negative mention in publicity relating to GHB. Xywav includes the same API as Xyrem, but uses a different mixture of salts. Patients, physicians and regulators may therefore view Xyrem or Xywav as the same as or similar to illicit GHB. In addition, there are regulators and some law enforcement agencies that oppose the prescription and use of Xyrem, and potentially other oxybate products generally because of their connection to GHB. The labels for Xyrem and Xywav authorized in the United States include information about adverse events from GHB. Delays or problems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure to comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of operations and growth prospects. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the API and the finished product in sufficient quantities while meeting detailed product specifications on a repeated basis. We and our suppliers may encounter difficulties in production, including difficulties with procurement of manufacturing materials, production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, and compliance with strictly enforced U.S., state and non-U.S. regulations. In addition, we and our suppliers are subject to FDA’s current Good Manufacturing Practices, or cGMP, requirements, DEA regulations and equivalent rules and regulations prescribed by non-U.S. regulatory authorities. If we or any of our suppliers encounter manufacturing, quality or compliance difficulties with respect to any of our products, whether due to the evolving effects of the COVID-19 pandemic (including as a result of disruptions of global shipping and the transport of products) or otherwise, we may be unable to obtain or maintain regulatory approval or meet commercial demand for such products, which could adversely affect our business, financial condition, results of operations and growth prospects. In addition, we could be subject to enforcement action by regulatory authorities for our failure to comply with cGMP with respect to the products we manufacture in our facilities as well as for our failure to adequately oversee compliance with cGMP by any of our third party suppliers operating under contract. Moreover, failure to comply with applicable legal and regulatory requirements subjects us and our suppliers to possible regulatory action, including restrictions on supply or shutdown, which may adversely affect our or a supplier’s ability to supply the ingredients or finished products we need. We have a manufacturing and development facility in Athlone, Ireland where we manufacture Xyrem and Xywav, and a manufacturing plant in Italy where we produce the defibrotide drug substance. We currently do not have our own commercial manufacturing or packaging capability for our other products, product candidates or their APIs. As a result, our ability to develop and supply products in a timely and competitive manner depends primarily on third party suppliers being able to meet our ongoing commercial and clinical trial needs for API, other raw materials, packaging materials and finished products. Our manufacturing facility in Athlone, Ireland currently continues to be operational with essential staff onsite and office-based staff working remotely. In March 2020, we temporarily ceased operations at our Villa Guardia, Italy manufacturing facility, which produces defibrotide, to ensure the safety of our employees and communities in northern Italy. We reopened the facility in the second quarter of 2020 taking into account applicable public health authority and local government guidelines as well as employee safety, and the facility has now resumed operations with essential staff onsite and office-based staff working remotely. However, the effects of the COVID-19 pandemic continue to rapidly evolve and even if our employees more broadly return to work in our global offices, the field and our manufacturing facilities, we may

109 nevertheless have to resume a remote work model, whether as a result of spikes or surges in COVID-19 infection or hospitalization rates or otherwise. In part due to the limited market size for our products and product candidates, we have a single source of supply for most of our marketed products, product candidates and their APIs. Single sourcing puts us at risk of interruption in supply in the event of manufacturing, quality or compliance difficulties. If one of our suppliers fails or refuses to supply us for any reason, it would take a significant amount of time and expense to implement and execute the necessary technology transfer to, and to qualify, a new supplier. FDA and similar international or national regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in our products. If there are delays in qualifying new suppliers or facilities or a new supplier is unable to meet FDA’s or similar international regulatory body’s requirements for approval, there could be a shortage of the affected products for the marketplace or for use in clinical studies, or both, which could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need. Vyxeos is manufactured by Baxter Oncology GmbH, or Baxter, which is a sole source supplier from a single site location. Baxter has experienced batch failures due to mechanical, component and other issues in the production of Vyxeos, and batches have been produced that have otherwise not been in compliance with applicable specifications. We are continuing to work with Baxter to address manufacturing complexities related to Vyxeos. Moreover, the proprietary technology that supports the manufacture of Vyxeos is not easily transferable. Consequently, engaging an alternate manufacturer may be difficult, costly and time-consuming. If we fail to obtain a sufficient supply of Vyxeos in accordance with applicable specifications on a timely basis, our sales of and revenues from Vyxeos, our future maintenance and potential growth of the market for this product, our ability to conduct ongoing and future clinical trials of Vyxeos, and our business, financial condition, results of operations and growth prospects could be materially adversely affected. In addition, while the APIs in Vyxeos, daunorubicin and cytarabine, are available from a number of suppliers, certain suppliers have received warning letters from FDA. As a result, we have qualified other suppliers for each API, and we provided the qualification data to FDA. If FDA restricts importation of API from either supplier, and we are unable to qualify API from additional suppliers in a timely manner, or at all, our ability to successfully commercialize Vyxeos and generate sales of this product at the level we expect and to conduct ongoing and future clinical trials of Vyxeos could be materially and adversely affected. In addition, in order to conduct our ongoing and any future clinical trials of, complete marketing authorization submissions for, and potentially launch our other product candidates, we also need to have sufficient quantities of product manufactured. Moreover, to obtain approval from FDA or a similar international or national regulatory body of any product candidate, we or our suppliers for that product must obtain approval by the applicable regulatory body to manufacture and supply product, in some cases based on qualification data provided to the applicable body as part of our regulatory submission. Any delay in generating, or failure to generate, data required in connection with submission of the chemistry, manufacturing and controls portions of any regulatory submission could negatively impact our ability to meet our anticipated submission dates, and therefore our anticipated timing for obtaining FDA or similar international or national regulatory body approval, or our ability to obtain regulatory approval at all. In addition, any failure of us or a supplier to obtain approval by the applicable regulatory body to manufacture and supply product or any delay in receiving, or failure to receive, adequate supplies of a product on a timely basis or in accordance with applicable specifications could negatively impact our ability to successfully launch and commercialize products and generate sales of products at the levels we expect. If the effects of the COVID-19 pandemic become more severe and begin to impact supply of manufacturing materials or essential distribution systems such as general delivery services, or require us or our suppliers to again cease or restrict operations at our respective manufacturing facilities, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our products, which would adversely impact our ability to generate sales of and revenues from our approved products and our business, financial condition, results of operations and growth prospects would be materially adversely affected.

110 Risks Related to Growth of Our Product Portfolio and Research and Development Our future success depends on our ability to successfully develop and obtain and maintain regulatory approvals for our late-stage product candidates and, if approved, to successfully launch and commercialize those product candidates. The testing, manufacturing and marketing of our products require regulatory approvals, including approval from FDA and similar bodies in Europe and other countries. If FDA, the EC or the competent authorities of the EU member states or other European countries determine that our quality, safety or efficacy data do not warrant marketing approval for a product candidate, we could be required to conduct additional clinical trials as a condition to receiving approval, which could be costly and time-consuming and could delay or preclude the approval of our application. Our inability to obtain and maintain regulatory approval for our product candidates in the U.S. and Europe and to successfully commercialize new products that are approved would prevent us from receiving a return on our investments and could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Due to the evolving effects of the COVID-19 pandemic, it is possible that we could experience delays in the timing of marketing application review by regulatory authorities and/or our interactions with regulatory authorities due to limited staffing or working hours of governmental employees, governmental “stay-at-home” orders and travel restrictions with respect to physical inspections if required for regulatory approval, or the diversion of regulatory authority efforts and attention to approval of other therapeutics or other activities related to COVID-19, which could delay anticipated approval decisions and otherwise delay or limit our ability to make planned regulatory submissions or obtain new product approvals. It is possible that we could experience delays in regulatory interactions and review of submissions due to COVID-19 impacts described above, such as with respect to our BLA submission of JZP458 or our supplemental new drug application, or sNDA, submission of JZP258 for idiopathic hypersomnia. Even if we receive approval of a product, regulatory authorities may impose significant labeling restrictions or requirements, including limitations on the dosing of the product, requirements around the naming or strength of a product, restrictions on indicated uses for which we may market the product, the imposition of a boxed warning or other warnings and precautions, and/or the requirement for a REMS or equivalent obligation imposed in a European or other foreign country to ensure that the benefits of the drug outweigh the risks. FDA requires a REMS and a boxed warning for Xyrem and Xywav, and similar restrictions could be imposed on other products in the future. Our receipt of approval for narrower indications than sought, restrictions on marketing through a REMS or equivalent obligation imposed in a European or other foreign country, or significant labeling restrictions or requirements in an approved label such as a boxed warning, could have a negative impact on our ability to recoup our research and development costs and to successfully commercialize that product, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects. Regulatory authorities may also impose post-marketing obligations as part of their approval, which may lead to additional costs and burdens associated with commercialization of the drug, and may pose a risk to maintaining approval of the drug. We are subject to certain post-marketing requirements and commitments in connection with the approval of certain of our products, including Zepzelca, Vyxeos, Defitelio, Erwinaze and Sunosi. These post- marketing requirements and commitments include satisfactorily conducting multiple post-marketing clinical trials and safety studies. For example, FDA granted accelerated approval to Zepzelca for relapsed SCLC based on data from a Phase 2 trial, which approval is contingent upon verification and description of clinical benefit in a post- marketing clinical trial. However, FDA confirmed that the clinical benefit of Zepzelca based on the results of the ATLANTIS Phase 3 clinical trial evaluating Zepzelca in combination with doxorubicin for relapsed SCLC did not provide sufficient verification and we and PharmaMar will therefore need to conduct one or more additional clinical trials of Zepzelca to confirm its clinical benefit. Our failure to do so could result in the withdrawal of approval of Zepzelca, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any event, if we are unable to comply with our post-marketing obligations imposed as part of the marketing approvals in the U.S., the EU, or other European countries, our approval may be varied, suspended or revoked, product supply may be delayed and our sales of and revenues from our products could be materially adversely affected. We are pursuing activities related to the development of additional asparaginase products for patients with ALL or other hematological malignancies. Several of our external research and development collaborations are focused on these efforts, including our agreement with Ligand Pharmaceuticals Incorporated, or Ligand. Among the product candidates being developed under our Ligand agreement is JZP458, a recombinant Erwinia asparaginase

111 product candidate, for the potential treatment of ALL and lymphoblastic lymphoma who have hypersensitivity to E. coli-derived asparaginase. We also have clinical development efforts focused on expanding the potential of Vyxeos, Defitelio, Sunosi and Xywav, as well as clinical development efforts focused on JZP385 for the treatment of essential tremor. Because combination regimens and the continual generation of new data have become particularly important in AML, if we are unable to initiate multiple combination studies, safely combine Vyxeos with novel agents, or if efficacy results do not meet clinicians’ expectations, our growth prospects could be materially adversely affected. If we are not successful in the clinical development of our product candidates, if we are unable to obtain regulatory approval for our product candidates in a timely manner, or at all, or if sales of an approved product do not reach the levels we expect, our anticipated revenue from our product candidates would be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We may not be able to successfully identify and acquire or in-license additional products or product candidates to grow our business, and, even if we are able to do so, we may otherwise fail to realize the anticipated benefits of these transactions. In addition to continued investment in our research and development pipeline, we intend to grow our business by acquiring or in-licensing, and developing, including with collaboration partners, additional products and product candidates that we believe are highly differentiated and have significant commercial potential. However, we may be unable to identify or consummate suitable acquisition or in-licensing opportunities, and this inability could impair our ability to grow our business. Other companies, many of which may have substantially greater financial, sales and marketing resources, compete with us for these opportunities. Even if appropriate opportunities are available, we may not be able to successfully identify them, or we may not have the financial resources necessary to pursue them. Even if we are able to successfully identify and acquire, in-license or develop additional products or product candidates, we may not be able to successfully manage the risks associated with integrating any products or product candidates into our portfolio or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions and in- licensing transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks, liabilities and uncertainties effectively, could have a material adverse effect on our business, results of operations and financial condition. In addition, product and product candidate acquisitions, particularly when the acquisition takes the form of a merger or other business consolidation, have required, and any similar future transactions also will require, significant efforts and expenditures, including with respect to transition and integration activities. We may encounter unexpected difficulties, or incur substantial costs, in connection with potential acquisitions and similar transactions, which include: •the need to incur substantial debt and/or engage in dilutive issuances of equity securities to pay for acquisitions; •the potential disruption of our historical core business; •the strain on, and need to continue to expand, our existing operational, technical, financial and administrative infrastructure; • the difficulties in integrating acquired products and product candidates into our portfolio; •the difficulties in assimilating employees and corporate cultures; •the failure to retain key managers and other personnel; •the need to write down assets or recognize impairment charges; •the diversion of our management’s attention to integration of operations and corporate and administrative infrastructures; and •any unanticipated liabilities for activities of or related to the acquired business or its operations, products or product candidates. Moreover, if the effects of the COVID-19 pandemic become more severe, we could experience an inability to access additional capital, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. As a result of these or other factors, products or product candidates we acquire, or obtain licenses to, may not produce the revenues, earnings or business synergies that we anticipated, acquired or in-licensed product candidates may not result in regulatory approvals, and acquired or licensed products may not perform as expected. Failure to manage effectively our growth through acquisitions or in-licensing transactions could adversely affect our growth prospects, business, results of operations and financial condition.

112 Conducting clinical trials is costly and time-consuming, and the outcomes are uncertain. A failure to prove that our product candidates are safe and effective in clinical trials, or to generate data in clinical trials to support expansion of the therapeutic uses for our existing products, could materially and adversely affect our business, financial condition, results of operations and growth prospects. As a condition to regulatory approval, each product candidate must undergo extensive and expensive preclinical studies and clinical trials to demonstrate to a statistically significant degree that the product candidate is safe and effective. The results at any stage of the development process may lack the desired safety, efficacy or pharmacokinetic characteristics. If FDA determines that the safety or efficacy data to be submitted to FDA in the BLA for JZP458 or the sNDA for JZP258 for idiopathic hypersomnia, do not warrant marketing approval, we may be required to conduct additional clinical trials, which could be costly and time-consuming. Even if we believe we have successfully completed testing, FDA or any equivalent non-U.S. regulatory agency may determine our data is not sufficiently compelling to warrant marketing approval for the indications sought, if at all, and may require us to engage in additional clinical trials or provide further analysis which may be costly and time-consuming. Any adverse events or other data generated during the course of clinical trials of our product candidates and/or clinical trials related to additional indications for our commercialized products could result in action by FDA or a non-U.S. regulatory agency, which may restrict our ability to sell, or adversely affect sales of, currently marketed products, or such events or other data could otherwise have a material adverse effect on a related commercial product, including with respect to its safety profile. Any failure or delay in completing such clinical trials could materially and adversely affect the maintenance and growth of the markets for the related marketed products, which could adversely affect our business, financial condition, results of operations and overall growth prospects. In addition to issues relating to the results generated in clinical trials, clinical trials can be delayed or halted for a variety of reasons, including: •direct and indirect impacts of the evolving effects of the COVID-19 pandemic on various aspects and stages of the clinical development process, including the inherent limitations of remote and virtual approaches; •difficulty identifying, recruiting or enrolling eligible patients, often based on the number of clinical trials, particularly in oncology, with enrollment criteria targeting the same patient population; •significant reprioritization and diversion of healthcare resources away from the conduct of clinical trials as a result of the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; •difficulty identifying a clinical development pathway, including viable indications and appropriate clinical trial protocol design, particularly where there is no applicable regulatory precedent; •delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to our product candidates or similar product candidates of our competitors or failure to follow regulatory guidelines; •interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the COVID-19 pandemic; •delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidate for use in trials; •delays or failures in reaching agreement on acceptable terms with prospective study sites; •delays or failures in obtaining approval of our clinical trial protocol from an institutional review board, known as an ethics committee in Europe, to conduct a clinical trial at a prospective study site; •failure of our clinical trials and clinical investigators, including contract research organizations or other third parties assisting us with clinical trials, to satisfactorily perform their contractual duties, meet expected deadlines and comply with FDA and other regulatory agencies’ requirements, including good clinical practices; •unforeseen safety issues; •inability to monitor patients adequately during or after treatment; •difficulty monitoring multiple study sites; or •insufficient funds to complete the trials. In light of the evolving effects of the COVID-19 pandemic, we have taken measures to implement remote and virtual approaches, including remote data monitoring where possible, to maintain patient safety and trial continuity and to preserve study integrity. We have seen limited COVID-19-related impact to our mid- and late-stage clinical trial activity, despite delays in initiating trial sites. For example, while we temporarily suspended two of our healthy

113 volunteer clinical development programs, JZP385 and JZP324, in the interest of volunteer safety, we were able to restart these clinical trials in the third quarter of 2020 with the implementation of appropriate safety protocols. While it has not been the case thus far, we could still see an impact on the ability to supply study drug, report trial results, or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority employee resources or otherwise. In addition, we rely on contract research organizations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the evolving effects of the COVID-19 pandemic. If these effects become more severe, we could experience significant disruptions to our clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects. In addition, some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact our clinical trial operations. Risks Related to Our Intellectual Property It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. Our commercial success depends in part on obtaining, maintaining and defending intellectual property protection for our products and product candidates, including protection of their use and methods of manufacturing and distribution. Our ability to protect our products and product candidates from unauthorized making, using, selling, offering to sell or importation by third parties depends on the extent to which we have rights under valid and enforceable patents or have adequately protected trade secrets that cover these activities. The degree of protection to be afforded by our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: •our patent applications, or those of our licensors or partners, may not result in issued patents; •others may independently develop similar or therapeutically equivalent products without infringing our patents, or those of our licensors, such as products that are not covered by the claims of our patents, or for which we do not have adequate exclusive rights under our license agreements; •our issued patents, or those of our licensors or partners, may be held invalid or unenforceable as a result of legal challenges by third parties or may be vulnerable to legal challenges as a result of changes in applicable law; •we or our licensors or partners might not have been the first to invent or file, as appropriate, subject matters covered by our issued patents or pending patent applications or those of our licensors or partners; •competitors may manufacture products in countries where we have not applied for patent protection or that have a different scope of patent protection or that do not respect our patents; or •others may be issued patents that prevent the sale of our products or require licensing and the payment of significant fees or royalties. Patent enforcement generally must be sought on a country-by-country basis, and issues of patent validity and infringement may be judged differently in different countries. For example, in the EU, approval of a generic pharmaceutical product can occur independently of whether the reference brand product is covered by patents, and enforcement of such patents generally must await approval and an indication that the generic product is being offered for sale. Changes in either the patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property portfolio. Even if we are able to obtain patents covering our products and product candidates, any patent may be challenged, and potentially invalidated or held unenforceable, including through patent litigation or through patent office procedures that permit challenges to patent validity. Patents can also be circumvented, potentially including by FDA approval of an ANDA or Section 505(b)(2) application that avoids infringement of our intellectual property. We have settled patent litigation with nine companies seeking to introduce generic versions of Xyrem in the U.S. by granting those companies licenses to launch their generic products (and in certain cases, an authorized generic version of Xyrem) in advance of the expiration of the last of our patents. Notwithstanding our Xyrem patents and settlement agreements, additional third parties may also attempt to introduce generic versions of Xyrem or other sodium oxybate products for treatment of cataplexy and/or EDS in narcolepsy that design around our patents or assert that our patents are invalid or otherwise unenforceable. Such third parties could launch a generic or

114 505(b)(2) product referencing Xyrem before the dates provided in our patents or settlement agreements. For example, we have several method of use patents listed in FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” or the Orange Book, that expire in 2033 that cover treatment methods included in the Xyrem label related to a drug-drug interaction, or DDI, with divalproex sodium. Although FDA has stated, in granting a Citizen Petition we submitted in 2016, that it would not approve any sodium oxybate ANDA referencing Xyrem that does not include the portions of the currently approved Xyrem label related to the DDI patents, we cannot predict whether a future ANDA filer, or a company that files a Section 505(b)(2) application for a drug referencing Xyrem, may pursue regulatory strategies to avoid infringing our DDI patents notwithstanding FDA’s response to the Citizen Petition, or whether any such strategy would be successful. Likewise, we cannot predict whether we will be able to maintain the validity of these patents or will otherwise obtain a judicial determination that a generic or other sodium oxybate product, its package insert or the generic sodium oxybate REMS or another separate REMS will infringe any of our patents or, if we prevail in proving infringement, whether a court will grant an injunction that prevents a future ANDA filer or other company introducing a different sodium oxybate product from marketing its product, or instead require that party to pay damages in the form of lost profits or a reasonable royalty. Since Xyrem’s regulatory exclusivity has expired in the EU, we are aware that generic or hybrid generic applications have been approved by various EU regulatory authorities, and additional generic or hybrid generic applications may be submitted and approved. We cannot predict whether our licensee in the EU will be able to enforce our existing European patents against generic or hybrid generic filers in the EU. We also currently rely on trade secret protection for several of our products, including Defitelio and Erwinaze. Trade secret protection does not protect information or inventions if another party develops that information or invention independently, and establishing that a competitor developed a product through trade secret misappropriation rather than through legitimate means may be difficult to prove. Trade secret protection also requires that information be secret and subject to reasonable efforts to maintain secrecy, and this requirement may come into conflict with requirements to provide information to employees, consultants, business partners, and regulatory bodies. We seek to protect our trade secrets and other unpatented proprietary information in part through confidentiality and invention agreements with our employees, consultants, advisors and partners. Nevertheless, our employees, consultants, advisors and partners may unintentionally or willfully disclose our proprietary information to competitors, and we may not have adequate remedies for such disclosures. Moreover, if a dispute arises with our employees, consultants, advisors or partners over the ownership of rights to inventions, including jointly developed intellectual property, we could lose patent protection or the confidentiality of our proprietary information, and possibly also lose the ability to pursue the development of certain new products or product candidates. We have incurred and may in the future incur substantial costs as a result of litigation or other proceedings relating to patents, other intellectual property rights and related matters, and we may be unable to protect our rights to, or commercialize, our products. Our ability, and that of our partners, to commercialize any approved products will depend, in part, on our ability to obtain patents, enforce those patents and operate without infringing the proprietary rights of third parties. If we choose to go to court to stop a third party from infringing our patents, our licensed patents or our partners’ patents, that third party has the right to ask the court or an administrative agency to rule that these patents are invalid and/or should not be enforced. These lawsuits and administrative proceedings are expensive and consume time and other resources, and we may not be successful in these proceedings or in stopping infringement. In addition, the inter partes review process, or IPR, under the Leahy-Smith America Invents Act permits any person, whether they are accused of infringing the patent at issue or not, to challenge the validity of certain patents through a proceeding before the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office. There is a risk that a court or the PTAB could decide that our patents or certain claims in our patents are not valid or infringed, and that we do not have the right to stop a third party from using the inventions covered by those claims, as happened with six of our patents covering the Xywav and Xyrem REMS, which were invalidated through the IPR process and delisted from the Orange Book. In addition, even if we prevail in establishing that another product infringes a valid claim of one of our patents, a court may determine that we can be compensated for the infringement in damages, and refuse to issue an injunction. As a result, we may not be entitled to stop another party from infringing our patents for their full term. Litigation involving patent matters is frequently settled between the parties, rather than continuing to a court ruling, and we have settled patent litigation with all nine Xyrem ANDA filers. The FTC has publicly stated that, in

115 its view, certain types of agreements between branded and generic pharmaceutical companies related to the settlement of patent litigation or the manufacture, marketing and sale of generic versions of branded drugs violate the antitrust laws and has commenced investigations and brought actions against some companies that have entered into such agreements. In particular, the FTC has expressed its intention to take aggressive action to challenge settlements that include an alleged transfer of value from the brand company to the generic company (so-called “pay for delay” patent litigation settlements). The U.S. Congress and state legislatures have also identified pharmaceutical patent litigation settlements as potential impediments to generic competition and have introduced, and in states like California passed, legislation to regulate them. Third party payors have also challenged such settlements on the grounds that they increase drug prices. Because there is currently no precise legal standard with respect to the lawfulness of such settlements, many pharmaceutical companies, including us, have faced extensive litigation over whether patent litigation settlements they have entered into are reasonable and lawful. From June to September 2020, a number of class action lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement agreements we entered with Hikma and other ANDA filers violate state and federal antitrust and consumer protection laws. For additional information on these class action complaints, see Note 27, Commitments and Contingencies-Legal Proceedings of the Notes to Consolidated Financial Statements included in this Annual Report. It is possible that additional lawsuits will be filed against us making similar or related allegations. We cannot predict the outcome of these or potential additional lawsuits or government actions; however, if the plaintiffs in the class action complaints were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Parties to such settlement agreements in the U.S. are required by law to file the agreements with the FTC and the U.S. Department of Justice, or DOJ, for review. Accordingly, we have submitted our patent litigation settlement agreements to the FTC and the DOJ for review. We may receive formal or informal requests from the FTC regarding our ANDA litigation settlements, and there is a risk that the FTC may commence a formal investigation or action against us, which could divert the attention of management and cause us to incur significant costs, regardless of the outcome. Any claim or finding that we or our business partners have failed to comply with applicable laws and regulations could be costly to us and could have a material adverse effect on our business, financial condition, results of operations and growth prospects. A third party may claim that we or our manufacturing or commercialization partners are using inventions covered by the third party’s patent rights, or that we or such partners are infringing, misappropriating or otherwise violating other intellectual property rights, and may go to court to stop us from engaging in our normal operations and activities, including making or selling our products. Such lawsuits are costly and could affect our results of operations and divert the attention of management and development personnel. There is a risk that a court could decide that we or our partners are infringing, misappropriating or otherwise violating third party patent or other intellectual property rights, which could be very costly to us and have a material adverse effect on our business. If we are sued for patent infringement, we would need to demonstrate that our products or methods do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, which we may not be able to do. Other Risks Related to Our Business and Industry Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to obtain directors and officers liability insurance, and such insurance coverage may have reduced policy limits and coverage, may not be sufficient to cover our potential liabilities and may make it more difficult for us to attract and retain directors and officers. In recent months, the market for directors and officers liability insurance for biopharmaceuticals and life sciences companies has changed in ways adverse to us. Fewer insurance companies are offering quotes for directors and officers liability coverage, the premiums charged for such policies have generally increased and the terms of such policies have generally become less favorable, and these trends may continue or worsen in the future. In addition, these market conditions are generally presenting more challenges for companies like ours that actively pursue corporate development transactions such as the GW Acquisition and that experience regular share price volatility, including volatility that may be unrelated or disproportionate to our operating performance. As a result, it is currently expensive and may become significantly more expensive for us to maintain directors and officers liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In any event, there can be no assurance that directors and officers liability insurance will be adequate to cover our potential liabilities or will be generally available to us in the

116 future or, if available, that the cost of such insurance will be commercially justifiable. The increased cost and decreased availability of directors and officers liability insurance could make it more difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers, and could also make it more difficult and more expensive for us to negotiate and consummate future corporate development transactions, all of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Our business is currently adversely affected and could be materially and adversely affected in the future by the evolving effects of the COVID-19 pandemic and related global economic slowdown as a result of the current and potential future impacts on our commercialization efforts, clinical trial activity, research and development activities, supply chain and corporate development activities and other business operations, in addition to the impact of a global economic slowdown. The COVID-19 pandemic continues to have a significant impact on the global healthcare delivery system. Many healthcare systems have had to restructure operations to prioritize caring for COVID-19 patients and limit or cease other activities. The severe burden on healthcare systems caused by this pandemic has impaired the ability to diagnose and treat patients with non-COVID-19 related conditions and impaired the ability of many clinical research sites to start new studies, enroll new patients and monitor patients in clinical trials. The evolving effects of the COVID-19 pandemic and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as significant reductions in business related activities have occurred, supply chains have been disrupted, and manufacturing and clinical development activities have been curtailed or suspended. Continued remote work policies, quarantines, shelter-in-place and similar government orders, shutdowns or other restrictions on the conduct of business operations related to the effects of the COVID-19 pandemic may materially and adversely affect our business, our ability to generate sales of and revenues from our approved products, our supply chain, regulatory, clinical development and corporate development activities. With respect to our commercialization activities, the evolving effects of the COVID-19 pandemic continue to have a negative impact on demand, new patient starts and treatments for our products, primarily due to the inherent limitations of telemedicine and a reprioritization of healthcare resources toward COVID-19. Due to the nature of the pandemic, we are not able to accurately predict the duration or extent of these impacts on demand for our products. Beginning in March 2020, we transitioned our field-based sales, market access, reimbursement and medical employees out of the field and suspended work-related travel and in-person customer interactions. We utilized technology to continue to engage healthcare professionals and other customers virtually to support patient care. In late June 2020, as clinics and institutions began to allow in-person interactions pursuant to local health authority and government guidelines, our field teams resumed in-person interactions with healthcare professionals and clinics combined with virtual engagement. The level of renewed engagement varies by account, region and country and may be adversely impacted in the future as a result of the continuing impact of the COVID-19 pandemic. For Xyrem and Xywav, COVID-19 protocols and staffing shortages at sleep labs across the U.S. have resulted in reduced access to sleep testing. Since the end of the first quarter of 2020, we have seen a decline in prescribers’ ability to diagnose new narcolepsy patients and a related overall decline in new patients starting on therapy. Although patient persistence and compliance with oxybate therapy have increased during 2020, we continue to expect that delays in obtaining a narcolepsy diagnosis will have a negative impact on new Xyrem and Xywav patient enrollments in future quarters. For Sunosi, the impact on demand has been primarily related to the reduced ability of our field-based teams to interact with prescribers and patients’ inability to meet with healthcare providers during this time. As a result, we have seen slower than expected growth of Sunosi prescribers and new patient starts in the U.S. We also anticipate that pricing and reimbursement reviews by certain European regulatory authorities may take longer in certain countries due to the pandemic, which could delay our rolling Sunosi launch in those EU member states. In addition, due to the ongoing impacts of the COVID-19 pandemic, we continue to expect a negative impact on demand for and utilization of Defitelio and Vyxeos. We have also seen an upward trend in demand for patient assistance programs since the end of the first quarter of 2020. In this regard, total net product sales of Xywav for the year ended December 31, 2020 were offset by the cost of launch related co-pay coupons and a free product program for qualified patients. Depending on the ultimate duration and severity of the COVID-19 pandemic and the extent of a global economic slowdown, widespread unemployment and resulting loss of employer-sponsored insurance coverage, we may experience an increasing shift from commercial payor coverage to government payor coverage or increasing demand for patient assistance and/or free drug programs, which could continue to adversely affect net product sales.

117 In addition, the COVID-19 pandemic continues to rapidly evolve and has resulted in significant volatility in the global financial markets. If this volatility persists and deepens, we could experience an inability to access additional capital or an impact on liquidity, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. In addition, the current recession or additional market corrections resulting from the impact of the evolving effects of the COVID-19 pandemic could materially affect our business and the value of our ordinary shares. While we expect these effects to adversely affect our business operations and financial results, the extent of the impact on our ability to generate sales of and revenues from our approved products, execute on new product launches, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration and severity of the pandemic, governmental “stay-at-home” orders and travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Ireland and other countries, and the effectiveness of actions taken globally to contain and treat the disease, including the effectiveness and timing of vaccination programs in the U.S. and worldwide. For example, the inability of our workforce to return to office and field-based work and the ongoing stress and reprioritization within the healthcare systems in our key markets may require us to reassess the timing and scope of key business activities for the remainder of 2021, including with respect to our ability to continue the launch momentum for Sunosi, Xywav and Zepzelca. These effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, as further described in the risks and uncertainties described elsewhere in this ‘‘Risk Factors’’ section. We have substantially expanded our international footprint and operations, and we may expand further in the future, which subjects us to a variety of risks and complexities which, if not effectively managed, could negatively affect our business. We are headquartered in Dublin, Ireland and have multiple offices in the U.S., Canada, the UK, Italy and other countries in Europe and an affiliate in Australia. We may further expand our international operations into other countries in the future, either organically or by acquisition. Conducting our business in multiple countries subjects us to a variety of risks and complexities that may materially and adversely affect our business, results of operations, financial condition and growth prospects, including: •the diverse regulatory, financial and legal requirements in the countries where we are located or do business, and any changes to those requirements; •the impact of Brexit on trade relations between the EU and the UK; •challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies, benefits and compliance programs to differing labor and employment law and other regulations, as well as maintaining positive interactions with our unionized employees; •costs of, and liabilities for, our international operations, products or product candidates; and •public health risks, such as the COVID-19 pandemic and potential related effects on supply chain, travel and employee health and availability. In addition, there can be no guarantee that we will effectively manage the increasing, global complexity of our business without experiencing operating inefficiencies or control deficiencies. Our failure to do so could have a material adverse effect on our business, financial condition, results of operations and growth prospects. The UK’s withdrawal from the EU, commonly referred to as Brexit, could increase our cost of doing business, reduce our gross margins or otherwise negatively impact our business and our financial results. Brexit will continue to create significant uncertainty concerning the future relationship between the UK and the EU, following the UK withdrawal from the EU in January 2020. Since a significant portion of the regulatory framework in the UK is derived from EU laws, Brexit materially impacts the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the UK or the EU. In this regard, in December 2020, the EU and UK reached an agreement in principle on the framework for their future relationship, the EU-UK Trade and Cooperation Agreement, or TCA. The TCA primarily focuses on ensuring free trade between the EU and the UK in relation to goods, including medicinal products. Although the body of the TCA includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the TCA. The Annex provides a framework for the recognition of Good Manufacturing Practice, or GMP, inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extended to procedures such as batch release certification. Among the changes that will now occur are that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will, with

118 regard to EU regulations, continue to follow the EU regulatory rules. As part of the TCA, the EU and the UK will recognize GMP inspections carried out by the other party and the acceptance of official GMP documents issued by the other party. The TCA also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to accept EU batch testing and batch release for a period of at least 2 years until January 1, 2023. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As it relates to marketing authorizations, Great Britain will have a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the EC. For example, the scope of a marketing authorization for a medicinal product granted by the EC or by the competent authorities of EU member states will no longer encompass Great Britain (England, Scotland and Wales). In these circumstances, a separate marketing authorization granted by the UK competent authorities will be required to place medicinal products on the market in Great Britain. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the EC. All of these changes could increase our costs and otherwise adversely affect our business. We have an office in Oxford, England, which is focused on commercialization of our products outside of the U.S. We do not know to what extent, or when, the UK’s withdrawal from the EU will impact our business, particularly our ability to conduct international business from a base of operations in the UK. The UK could lose the benefits of global trade agreements negotiated by the EU on behalf of its member states, possibly resulting in increased trade barriers, which could make doing business in Europe more difficult and/or costly. Moreover, in the U.S., tariffs on certain U.S. imports have been imposed, and the EU and other countries have responded with retaliatory tariffs on certain U.S. exports. We cannot predict what effects these and potential additional tariffs will have on our business, including in the context of escalating global trade and political tensions. However, these tariffs and other trade restrictions, whether resulting from the UK’s withdrawal from the EU or otherwise, could increase our cost of doing business, reduce our gross margins or otherwise negatively impact our business and our financial results. Significant disruptions of information technology systems or data security breaches could adversely affect our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal data. We have also outsourced some of our operations (including parts of our information technology infrastructure) to a number of third party vendors who may have, or could gain, access to our confidential information. In addition, many of those third parties, in turn, subcontract or outsource some of their responsibilities to third parties. Our information technology systems, and those of our vendors, are large and complex and store large amounts of confidential information. The size and complexity of these systems make them potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third party vendors and/or business partners, or from cyber-attacks by malicious third parties. Attacks of this nature are increasing in frequency, persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, “hacktivists,” nation states and others. In addition to the extraction of important information, such attacks could include the deployment of harmful malware, ransomware, denial-of- service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of our information. Although the aggregate impact on our operations and financial condition has not been material to date, we and our vendors have been the target of events of this nature and expect them to continue. Significant disruptions of our, our third party vendors’ and/or business partners’ information technology systems or security breaches, including in our remote work environment as a result of the COVID-19 pandemic, could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal data), and could result in financial, legal, business and reputational harm to us. Any such event that leads to unauthorized access, use or disclosure of personal data, including personal data regarding our patients or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory

119 corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal data. This could disrupt our business, result in increased costs or loss of revenue, and/or result in significant legal and financial exposure. In addition, security breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may further harm us. Moreover, the prevalent use of mobile devices to access confidential information increases the risk of security breaches. While we have implemented security measures to protect our information technology systems and infrastructure, there can be no assurance that such measures will prevent service interruptions or security breaches that could adversely affect our business. In addition, failure to maintain effective internal accounting controls related to security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and subject us to regulatory scrutiny. We are subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense and limit our ability to commercialize our products. FDA and Equivalent Non-U.S. Regulatory Authorities Our activities are subject to extensive regulation encompassing the entire life cycle of our products, from research and development activities to marketing approval (including specific post-marketing obligations), manufacturing, labeling, packaging, adverse event and safety reporting, storage, advertising, promotion, sale, pricing and reimbursement, recordkeeping, distribution, importing and exporting. The failure by us or any of our third party partners, including our corporate development and collaboration partners, clinical trial sites, suppliers, distributors and our central pharmacy for Xyrem and Xywav, to comply with applicable requirements could subject us to administrative or judicial sanctions or other negative consequences, such as delays in approval or refusal to approve a product candidate, restrictions on our products, our suppliers, our other partners or us, the withdrawal, suspension or variation of product approval or manufacturing authorizations, untitled letters, warning letters, fines and other monetary penalties, unanticipated expenditures, product recall, withdrawal or seizure, total or partial suspension of production or distribution, interruption of manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, civil penalties and/or criminal prosecution, any of which could result in a significant drop in our revenues from the affected products and harm to our reputation and could have a significant impact on our sales, business and financial condition. We monitor adverse events resulting from the use of our products, as do the regulatory authorities, and we file periodic reports with the authorities concerning adverse events. The authorities review these events and reports, and if they determine that any events and/or reports indicate a trend or signal, they can require a change in a product label, restrict sales and marketing and/or require conduct or other actions, potentially including variation, withdrawal or suspension of the marketing authorization, any of which could result in reduced market acceptance and demand for our products, could harm our reputation and our ability to market our products in the future, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects. FDA, the competent authorities of the EU member states on behalf of the EMA, and the competent authorities of other European countries, also periodically inspect our records related to safety reporting. The EMA’s Pharmacovigilance Risk Assessment Committee may propose to the Committee for Medicinal Products for Human Use that the marketing authorization holder be required to take specific steps or advise that the existing marketing authorization be varied, suspended or revoked. Failure to adequately and promptly correct the observation(s) can result in further regulatory enforcement action, which could include the variation, suspension or withdrawal of marketing authorization or imposition of financial penalties or other enforcement measures. Erwinaze, defibrotide and Vyxeos are available on a named patient basis or through a compassionate use process in many countries where they are not commercially available. If any such country’s regulatory authorities determine that we are promoting such products without proper authorization, we could be found to be in violation of pharmaceutical advertising laws or the regulations permitting sales under named patient programs. In that case, we may be subject to financial or other penalties. Any failure to maintain revenues from sales of Erwinaze, defibrotide and/or Vyxeos on a named patient basis and/or to generate revenues from commercial sales of these products exceeding historical sales on a named patient basis could have a material adverse effect on our business, financial condition, results of operations and growth prospects. FDA, the competent authorities of the EU member states and other European countries, and other governmental authorities require advertising and promotional materials to be truthful and not misleading, and products to be marketed only for their approved indications and in accordance with the provisions of the approved label. Regulatory authorities actively investigate allegations of off-label promotion in order to enforce regulations

120 prohibiting these types of activities. A determination that we have promoted an approved product for off-label uses could subject us to significant liability, including civil and administrative financial penalties and other remedies as well as criminal financial penalties, other sanctions and imprisonment. Even if we are not determined to have engaged in off-label promotion, an allegation that we have engaged in such activities could have a significant impact on our sales, business and financial condition. The U.S. government has also required companies to enter into complex corporate integrity agreements and/or non-prosecution agreements that impose significant reporting and other burdens on the affected companies. Failure to maintain a comprehensive and effective compliance program, and to integrate the operations of acquired businesses into a combined comprehensive and effective compliance program on a timely basis, could subject us to a range of regulatory actions and/or civil or criminal penalties that could affect our ability to commercialize our products and could harm or prevent sales of the affected products, or could substantially increase the costs and expenses of commercializing and marketing our products. Other Regulatory Authorities We are also subject to regulation by other regional, national, state and local agencies, including the DEA, the DOJ, the FTC, the United States Department of Commerce, the Office of Inspector General of the U.S. Department of Health and Human Services, or OIG, and other regulatory bodies, as well as similar governmental authorities in those non-U.S. countries in which we commercialize our products. We are subject to numerous fraud and abuse laws and regulations globally and our sales, marketing, patient support and medical activities may be subject to scrutiny under these laws and regulations. While we maintain a comprehensive compliance program to try to ensure that our practices and the activities of our third-party contractors and employees fall within the scope of available statutory exceptions and regulatory safe harbors whenever possible, and otherwise comply with applicable laws, regulations or guidance, regulators and enforcement agencies may disagree with our assessment or find fault with the conduct of our employees or contractors. In addition, existing regulations are subject to regulatory revision or changes in interpretation by the DOJ or OIG. For example, in November 2020, the U.S. Department of Health and Human Services finalized a previously abandoned proposal to amend the discount safe harbor regulation of the federal anti-kickback statute in a purported effort to create incentives to manufacturers to lower their list prices, and to lower federal program beneficiary out-of-pocket costs. The rule, which takes full effect January 1, 2022, revises the discount safe harbor to exclude manufacturer rebates to Medicare Part D plans, either directly or through PBMs, creates a new safe harbor for point-of-sale price reductions that are set in advance and are available to the beneficiary at the point-of-sale, and creates a new safe harbor for service fees paid by manufacturers to PBMs for services rendered to the manufacturer. It is too early to know what the effect of the rule will be on negotiations of coverage for our products with Medicare Part D plans, or whether the rule will affect our coverage arrangements with commercial insurers. It is also unclear whether the rule will have the intended effect of reducing net prices and beneficiary out-of-pocket costs without also increasing Medicare Part D premiums, which may impact the willingness of Part D plans to cover our products and the price concessions or other terms the plans or their PBMs may seek from us. Many companies have faced government investigations or lawsuits by whistleblowers who bring a qui tam action under the False Claims Act on behalf of themselves and the government for a variety of alleged improper marketing activities, including providing free product to customers expecting that the customers would bill federal programs for the product, providing consulting fees, grants, free travel and other benefits to physicians to induce them to prescribe the company’s products, and inflating prices reported to private price publication services, which are used to set drug reimbursement rates under government healthcare programs. In addition, the government and private whistleblowers have pursued False Claims Act cases against pharmaceutical companies for causing false claims to be submitted as a result of the marketing of their products for unapproved uses or violations of the federal anti-kickback statute. If we become the subject of a government False Claims Act or other investigation or whistleblower suit, we could incur substantial legal costs (including settlement costs) and business disruption responding to such investigation or suit, regardless of the outcome. Public reporting under the Physician Payment Sunshine Act, or Sunshine provisions, and other similar state laws, has resulted in increased scrutiny of the financial relationships between industry, teaching hospitals, physicians and other healthcare providers. Such scrutiny may negatively impact our ability to engage with physicians and other health care providers on matters of importance to us. In addition, government agencies and private entities may inquire about our marketing practices or pursue other enforcement activities based on the disclosures in those public reports. If the data reflected in our reports are found to be in violation of any of the Sunshine provisions or any other U.S. federal, state or local laws or regulations that may apply, or if we otherwise fail to comply with the Sunshine

121 provisions or similar requirements of state or local regulators, we may be subject to significant civil, and administrative penalties, damages or fines. We have various programs to help patients access our products, including patient assistance programs, which include co-pay coupons for certain of our products, assistance to help patients determine their insurance coverage for our products, and a free product program. Co-pay coupon programs for commercially insured patients, including our program for Xyrem, have received negative publicity related to allegations regarding their use to promote branded pharmaceutical products over other less costly alternatives, and some states have imposed restrictions on manufacturer co-pay programs when therapeutic equivalents are available. In September 2014, the OIG issued a Special Advisory Bulletin warning manufacturers that they may be subject to sanctions under the federal Anti- Kickback Statute and other laws if they do not take appropriate steps to exclude Medicare Part D beneficiaries from using co-pay coupons. It is possible that changes in insurer policies regarding co-pay coupons and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these patient support programs, which could result in fewer patients using affected products, including Xyrem, and therefore could have a material adverse effect on our sales, business and financial condition. We have established programs to consider grant applications submitted by independent charitable organizations, including organizations that provide co-pay support to patients who suffer from the diseases treated by our drugs. The OIG has issued guidance for how pharmaceutical manufacturers can lawfully make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations, among other things, are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria, and do not link aid to use of a donor’s product. In April 2019, we finalized our civil settlement agreement with the DOJ and OIG and entered into a corporate integrity agreement requiring us to maintain our ongoing corporate compliance program and obligating us to implement or continue, as applicable, a set of defined corporate integrity activities for a period of five years from the effective date of the corporate integrity agreement. Although we have structured our programs to follow available guidance and the requirements of our corporate integrity agreement, if we or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or evolving government guidance in the operation of these programs, such facts could be used as the basis for an enforcement action against us by the federal government or other enforcement agencies or private litigants, or we could become liable for payment of certain stipulated penalties or could be excluded from participation in federal health care programs, which would have a material adverse effect on our sales, business and financial condition. We may also become subject to similar investigations by other state or federal governmental agencies or offices of our patient assistance programs or other business practices, which could result in damages, fines, penalties, exclusion from participation in federal health care programs or other criminal, civil or administrative sanctions or enforcement actions, as well as negative publicity, reduction in demand for, or patient access to, our products and/or reduce coverage of our products, including by federal and state health care programs. If any or all of these events occur, our business, financial condition, results of operations and stock price could be materially and adversely affected. Our business activities outside of the U.S. are subject to the U.S. Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the UK Bribery Act of 2010, or the UK Bribery Act. In certain countries, the health care providers who prescribe pharmaceuticals are employed by their government and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers may be subject to regulation under the FCPA and the UK Bribery Act. Recently the U.S. Securities and Exchange Commission and the DOJ have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violation of these laws by us or our suppliers and other third party agents for which we may be liable may result in civil or criminal sanctions, which could include monetary fines, criminal penalties, and disgorgement of past profits, which could have a material adverse impact on our business and financial condition. Outside the U.S., interactions between pharmaceutical companies and physicians are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self- regulation codes of conduct and physicians’ codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. Xyrem, Sunosi and Xywav are controlled substances under the Controlled Substances Act. Our suppliers, distributors, clinical sites and prescribers, as well as retail pharmacies for Sunosi and the central pharmacy for

122 Xyrem and Xywav, are subject to DEA and state regulations relating to manufacturing, storage, distribution and physician prescription procedures, including limitations on prescription refills, and are required to maintain DEA registration and state licenses, when handling these drugs and their APIs. The DEA periodically inspects facilities for compliance with its rules and regulations. Failure to comply with current and future regulations of the DEA, relevant state authorities or any comparable international requirements could lead to a variety of sanctions, including revocation or denial of renewal of DEA registrations, fines, injunctions, or civil or criminal penalties, could result in, among other things, additional operating costs to us or delays in shipments outside or into the U.S. and could have an adverse effect on our business and financial condition. We are also subject to federal, state and international laws and regulations governing the privacy and security of the personal data we collect and maintain (e.g., Section 5 of the Federal Trade Commission Act, the California Consumer Privacy Act, or CCPA, and the EU’s General Data Protection Regulation, or GDPR). These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. Because of the remote work policies we implemented due to the COVID-19 pandemic, information that is normally protected, including company confidential information, may be less secure. Cybersecurity and data security threats continue to evolve and raise the risk of an incident that could affect our operations or compromise our business information or sensitive personal data, including health data. We may also need to collect more extensive health-related information from our employees to manage our workforce. If we or our third party partners fail to comply or are alleged to have failed to comply with applicable data protection and privacy laws and regulations, and related employment rules, or if we were to experience a data breach involving personal data, we could be subject to government enforcement actions or private lawsuits. In addition, our business could be adversely impacted if our ability to transfer personal data outside of the European Economic Area or Switzerland is restricted, which could adversely impact our operating results. For example, in July 2020, the Court of Justice of the European Union, or the Court of Justice, declared the Privacy Shield Decision (Decision 2018/1250) invalid, which could adversely impact our ability to transfer personal data from the EU to the U.S. The Court of Justice further ruled that in order to transfer data outside of the EU, under the existing mechanism known as the Standard Contractual Clauses, or SCCs, the importing country’s level of protection must be adequate. In addition, on September 8, 2020 the Federal Data Protection and Information Commissioner, or FDPIC, of Switzerland issued an opinion concluding that the Swiss-U.S. Privacy Shield Framework does not provide an adequate level of protection for data transfers from Switzerland to the United States. The FDPIC also found that SCCs may still be legally adequate at an individual level provided that they can pass a risk assessment conducted by the FDPIC. If the level of protection in the U.S. or any other importing country is called into question under the SCCs, this could further impact our ability to transfer data outside of the EU or Switzerland. In addition, although we are not directly subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, or HIPAA, other than with respect to providing certain employee benefits, we potentially could be subject to criminal penalties if we, our affiliates or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. We also may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. In addition, numerous other federal, state and international laws and regulations govern the privacy and security of the personal data we collect and maintain, including data breach notification laws, state health information and/or genetic privacy laws, federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act, and CCPA), and laws outside of the United States that may apply to us, such as the GDPR and other country laws. Many of these laws and regimes, across countries but even within the United States across states, differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Compliance with these laws is difficult, constantly evolving, and time consuming. International regulators, federal regulators, state attorneys general, and plaintiffs’ attorneys, including class action attorneys, have been and will likely continue to be active in this space. In California, the CCPA took effect on January 1, 2020. The CCPA establishes certain requirements for data use and sharing transparency and creates new data privacy rights for consumers. These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. Similarly, there are a number of legislative proposals in the European Union, the United States, at both the federal and state level, as well as other jurisdictions that could impose new obligations or limitations in areas affecting our business. In addition, some countries are considering or have passed legislation implementing data

123 protection or privacy requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of delivering our services and research activities. If we or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection and privacy laws and regulations, or if we were to experience a data breach involving personal data, we could be subject to government enforcement actions or private lawsuits. Any associated claims, inquiries, or investigations or other government actions could lead to unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other remedies that harm our business, including orders that we modify or cease existing business practices. If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We participate in the Medicaid Drug Rebate program, the 340B program, the U.S. Department of Veterans Affairs, Federal Supply Schedule, or FSS, pricing program, and the Tricare Retail Pharmacy program, and have obligations to report the average sales price for certain of our drugs to the Medicare program. Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies and the courts, which can change and evolve over time. In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. The Centers for Medicare and Medicaid Services, or CMS, could also decide to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect. Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively impact our financial results. CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate program under the Healthcare Reform Act. On December 21, 2020, CMS issued a final regulation that modified prior Medicaid Drug Rebate program regulations to permit reporting multiple best price figures with regard to value-based purchasing arrangements (beginning in 2022); provide definitions for “line extension,” “new formulation,” and related terms, with the practical effect of expanding the scope of drugs considered to be line extensions that are subject to an alternative rebate formula (beginning in 2022); and revise best price and average manufacturer price exclusions of manufacturer-sponsored patient benefit programs, specifically regarding applicability of such exclusions in the context of pharmacy benefit manager “accumulator” programs (beginning in 2023). It is currently unclear whether the Biden administration will delay or suspend implementation of this final rule. The issuance of the final regulation, as well as any other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate program, has increased and will continue to increase our costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS challenges the approach we take in our implementation of the final regulation. The Health Resources and Services Administration, or HRSA, issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019. Implementation of this regulation could affect our obligations and potential liability under the 340B program in ways we cannot anticipate. We are also required to report the 340B ceiling prices for our covered outpatient drugs to HRSA, which then

124 publishes them to 340B covered entities. Any charge by HRSA that we have violated the requirements of the program or the regulation could negatively impact our financial results. Moreover, HRSA newly established an administrative dispute resolution, or ADR, process under a final regulation effective January 13, 2021, for claims by covered entities that a manufacturer engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could potentially subject us to discovery by covered entities and other onerous procedural requirements and could result in additional liability. Further, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting, and any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the Healthcare Reform Act or otherwise could affect our 340B ceiling price calculations and negatively impact our results of operations. We have obligations to report the average sales price for certain of our drugs to the Medicare program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for our products and the resulting Medicare payment rate, and could negatively impact our results of operations. Pursuant to applicable law, knowing provision of false information in connection with price reporting under the U.S. Department of Veterans Affairs, FSS or Tricare Retail Pharmacy, or Tricare, programs can subject a manufacturer to civil monetary penalties. These program obligations also contain extensive disclosure and certification requirements. If we overcharge the government in connection with our arrangements with FSS or Tricare, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Product liability and product recalls could harm our business. The development, manufacture, testing, marketing and sale of pharmaceutical products are associated with significant risks of product liability claims or recalls. Side effects or adverse events known or reported to be associated with, or manufacturing defects in, the products sold by us could exacerbate a patient’s condition, or could result in serious injury or impairment or even death. This could result in product liability claims against us and/or recalls of one or more of our products. In many countries, including in EU member states, national laws provide for strict (no-fault) liability which applies even where damages are caused both by a defect in a product and by the act or omission of a third party. Product recalls may be issued at our discretion or at the discretion of our suppliers, government agencies and other entities that have regulatory authority for pharmaceutical sales. Any recall of our products could materially adversely affect our business by rendering us unable to sell that product for some time and by adversely affecting our reputation. A recall could also result in product liability claims by individuals and third party payors. In addition, product liability claims could result in an investigation of the safety or efficacy of our products, our manufacturing processes and facilities, or our marketing programs conducted by FDA, the EMA or the competent authorities of the EU member states. Such investigations could also potentially lead to a recall of our products or more serious enforcement actions, limitations on the therapeutic indications for which they may be used, or suspension, variation, or withdrawal of approval. Any such regulatory action by FDA, the EC or the competent authorities of the EU member states could lead to product liability lawsuits as well. Product liability insurance coverage is expensive, can be difficult to obtain and may not be available in the future on acceptable terms, or at all. Our product liability insurance may not cover all of the future liabilities we might incur in connection with the development, manufacture or sale of our products. A successful claim or claims brought against us in excess of available insurance coverage could subject us to significant liabilities and could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Such claims could also harm our reputation and the reputation of our products, adversely affecting our ability to market our products successfully.

125 We use hazardous materials in our manufacturing facilities, and any claims relating to the improper handling, storage, release or disposal of these materials could be time-consuming and expensive. Our operations are subject to complex and increasingly stringent environmental, health and safety laws and regulations in the countries where we operate and, in particular, in Italy and Ireland where we have manufacturing facilities. If an accident or contamination involving pollutants or hazardous substances occurs, an injured party could seek to hold us liable for any damages that result and any liability could exceed the limits or fall outside the coverage of our insurance. We may not be able to maintain insurance with sufficient coverage on acceptable terms, or at all. Costs, damages and/or fines may result from the presence, investigation and remediation of such contamination at properties currently or formerly owned, leased or operated by us or at off-site locations, including where we have arranged for the disposal of hazardous substances or waste. In addition, we may be subject to third party claims, including for natural resource damages, personal injury and property damage, in connection with such contamination. Risks Related to Our Financial Condition and Results We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position, and our business would be adversely affected if we are unable to service our debt obligations. As of December 31, 2020, we had total indebtedness of approximately $2.4 billion. Our substantial indebtedness may: •limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes; •limit our ability to use our cash flow or obtain additional financing for working capital, capital expenditures, acquisitions, investments or other general business purposes; •require us to use a substantial portion of our cash flow from operations to make debt service payments; •limit our flexibility to plan for, or react to, changes in our business and industry, or our ability to take specified actions to take advantage of certain business opportunities that may be presented to us; •result in dilution to our existing shareholders in the event exchanges of our exchangeable senior notes are settled in our ordinary shares; •place us at a competitive disadvantage compared to our less leveraged competitors; and •increase our vulnerability to the impact of adverse economic and industry conditions. If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay investments and capital expenditures, seek additional capital or restructure or refinance our debt. These alternative measures may not be successful and may not permit us to meet our debt service obligations. In the absence of such cash flows and resources, we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt service and other obligations. In addition, if we are unable to repay amounts under our secured credit agreement that we entered into in June 2015 and subsequently amended, which we refer to as the amended credit agreement, the lenders under the amended credit agreement could proceed against the collateral granted to them to secure that debt, which would seriously harm our business. Covenants in our amended credit agreement restrict our business and operations in many ways and if we do not effectively manage our covenants, our financial conditions and results of operations could be adversely affected. The amended credit agreement contains various covenants that, among other things, limit our ability and/or our restricted subsidiaries’ ability to: •incur or assume liens or additional debt or provide guarantees in respect of obligations of other persons; •pay dividends or distributions or redeem or repurchase capital stock; •prepay, redeem or repurchase certain debt; •make loans, investments, acquisitions (including acquisitions of exclusive licenses) and capital expenditures; •enter into agreements that restrict distributions from our subsidiaries; •sell assets and capital stock of our subsidiaries; and •consolidate or merge with or into, or sell substantially all of our assets to, another person. The amended credit agreement also includes certain financial covenants that require us to maintain a maximum secured leverage ratio and a minimum interest coverage ratio. Our failure to comply with any of the covenants could result in a default under the amended credit agreement, which could permit the lenders to declare all

126 or part of any outstanding borrowings to be immediately due and payable, or to refuse to permit additional borrowings under the revolving credit facility. Moreover, our failure to repurchase our exchangeable senior notes at a time when the repurchase is required by the indentures governing our exchangeable senior notes or to pay any cash payable on future exchanges of our exchangeable senior notes as required by those indentures would constitute a default under those indentures. A default under those indentures could also lead to a default under other debt agreements or obligations, including the amended credit agreement. Likewise, a default under the amended credit agreement could also lead to a default under other debt agreements or obligations, including the indentures governing our exchangeable senior notes. To continue to grow our business, we will need to commit substantial resources, which could result in future losses or otherwise limit our opportunities or affect our ability to operate and grow our business. The scope of our business and operations has grown substantially since 2012, including through a series of business combinations and acquisitions. To continue to grow our business over the longer term, we plan to commit substantial resources to product acquisition and in-licensing, product development, clinical trials of product candidates and expansion of our commercial, development, manufacturing and other operations. Acquisition opportunities that we pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the effects of the COVID-19 pandemic. In addition, under Irish law, we must have authority from our shareholders to issue any ordinary shares, including ordinary shares that are part of our authorized but unissued share capital. Moreover, when an Irish company issues shares for cash to new shareholders, it is required first to offer those shares on the same or more favorable terms to existing shareholders on a pro-rata basis unless otherwise authorized by its existing shareholders. While we are currently authorized to issue all ordinary shares that are part of our authorized but unissued share capital on a non- pre-emptive basis, these share issuance authorities are scheduled to expire in August 2021. If we are unable to obtain renewal of our existing share issuance authorities from our shareholders, or are otherwise limited by the terms of new share issuance authorities approved by our shareholders, our ability to use our unissued share capital to effect or to fund in-licensing or acquisition opportunities, or to otherwise raise capital, could be adversely affected after expiration of our existing share issuance authorities in August 2021. An inability to borrow or raise additional capital on attractive terms, or at all, could prevent us from expanding our business and otherwise could have a material adverse effect on our business and growth prospects. In addition, if we use a substantial amount of our funds to acquire or in-license products or product candidates, we may not have sufficient additional funds to conduct all of our operations in the manner we would otherwise choose. We have significant intangible assets and goodwill. Consequently, the future impairment of our intangible assets and goodwill may significantly impact our profitability. Our intangible assets and goodwill are significant and are subject to an impairment analysis whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. Additionally, goodwill and indefinite-lived assets are subject to an impairment test at least annually. Events giving rise to impairment are an inherent risk in the pharmaceutical industry and cannot be predicted. Our results of operations and financial position in future periods could be negatively impacted should future impairments of intangible assets or goodwill occur. For example, in the first quarter of 2020, we recorded a $136.2 million asset impairment charge following the decision to stop enrollment in our Phase 3 clinical study of defibrotide for the prevention of VOD due to a determination that the study is highly unlikely to reach one of its primary endpoints. Our financial results have been and may continue to be adversely affected by foreign currency exchange rate fluctuations. Because our financial results are reported in U.S. dollars, we are exposed to foreign currency exchange risk as the functional currency financial statements of non-U.S. subsidiaries are translated to U.S. dollars for reporting purposes. To the extent that revenue and expense transactions are not denominated in the functional currency, we are also subject to the risk of transaction losses. For example, because our Sunosi, Vyxeos, Defitelio and Erwinase product sales outside of the U.S. are primarily denominated in the euro, our sales of those products have been and may continue to be adversely affected by fluctuations in foreign currency exchange rates. Given the volatility of exchange rates, as well as our expanding operations, there is no guarantee that we will be able to effectively manage currency transaction and/or translation risks, which could adversely affect our operating results. Although we utilize

127 foreign exchange forward contracts to manage currency risk primarily related to certain intercompany balances denominated in non-functional currencies, our efforts to manage currency risk may not be successful. Changes in our effective tax rates could adversely affect our business and financial condition, results of operations and growth prospects. We are incorporated in Ireland and maintain subsidiaries in North America and a number of other foreign jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various jurisdictions where we operate. Our effective tax rate may fluctuate depending on a number of factors, including, but not limited to, the distribution of our profits or losses between the jurisdictions where we operate and changes to or differences in interpretation of tax laws. We are subject to reviews and audits by the U.S. Internal Revenue Services, or IRS, and other taxing authorities from time to time, and the IRS or other taxing authority may challenge our structure, transfer pricing arrangements and tax positions through an audit or lawsuit. Responding to or defending against challenges from taxing authorities could be expensive and consume time and other resources. If we are unsuccessful, we may be required to pay taxes for prior periods, interest, fines or penalties, and may be obligated to pay increased taxes in the future, any of which could require us to reduce our operating expenses, decrease efforts in support of our products or seek to raise additional funds. Any of these actions could have a material adverse effect on our business, financial condition, results of operations and growth prospects. The IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S. federal tax purposes. Although we are incorporated in Ireland, the IRS may assert that we should be treated as a U.S. corporation (and, therefore, a U.S. tax resident) for U.S. federal tax purposes pursuant to Section 7874 of the U.S. Internal Revenue Code, or the Code. For U.S. federal tax purposes, a corporation generally is considered a tax resident in the jurisdiction of its organization or incorporation. Because we are an Irish incorporated entity, we would be classified as a foreign corporation (and, therefore, a non-U.S. tax resident) under these rules. Section 7874 of the Code provides an exception under which a foreign incorporated entity may, in certain circumstances, be treated as a U.S. corporation for U.S. federal tax purposes. Because we indirectly acquired all of Jazz Pharmaceuticals, Inc.’s assets through the acquisition of the shares of Jazz Pharmaceuticals, Inc. common stock when the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma Public Limited Company were combined in a merger transaction in January 2012, or the Azur Merger, the IRS could assert that we should be treated as a U.S. corporation for U.S. federal tax purposes under Section 7874. The IRS continues to scrutinize transactions that are potentially subject to Section 7874, and has issued several sets of final and temporary regulations under Section 7874 since 2012. We do not expect these regulations to affect the U.S. tax consequences of the Azur Merger. Nevertheless, new statutory and/or regulatory provisions under Section 7874 of the Code or otherwise could be enacted that adversely affect our status as a foreign corporation for U.S. federal tax purposes, and any such provisions could have prospective or retroactive application to us, our shareholders, Jazz Pharmaceuticals, Inc. and/or the Azur Merger. Our U.S. affiliates’ ability to use their net operating losses to offset potential taxable income and related income taxes that would otherwise be due is limited under Section 7874 of the Code and could be subject to further limitations if we do not generate taxable income in a timely manner or if the “ownership change” provisions of Sections 382 and 383 of the Code result in further annual limitations. Following certain acquisitions of a U.S. corporation by a foreign corporation, Section 7874 of the Code can limit the ability of the acquired U.S. corporation and its U.S. affiliates to utilize U.S. tax attributes such as net operating losses, or NOLs, to offset U.S. taxable income resulting from certain transactions. Our U.S. affiliates have a significant amount of NOLs. As a result of Section 7874 of the Code, after the Azur Merger, our U.S. affiliates have not been able and will continue to be unable, for a period of time, to utilize their U.S. tax attributes to offset their U.S. taxable income, if any, resulting from certain taxable transactions. While we expect to be able to fully utilize our U.S. affiliates’ U.S. NOLs prior to their expiration, as a result of this limitation, it may take our U.S. affiliates longer to use their NOLs. Our ability to use these NOLs to offset potential future taxable income and related income taxes that would otherwise be due is also dependent upon our generation of future taxable income before the expiration dates of the NOLs, and we cannot predict with certainty when, or whether, our U.S. affiliates will generate sufficient taxable income to use all of the NOLs. In addition, the use of NOLs to offset potential future taxable income and related income taxes that would otherwise be due is subject to annual limitations under the “ownership change” provisions of Sections 382 and 383 of the Code and similar state provisions, which may result in the expiration of additional NOLs before future utilization.

128 Changes to tax laws relating to multinational corporations could adversely affect us. The U.S. Congress, the EU, the Organization for Economic Co-operation and Development, or OECD, and other government agencies in jurisdictions where we and our affiliates do business have had an extended focus on issues related to the taxation of multinational corporations. One example is the OECD’s initiative in the area of “base erosion and profit shifting,” where payments are made between affiliates from a jurisdiction with high tax rates to a jurisdiction with lower tax rates. Many countries have begun to implement legislation and other guidance to align their international tax rules with the OECD’s recommendation. As a result of the focus on the taxation of multinational corporations, the tax laws in Ireland, the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis, and any such changes could adversely affect us. On December 22, 2017, the U.S. Tax Cuts and Jobs Act, or U.S. Tax Act, was signed into law. The U.S. Tax Act made broad and complex changes to the U.S. tax code. The U.S. Department of Treasury has issued regulations and other interpretive guidance under the U.S. Tax Act, and is expected to issue additional guidance, the impact of which is uncertain but could adversely affect us. Furthermore, the impact of this tax reform on certain holders of our ordinary shares could be adverse. Among other things, changes to the rules for determining a foreign corporation’s status as a controlled foreign corporation could have an adverse effect on U.S. persons who are treated as owning (directly or indirectly) at least 10% of the value or voting power of our ordinary shares. Investors should consult their own advisers regarding the potential application of these rules to their investments. Further, the results of the recent U.S. presidential and Senate elections could lead to changes in U.S. tax laws, including an increase in the U.S. corporate income tax rate from that currently in effect under the U.S. Tax Act, which could adversely impact our tax provision, cash tax liability and effective tax rate. A substantial portion of our indebtedness bears interest at variable interest rates based on USD LIBOR and certain of our financial contracts are also indexed to USD LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise adversely affect our financial condition and results of operations. In July 2017, the Financial Conduct Authority, the authority that regulates the London Inter-bank Offered Rate, or LIBOR, announced that it intended to stop compelling banks to submit rates for the calculation of LIBOR after 2021. We have certain financial contracts, including the amended credit agreement and our interest rate swaps, that are indexed to USD LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness. Any transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that rely on LIBOR, reductions in the value of certain instruments or the effectiveness of related transactions such as hedges, increased borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes. The transition away from LIBOR may result in increased expenses, may impair our ability to refinance our indebtedness or hedge our exposure to floating rate instruments, or may result in difficulties, complications or delays in connection with future financing efforts, any of which could adversely affect our financial condition and results of operations. Risks Related to Our Ordinary Shares The market price of our ordinary shares has been volatile and is likely to continue to be volatile in the future, and the value of your investment could decline significantly. The stock market in general, including the market for life sciences companies, has experienced extreme price and trading volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies, including recently in connection with the evolving effects of the COVID-19 pandemic, which has resulted in decreased market prices, notwithstanding the lack of a fundamental change in the underlying business models of those companies. Worsening economic conditions and other adverse effects or developments relating to the evolving effects of the COVID-19 pandemic may negatively affect the market price of our ordinary shares, regardless of our actual operating performance. The market price for our ordinary shares is likely to continue to be volatile, particularly due to the evolving effects of the COVID-19 pandemic, and subject to significant price and volume fluctuations in response to market, industry and other factors, including the risk factors described in this “Risk Factors” section. Our share price may be dependent upon the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts’ forecasts, the expectations of our investors or the financial

129 guidance we provide to investors in any period, the market price of our ordinary shares could decline. Our ability to meet analysts’ forecasts, investors’ expectations and our financial guidance is substantially dependent on our ability to maintain or increase sales of our marketed products. In addition, the market price of our ordinary shares may decline if the effects of our strategic transactions on our financial or operating results are not consistent with the expectations of financial analysts or investors. The market price of our ordinary shares could also be affected by possible sales of our ordinary shares by holders of our exchangeable senior notes who may view our exchangeable senior notes as a more attractive means of equity participation in our company and by hedging or arbitrage trading activity involving our ordinary shares by the holders of our exchangeable senior notes. We are subject to Irish law, which differs from the laws in effect in the U.S. and may afford less protection to holders of our securities. It may not be possible to enforce court judgments obtained in the U.S. against us in Ireland based on the civil liability provisions of the U.S. federal or state securities laws. In addition, there is some uncertainty as to whether the courts of Ireland would recognize or enforce judgments of U.S. courts obtained against us or our directors or officers based on the civil liability provisions of the U.S. federal or state securities laws or hear actions against us or those persons based on those laws. We have been advised that the U.S. currently does not have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on U.S. federal or state securities laws, would not automatically be enforceable in Ireland. As an Irish company, we are governed by the Irish Companies Act 2014, which differs in some material respects from laws generally applicable to U.S. corporations and shareholders, including, among others, differences relating to interested director and officer transactions, mergers, amalgamations and acquisitions, takeovers and shareholder lawsuits. The duties of directors and officers of an Irish company are generally owed to the company only. Shareholders of Irish companies generally do not have a personal right of action against directors or officers of the company and may exercise such rights of action on behalf of the company only in limited circumstances. Accordingly, holders of our securities may have more difficulty protecting their interests than would holders of securities of a corporation incorporated in a U.S. jurisdiction. Our articles of association, Irish law and the indentures governing our exchangeable senior notes contain provisions that could delay or prevent a takeover of us by a third party. Our articles of association could delay, defer or prevent a third party from acquiring us, despite the possible benefit to our shareholders, or otherwise adversely affect the price of our ordinary shares. In addition to our articles of association, several mandatory provisions of Irish law could prevent or delay an acquisition of us. We are also subject to various provisions of Irish law relating to mandatory bids, voluntary bids, requirements to make a cash offer and minimum price requirements, as well as substantial acquisition rules and rules requiring the disclosure of interests in our shares in certain circumstances. Furthermore, the indentures governing our exchangeable senior notes require us to repurchase our exchangeable senior notes for cash if we undergo certain fundamental changes and, in certain circumstances, to increase the exchange rate for a holder of our exchangeable senior notes. A takeover of us may trigger the requirement that we purchase our exchangeable senior notes and/or increase the exchange rate, which could make it more costly for a potential acquirer to engage in a business combination transaction with us. These provisions, whether alone or together, may discourage potential takeover attempts, discourage bids for our ordinary shares at a premium over the market price or adversely affect the market price of, and the voting and other rights of the holders of, our ordinary shares. These provisions, whether alone or together, could also discourage proxy contests and make it more difficult for our shareholders to elect directors other than the candidates nominated by our board. Future sales and issuances of our ordinary shares, securities convertible into our ordinary shares or rights to purchase ordinary shares or convertible securities could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to decline. We expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations or for general corporate purposes. To the extent we raise additional capital by issuing equity securities or securities convertible into or exchangeable for ordinary shares, our shareholders may experience substantial dilution. We may sell ordinary shares, and we may sell

130 convertible or exchangeable securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell such ordinary shares, convertible or exchangeable securities or other equity securities in subsequent transactions, existing shareholders may be materially diluted. We have never declared or paid dividends on our capital stock and we do not anticipate paying dividends in the foreseeable future. We do not currently plan to pay cash dividends in the foreseeable future. Any future determination as to the payment of dividends will, subject to Irish legal requirements, be at the sole discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, compliance with the terms of the amended credit agreement and other factors our board of directors deems relevant. Accordingly, holders of our ordinary shares must rely on increases in the trading price of their shares for returns on their investment in the foreseeable future. In addition, in the event that we pay a dividend on our ordinary shares, in certain circumstances, as an Irish tax resident company, some shareholders may be subject to withholding tax, which could adversely affect the price of our ordinary shares.

General Risk Factors Our business and operations could be negatively affected if we become subject to shareholder activism or hostile bids, which could cause us to incur significant expense, hinder execution of our business strategy and impact our stock price. Shareholder activism, which takes many forms and arises in a variety of situations, has been increasingly prevalent. Recent stock price declines due to the evolving effects of the COVID-19 may also increase our vulnerability to unsolicited approaches. If we become the subject of certain forms of shareholder activism, such as proxy contests or hostile bids, the attention of our management and our board of directors may be diverted from execution of our strategy. Such shareholder activism could give rise to perceived uncertainties as to our future strategy, adversely affect our relationships with business partners and make it more difficult to attract and retain qualified personnel. Also, we may incur substantial costs, including significant legal fees and other expenses, related to activist shareholder matters. Our stock price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any shareholder activism. If we fail to attract, retain and motivate key personnel or to retain the members of our executive management team, our operations and our future growth may be adversely affected. Our success and our ability to grow depend in part on our continued ability to attract, retain and motivate highly qualified personnel, including our executive management team. We do not carry “key person” insurance. The loss of services and institutional knowledge of one or more additional members of our executive management team or other key personnel could delay or prevent the successful completion of some of our vital activities and may negatively impact our operations and future growth. In addition, changes in our organization as a result of executive management transition may have a disruptive impact on our ability to implement our strategy. Until we integrate new personnel, and unless they are able to succeed in their positions, we may be unable to successfully manage and grow our business. In any event, if we are unable to attract, retain and motivate quality individuals, or if there are delays, or if we do not successfully manage personnel and executive management transitions, our business, financial condition, results of operations and growth prospects could be adversely affected.

131 [THIS PAGE INTENTIONALLY LEFT BLANK]